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ABSTRACT 
The term Cystatin refers to proteins that specifically inhibit the activity 
of papain like lysosomal cysteine proteinase. They serve a protective function 
and regulate the activities of endogenous proteinases, which if not regulated 
may cause uncontrolled proteolysis and damage to cells and tissues . These 
endogenous thiol proteinase irihibitors are non covalent tight binding proteins 
which are widely distributed in animals, plants and microorganisms. Cystatin 
have been found to be evolutionary, structurally and functionally related 
proteins forming the cystatin superfamily .Members of tiiis family have been 
divided into tiiree groups of proteins known as family 1,2 and 3 . This 
classification is based on differences in amino acid sequences, molecular 
weight, sub cellular localization, disulphide bonds and number of amino acid 
residues. Family I cystatins called as Stefins are inti-acellular inhibitors which 
include members containing about 100 amino acid residues (MW 11,000), it 
lacks disulphide bridges and carbohydrate content. Family I I cystatins known 
as type 2 cystatins tiiey include inhibitors of about 115 amino acid residues 
(MW 13,000) and contain two disulphide loops towards tiie carboxyl terminal 
with no carbohydrates, They are found both in the cells and body fluids. 
Kininogens or Family I I I cystatins are large precursor molecules of the 
vasoactive kinins. They are single chain glycoproteins, which serve a variety 
of biological functions such as kinin delivery, induction of endogenous blood 
coagulation cascade and mediation of tiie acute phase response. They are 
found only in blood plasma. 
Cystatins have been purified from several mammalian sources like 
muscle, heart, kidney, spleen, liver, skin and placenta. In the present study a 
cystatin of molecular mass 44,000 has been purified firom buffalo brain 
(Bubalus bubalis). It has beein characterized in terms of its biochemical and 
biophysical properties. The purification has been achieved by a simple tiiree 
step procedure involving alkaline treatment at pH 11, ammonium sulphate 
fi'actionation (40-60%) and gel filtration chromatography on Sephadex G-75. 
gel Alteration profile showed two protein peaks (peak-I and peak - II) with 
significant inhibitory activity in peak -I it was named as BC (Brain Cystatin) the 
pooled fractions of the peak-I showed homogeneity on the basis of charge on 
7.5% polyacrylamide gel electrophoresis, was obtained with 64.13% yield and 
384.72 fold purification .Peak - I I was not taken into consideration because of 
its insignificant inhibitory activity and low protein content . Studies on the 
isolated cystatin include molecular mass detemnination, kinetics pH and 
temperature stability studies, carbohydrate content , sulphydryl group 
determination, fluorescence and UV spectral analysis. BC consist of two 
polypeptide chains as detemiined by SDS-PAGE in the presence and 
absence of p-mercaptoethanol. Indicating that the two chains are joined by 
noncovalent forces The molecular weight of the two subunits were 31.62 KDa 
and 12.58 KDa as detemiined by SDS PAGE, (44.2 KDa) this value was 43.6 
KDa by gel filtration chromatography . The stoke's radius of BC was found to 
be 27 A° indicating its compact globular structure. Cystatin was lacking in 
both carbohydrate content and disulphide bonds. The purified protien was 
found to be ma)dmally active in the temperature range of 25 - 60 °C and the 
pH stability was in t)etween pH 6.0 - 10.0. The inhibitor was found to be 
stable upto 40 minutes at 90°C showing 60% inhibitory activity. 
Purified BC strongly inhibited activities of proteases like papain, 
bromelain and ficin, but it did not inhibit serine proteases namely trypsin and 
chymotrypsin. The Inhibition kinetics revealed that the purified cystatin is a 
tight binding inhibitor. The respective Ki values of BC obtained for papain, ficin 
and bromelain were 1.0 nm 1.85 nm and 2.25nm respectively. The IC50 values 
for BC were 0.09pM, 0.12pM and 0.1 SpM for papain, ficin and bromelain, 
respectively, kinetic parameters taken together imply that the cystatin binds 
more effectively to papain, then bromelain and least with ficin. 
Ultraviolet spectra of the complex of BC with papain indicated that the 
environment of several aromatic amino acids residues in proteins have been 
perturbed by the Interactions. It showed Changes in the fluorescence 
emission intensity by a 10 nm red shift in spectra, upon formation of inhibitor -
papain complex indicating that there is some confonnational change or local 
interactions affecting chromopl-ioric groups of the two proteins involved in the 
complex formation. 
Because of the absence of carbohydrate content, lack of disulphide 
linkages, high molecular weight and analysis of all other results obtained for 
BC, it can be considered as a variant of class I cystatin, that is the Stefins 
class of cystatin superfamily.. 
A review of the existing literature showed that cystatins fr^om mammalian 
sources have species as well as organ differences, they differ not only in size 
but in several other physicochemical properties owing to the specific 
physiological functions they pejrform in the mammalian body Therefore, in 
view of the reported differences in molecular and functional properties of 
cystatin from various species and different tissues it was thought worthwhile 
to isolate and purify cystatin Irom a hitherto uninvestigated source and to 
characterize it on physicochemical basis. 
To investigate the effect of reactive nitrogen species on cystatin The 
effect of nitric oxide on structural and functional modifications of BC was 
investigated. It was found Ihat nitric oxide quenched the tryptophan 
fluorescence and lead to 66% loss of the inhibitory activity in the presence of 
NO. Effect of Curcumin and querecitin (widely used as scavengers of NO) 
were analyzed for their protective effect in the presence of NO. Both the 
scavengers were found to havcj very significant preventive effect against NO 
induced damage of BC. This protection was maximally effective by SOpM of 
curcumin (loss was only 8%) however at 250^M querecitin loss in tryptophan 
fluorescence was 13% , both the scavengers were able to protect 90% of 
antiproteolytic activity of cystatin in the presence of NO . 
In an attempt to explore the effect of reactive oxygen species (ROS) on 
cystatin HOCI and H2O2 were used as oxidants. The results reveal that BC, 
in the presence of HOCI lost ifc> antiproteolytic activity rapidly (within 30 min, 
82% loss occun^ ed at 5pM HOCI). Another oxidant hydrogen peroxide at 
250mM concentration showed significant functional and structural damage of 
cystatin , 60% loss of antiproteolytic activity occun^ ed in 30 min of incubation, 
moreover at the same H2O2 concentration , cystatin showed 82% decrease in 
tryptophan fluorescence. The use of scavengers and antioxidants showed that 
hydroxyl radicals were involved in the damage of the purified inhibitor 
curcumin and quercetin both of them provided 80% protection to damage. 
Riboflavin is a common reactive oxidants produced in the mammalian 
system under various metabolic conditions. Interaction of riboflavin (50|JM) 
with BC showed that oxidant inactivated the inhibitor to the extent of 76% for 
30 min of incubation with conrjplete loss of inhibitory activity at the same 
concentration for longer time of incubation. Oxidation by riboflavin was also 
observed in the form of changes; in fluorescence spectra .It showed quenching 
of tryptophan fluorescence. Free radical scavengers were used for detection 
of the type of ROS involved in the damage .the scavengers used were 
Glucose.KI .Sodium azide, Thiourea .Mannitoi and Sodium benzoate. Out of 
these sodium benzoate (89%) fliiourea(86%) and mannitoi (83%) provide 
significant protection . Results suggested that singlet oxygen and flavin triplet 
state were predominantly responsible for BC damage by riboflavin . 
Drug induced structural changes in BC were monitored by Intrinsic 
fluorescence and UV vis spedrophotometric analysis. Four drugs 
(amytriptyline, fluoxetine , haloperidol, donepezil) and two neurotransmitter 
(dopamine and serotonin) were analyzed for their effect on BC . 
Amytriptyline is a tricyclic antidepressant drug. It caused quenching of the 
intrinsic fluorescence of Cystalin, increasing concentration of amytriptyline 
caused no shift in wavelength, but fluorescence intensity decreased with 
increasing concentration of drug.A decrease in antiproteolytic activity was also 
noticed. 
Fluoxetine is approved for the treatment of major depression .The Drug 
caused quenching of the intrinsic fluorescence of Cystatin with 10 nm of blue 
shift in wavelength (Xmax was shifted from 340nm to 330nm) at 2 pM 
fluoxetine concentration. On interaction of cystatin with 0.5 pM fluoxetine, 
48% loss of cystatin inhibitory activity was observed . 
Haloperidol is a typical antipsychotic drug. Due to its strong central 
antidopaminergic action. It is also classified as a highly potent neuroleptic 
drug. Haloperidol at 0.02pM did not induce any change in emission Xmax, 
however 27% decline in fluorescence intensity was observed. A decline in 
antiproteolytic activity was also noticed. 
The thermodynamic parameters stem volmer constant (Ksv) for all the 
three drugs calculated indicate that both hydrogen bonds and hydrophobic 
interaction played a major role in the binding of antidepressants with BC . 
Donepezil, marketed under the trade name Aricept,is a reversible 
acetylcholinesterase inhibitor. Donepezil caused unfolding of the Cystatin as 
indicated by enhancement in fluorescence intensity accompanied by the red 
shift of 40nm while the drug (native) shows A.max at 370 nm , however when it 
forms complex with Cystatin there was a shift in Xmax of lOnm with significant 
enhancement in fluorescence intensity at 1.6 [M of the drug concentration . 
The inhibitor was analyzed for Its interaction with well known 
neurotransmitters dopamine and serotonin. Dopamine is a neurotransmitter 
essential for the normal functioning of the centi-al nervous system. It initiates 
as well as controls the movement and balance of the body . It causes 
quenching of the intrinsic fluorescence of BC accompanied by a blue shift (20 
nm) in wavelength at 10pM concenti'ation. These results indicated that there 
were interactions between dopamine and brain cystatin, tills binding reactions 
resulted in non-fluorescent complex. 
Serotonin a monoamine neuroti^ ansmitter helps to relay signals from 
one area of the brain to another and has various Unctions in biological system 
including depression alcoholism, pain , anxiety conh^ ol of appetite, mood and 
anger. On interaction with BC it caused unfolding of tiie cystatin as indicated 
by enhancement in fluorescenwj intensity. The study showed ttiat cystatin lost 
significant amount of inhibitory activity at 10 nM concenti^ ation of serotonin. 
Results of fluorescence for interaction of cystatin witti the drugs in 
which binding was observed were analyzed by stem volmer equation , for 
calculation of the number of binding sites, free energy change and binding 
affinity of the drugs with cystatin, results revealed that there was one binding 
site for each drug tiie values were 0.89 ,0.79 ,1.1 and 0.798 for amtriptyline 
Fluoxetine haloperidol dopamine respectively . The binding affinity values for 
the four drugs were as follows amtriptyline (3.018 x 10 )^ Fluoxetine (5.0317 x 
10^ ) haloperidol (7.988 x 10^ ) and dopamine (2.592 x 10 )^. Indicating highest 
binding affinity for haloperidol.The free energy change (AG°) values were in 
tiie order of -39.377 > -38.232 > -36.966 >-36.589 for haloperidol , 
Fluoxetine , amtriptyline and dopamine respectively showing the reactions to 
be spontaneous. The stem volmer constant values were in the range for 
amtriptyline (0.115 x 10^), Fluoxetine (0.5 x 10^), haloperidol (15 x 10 )^ and 
dopamine (0.5 x 10®) respectively .indicating the type of quenching to be static 
Since cystatins have important roles to play in normal body processes 
owing to their cysteine proteinase inhibitory activity, it is of utmost importance 
that their conformation should be stable for maximum functional activity. The 
present study on cystatin not only gives a detailed characterization of the 
inhibitor isolated from bu^lo brain on physiochemical basis but tiie 
investigations in this work also provide useful information on the drug-protein 
interaction. Understanding the confonmational changes that result in a protein 
by various drug treatments may provide a powerful tool for drug design. 
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1. INTRODUCTION 
Proteolytic enzymes also termed as proteases, hydrolyze susceptible 
peptide bonds in proteins and are of universal occurrence in mammalian 
system. The term proteinase is a general term applied for both exopeptidases 
and endopeptidases. A protease is classified as a proteinase if it exhibits a 
significant endopeptidases activity regardless of whether it exhibits 
exopeptidases activity. However proteases and proteinases are 
synonymously used in literature. Proteinases are further divided into fours 
classes - serine proteinases, acid proteinases, metalloproteinases and thiol 
proteinases. Serine proteinases require the presence of serine residue at their 
active sites, acid proteinases require low pH conditions for their activity, 
metalloproteinases need metal ions for their full activity and thiol proteinases 
have cysteine residue at their sites. Serine proteinases and their endogenous 
inhibitors are much more explored as compared to thiol proteinases and their 
inhibitors. 
Thiol proteinases synonymous with cysteine proteinases comprise a 
group of proteolytic enzymes which are widely distributed among living 
organisms [Ban^ett et al. (1986a)]. They are proteins of MW of about 25-35 
KDs. These proteinases are synthesized in a precursor form and are later 
subjected to co-translational and post translational modifications that convert 
them to catalytically active n-iature enzymes [ Cygler and Mort (1997), Turk et 
al. (2000)]. They contain two principal catalytic amino acid residues, cysteine 
and histidine at their active sites which are involved in the cleavage of peptide 
bonds [Stennicke (1999)]. Cysteine proteinases play an important role in the 
catabolism of proteins and peptides, processing of prohormones, maturation 
and cleavage of a number of precursor proteins [Siewinski (1993)] 
About 40 different families of cysteine proteinases have so far been 
characterized [Barrett et al. (1998)]. The first clearly recognized and 
extensively studied cysteine proteinase was papain, isolated from the latex of 
the plant, Carica papaya. Nearly half of the known families of cysteine 
proteinases are represented only in viruses some occur in bacteria, whereas 
others exist in eukaryotic organisms [Rawlings and Barrett (1994)]. Current 
evidence suggests that eleven lysosomal cathepsins [B, H, L, S, C, K, 0, F, V, 
1 
Xand W] among the known to date proteinases are members of papain family 
[Kotyza and Krepela (2002)]. 
Mammalian thiol proteinases have been classified into four different classes 
1. Cathepsins 2. Leguimain 3. Calpains 4. Caspases 
Cathepsins They are relatively small proteins with the exception of 
cathepsin C which is an oligomeric enzyme of molecular weight of about 200 
KDa. They are present in the lysosomes of cells and are involved in 
intracellular protein tumover, proteolytic degradation and cleavage of a 
number of precursor proteins and hormones. These are present in high 
concentrations in spleen [McDonald and ELIS (1975)], kidney, liver [Knight 
(1980), Quinn andJudah (1978)] and brain [Suharand Marks (1979)] 
Legumain It is an asparaginyl endopeptidase present in lysosomes. 
These are involved in MHC class II - restricted antigen presentation [Manoury 
et al. (1998)] and local negative regulation of osteoclasts formation and 
activity [Choi et al. (1994)]. 
Calpains and Caspases they are cytoplasmic thiol proteinases. 
Calpains participate in many intracellular processes such as turnover of 
cytoskeletal proteins, cell differentiations and regulation of signal peptides. 
Mammalian calpains have molecular mass of about 110 KDa [Yajima and 
Kawashima (2001)]. 
Caspases are the cysteine aspartate specific proteinases. The central 
component of cell apoptosis consists of proteolytic systems involving 
caspases [Nicholson (1999), Stennicke and Salvensen (2000)]. 
The lysosomal cysteine proteinases have been associated with a 
number of pathologies including cancer [Koppel et al (1994)], inflammation, 
rheumatoid arthritis [Trabandt et al. (1991)] and osteoarthritis, Alzheimer 
disease [Nakamura et al. (1991)], multiple sclerosis [Bever et al. (1995)], 
muscular dystrophy [Sohar et al. (1998)], pancreatitis, liver disorders, lung 
disorders, lysosomal disorders [Sloane and Honn (1984)], diabetes and 
myocardial disorders [Hopsu-Havu et al. (1983b)] In many of these diseased 
lysosomal enzymes have been found in the extracellular and extra lysosomal 
environments in their preforms, which are substantially more stable than their 
mature enzymes [Barrett et al. (1998) Turk et al. (2001)]. 
1.1 REGULATION OF LYSOSOMAL THIOL PROTEINASE ACTIVITY 
Proteolysis is a key process in all living organisms and must be 
carefully controlled In order not to be hazardous to the organism itself. It is, 
therefore, not surprising that a large number of proteinase inhibitors have 
been found in animals, plants and micro organisms [Ryan (1990)] Naturally 
occurring protelnaceous Pis (protein inhibitors) are primarily classified into 
different classes, based on the type{s) of enzyme they inhibit [Bode and 
Huber (2000)] such as serine proteinase inhibitors. Which inhibit serine 
proteinases. Next to tills criterion, classification of Proteinase inhibitor Is also 
performed based on sequence homology, such as is done for Kunitz-type 
inhibitors. A further classification of these inhibitors has been done on the 
basis of their molecular mass, their protein architecture (monomeric or 
multimeric), the number of disulfide bridges present and their isoelectric points 
as in the case of thiol proteinase inhibitors. These criteria determine In which 
family a proteinase inhibitor can be classified in animals and plants, 
1. Serine proteinase inhibitors 
The serine proteinase inhibitors are by far the largest class of proteinase 
inhibitors when looking at the number of families. Serine proteinase inhibitors 
can be classified into 13 structurally distinct families, based on their origin. 
2. Aspartate proteinase inhibitors 
In contrast to the widespread distribution of the aspartate proteinases, 
the aspartate proteinase inhibitors are relatively uncommon. The aspartate 
proteinase inhibitors from Solanaceae are the most well known and well 
characterised in plant [Mares et al. (1989)] Until now, only one family has 
been described. This family comprises proteinase Inhibitors with a molecular 
mass of 20-22 kDa, and ttiat contain two S-S bridges. They show sequence 
homology with the Kunit:-type inhibitors and are therefore, classified as 
members of the Kunltz-type family. They all inhibit cathepsin D and in some 
cases they Inhibit trypsin also. 
3 Metallo proteinase inhibitors 
Only one family of the class of metallo proteinase inhibitors has so far 
been discovered. The potato carboxypeptidase Inhibitor (PCI) from Solanum 
tuberosum [Molina et al. (1994)]. PC! is a small of 38-39 amino acid residues, 
containing 3 S-S bridges and is known to be highly thermostable [Huang et al. 
(1981)1 
4 Cysteine proteinase inhibitors 
Cysteine proteinase in animals plants and microorganism such as e.g. 
papain, bromelain, cathepsin B, H, and L and also several other lysosomal 
cysteine proteinases, which are responsible for protein degradation. [Ban-ett 
(1987)]. The class of cysteine proteinase inhibitors which regulate the activity 
of these proteins is also known as the "Cystatin superfamily".Generally 
members of Cystatin superfamily are monomeric proteins and contain a highly 
conserved region of 5 amino acids (GIn-X-Val-X Gly) always located in 
position starting from 57. 
The process of proteolysis in cells is under biological control acting at 
the level of protein biosynlthesis or mediated through protein inhibitors.The 
biological activity of cysteine proteinases is regulated not only by specific and 
non specific inhibitors but also by pH and zymogen activation [Turk et al 
(1997)]. The Non - specific inhibitors of these peptidases in general are a-
macroglobulin , which bind and Inhibit irreversibly most proteinases, peptide 
aldehydes like leupeptin and antlpain, (acting as reversible transition-state 
analogues) and peptide chloromethyl ketones which inactivate proteinases by 
binding the inhibitor and alkylating the active site [Salvesen and Nagase 
(1989)1 Peptide diazomethanes and peptide epoxides alkylate active-site 
cysteine inhibiting particularly cysteine proteinases but they cannot 
discriminate between different cysteine proteinases [Salvesen and Nagase 
(1989)] All papain-like cysteine proteinases are synthesized as inactive 
proenzymes (zymogens). The proregion is needed for proper folding and 
transport of newly synthesizBd enzymes [Cygler and Mort (1997)] Cathepsins 
are transported from the Golgl apparatus to the lysosomes where the pH is 
acidic [Cygler and Mori (1997)]. 
This acidic environment has two functions it triggers the proteolytic 
cleavage of propeptide yielding mature cathepsin [Jerala et al. (1998)] and 
provides the optimum pH for these enzymes to function [Kirschke et al. 
(1995)]. A neutral pH as well too acidic pH rapidly Inactivates cathepslns [Turk 
et al. (1999)]. Further, one mechanism of regulation is that cathepsins are 
stable only in a certain pH range which differs for every cathepsin. Throughout 
the maturation the pH declines in lysosomes. Therefore different cathepsins 
are activated at different maturation stages of lysosomes [Turk and Bode 
(1991)]. In mafejre lysosomes pH can reach values as low as 3.8 which Is 
sufficiently low to cause irreversible denaturation of cathepsins B, S and L 
[Turk etal. (2000)]. 
Several processes lead to increase of proteolysis in the cells e.g. 
starvation of animals increases the rate of protein degradation in liver [Dice et 
al. (1978)] and muscle [Li and Goldberg (1976)] and causes about two fold 
increase of Cathepsin D and A levels in the liver [Katunuma et al. (1982)]. 
Similarly, several hornniones are known to regulate average rates of 
protein degradation. Various pathological conditions have been associated 
with increased thiol proteinase activities like metastasizing cancer [Koppel et 
al. 1994)1 muscular dystrophy [Noda et al. (1981)], renal failure [Kabanda et 
al. (1995)] and rtieumatoid arthritis [Gabrijeleic et al. (1990)]. Hence the wide 
implications of the thiol proteinases in various biological functions need to be 
effectively regulated by opposing effecte of activators and Inhibitors. 
Specific Proteinase inhibitors are ubiquitously present in the living 
system and tiiey constitute a powerful regulatory system for the endogenous 
thiol proteinases. The members of cystatin superfamily, include stefins, 
cystatins and kininogens. These cystetins play a key role in regulatory 
process for endogenous cysteine proteinases whose activities if not contirolled 
will lead to unwanted tissue destruction. 
1.2 DISCOVERY OF CYSTATIN SUPERFAMILY 
Protein inhibitors of cysteine proteinases in mammalian tissues were 
first reported by Finkelstadt (1957), who reported a heat stable inhibitor of 
cathepsin B and dipeptidyl peptjdase-l in Rat liver cytosol. Sen and \/\Aiitaker 
discovered and partially characterized a protein from chicken egg white that 
inhibits papain and ficin [Sen and Whitaker (1973)]. This protein also inhibits 
cathepsin B and dipeptidyl peptldase-I as reported by Keilova and Tomasek 
(1975). 
The term cystatin was originally coined by Barrett (1981) for these 
inhibitors because of their unique property of arresting the activity of cysteine 
proteinases (CPs). Later, the name was given to a superfamily of 
evolutionary, structurally and functionally related proteins involved in the 
inhibition of CP activities. 
Later on, CPIs (cysteine proteinase inhibitors) were isolated and 
characterized from various mammalian tissues. These inhibitors resembled 
chicken cystatin in relative molecular mass and physicochemical properties. 
Subsequently, Machleidt et al. (1983) reported that the sequences of stefin 
and chicken cystatin are tiornologous [Green et al. (1984), Barrett (1985)]. 
Stefins however, differed in lacking cysteine residues and disulphide bonds 
and hence, were placed in a different family within "cystatin superfamily". 
Ail those cystatins faliing into a single family that is a group within 
which ail the membere can be shown to have a statistically significant relation 
with each other but do no resemble the members of the other super families 
comprise one family [Dayhoff et al. (1979a)]. Cystatin super family include 
three distinct families, the members of which are expected to have atleast half 
of their amino acid residues in common paytioff et al. (1979b)]. 
CLASSIFICATION OF CYSTATIN SUPERFAMILY 
The first international symposium on cysteine proteinases and their 
inhibitors in 1985 decided triat these inhibitors should be divided into three 
families 1, 2 and 3 [Banett. et al. (1986b)], Hence tiie proteins of cystatin 
superfamily are divided on the basis of sequence homology, molecular 
structure and the number of amino acids in the following ttiree families 
[Rawlings and Banett (1990), Turk et al. (1997), Brzin et al. (1984)][Fig -1] 
FAMILY I (TYPE 1 CYSTATIN): STEFINS 
The term stefin has been assigned to this family to emphasize the 
structural difference betweejn these proteins and other members of the super 
family. The proteins of this family are the smallest among the members of the 
cystatin superfemily lacking in disulphide bonds and carbohydrate moieties 
[Brzin et al. (1983)]. Stefins are single chain proteins, synthesized without 
signal peptide and consist of about 100 amino acid residues (MW11000). All 
type I cystatins have blocked N-termlnal and contain methionine representing 
the points of initiation of translation [Turk et al. (1995)], There are three 
important members of this family, cystatin A and B isolated from human 
[Green et al. (1984) Lenney et al. (1979)] and stefin C purified from bovine 
tissues. Cystatins a and p are considered to be simply the rat species variants 
of cystatins A and B^  [Lenney (1979)]. The amino add sequence of these 
proteins closely resembles each other [Barrett et al. (1986)] [Fig 2a&b] 
Cystatin A 
It is an inhibitor of cathepsin B in human skin discovered by Fraki 
(1976). Later on Jarvinen (1978) studied it as 'acid cysteine proteinase 
inhibitor" (ACPI). Brzin et al. (1983) purified an inhibitor from blood leucocytes 
and named it as 'stefin'. The amino acid sequence was determined by 
Machleidt et al. (1983). Green et al. (1984) characterized same type of CPI 
from human liver and later renamed it as cystatin A. Cystatin A occurs in 
multiple isoelectric fomis with predominantly acidic pi values in the range 4.5-
5.0 [Jan/inen (1978), Hopsu-Havu etal. (1983a)].Rinnie etal. (1978) detected 
cystatin A in extracts of scjuamous epithelia from oesophagus. It was also 
found in dendritic reticulum cells of the lymph nodes [Rinnie et al. (1983)], 
seminal plasma [Minakata and Asano (1985)], saliva, bovine skin [Turk et al. 
(1995), human nails [Tsushima (1993)] and in a number of epidennoid 
carcinomas [Rinnie et al. (1980, 1984a)]. 
Physiological concentrations of human cystatin A was reported by 
Hopsu-Havu et al. (1983b) in serum as (10-15Mg/ml). In tissues the 
concentrations were: epidermis of tongue and mouth, 65-200|jg/g; bone 
man-ow, Sp g/g, liver 5|jg/g, spleen Spg/g and lung 0.3pg/g.The N-terminal 
sequence of bovine stefin A was identified as a tixincated form of bovine 
Fig-1 Diagrammatic representation of the chain structure of 
proteins in the cystatini super family 
The stefins are single chain proteins without disulphide linkages. The 
cystatin ar also single chain but possess two disulhide bonds, The 
structure indicated for kiniinogens is that of L- kininogens, H-
kininogens have a longer Ccirboxyl terminal extension. The symbol • 
marks potential sites for the attachment of the carbohydrate chains 
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Fig- 2(a) 3D structure of stefin A 
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cystatin C [Hirado et al. (1985) Turk et at (1995)]. The sequence identity of 
this stefin A is 86% and 88% respectively with -N and C temninal parts of 
human cystatin A. 
Cystatin a 
Cystatin a is assumed to be a species variant of cystatin A found in 
rats. This protein was characterized by Jarvinen (1976) as specific inhibitor of 
CP from rat skin having MW of 13000. Cystatin a is generally found on the 
epidennal layer [Jarvinen et al. (1978)] and various other squamous epithelia 
[Rinnie et al. (1978)] Kominami et al. (1984) and Katunuma and Kominami 
(1985) quantified the concentation In skin and small intestine as 2800 pg/ml 
protein and 820 pg/ml protein respectively. The semm level of cystatin a In 
rats was 2.5|jg/ml.Green et aL (1984) purified it from human spleen and liver 
with separation of multiple fonns, Cystatin B is a relatively basic protein with pi 
values of 6.25 and 6.35 for the two fomns of cystatin B [Green et al. (1984)]. 
Cystatin B 
Cystatin B was detected as an inhibitor of cathepsin B and H in human 
tissues by Lenney el al. (1979). Jarvinen and Rinnie (1982) purified cystatin B 
from human spleen (1982) and reported its pi values of 6.0 and 6.5 Rinnie et 
al. (1984) reported the value as 6.5 and 7.5. Human cystatin B forms dimers 
but dimeric fomi does not show inhibitory activity [Jarvinen and Rinnie (1982) 
, Green et al. (1984)]. Cystatin B is ubiquitously distributed in various cells and 
tissues like epithelial cells, lymphocytes [Davies and Barrett (1984)], 
monocytes [Hopsu-Havu et al. (1984, 1985b)] and to much lesser extent in 
seminal plasma [Brzin (1982)]. Jarvinen et al. (1983) have shown cystatin B in 
cells of the upper layers of the epithelium of the oral mucosa. Confocal 
microscopic analysis showed the localization of cystatin mainly in the 
proliferating cells and both in the nucleus and cytoplasm of differentiated cells 
[Riccio (2001)]. This cystatin is involved in the protection against uncontrolled 
activity of lysosomal CP [Henskens (1996)1. Crystal structure of recombinant 
human cystatin B has been elucidated by X-ray crystallographic analysis 
[Stubbs et al. (1990)]. Cystalin B is more abundant in all cells than cystatin A 
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Nwith the exception of PMNs. Stefin B from bovine \was reported by Krizaj et a/. 
(1992). 
Cystatin p 
Finkelstadt (1957) and Lenney (1979) reported the existence of a 
themiostable and dialyzjable inhibitor of cathepsin B, H and dipeptidyl 
peptidase I in the supernatant of rat liver homogenate. Subsequently Hirado 
et al. (1981) isolated cystatin p from rat liver cytosol. The p1 values for 
cystatin p ranges from 5.04 to 5.6 [Kominami et al. (1981), Hirado et al. 
(1981)] Cystatin p has an almost even distribution In the tissues and is more 
abundant than cystatin a in all tissues except skin. This characteristic of 
cystatin p resembles cystatin B of human variant. 
Stefin C 
Several low MW CPIs have been found in bovine thymus, although 
kinetically similar they differ in the primary structure and pi values, Stefin C is 
unique among the inhibitors from stefin family which yNas found in multiple 
forms resulting from the cleavage of Asn 5-Leu 6 bond of the inhibitor, 
[Kopitaret al .(1989)]. The protein consists of 101 amino acid residues and its 
MW is calculated lo be 11,546. The inhibitor was found to be acidic with pi 
values from 4.5 and 5.6 Stefin C exhibits considerable sequence homology 
with other inhibitors from stefin family with maximum homology of 87.4% with 
bovine stefin B, 72.4% withi human cystatin B and 47.9% with human stefin A, 
It was identified as the first tryptophan containing stefin (at position 2) and it 
had prolonged N-termlnal [Turk et al. (1993)]. 
FAMILY 2 (TYPE-H): CYSTATINS 
Family 2 cystatins like slefins are low MW Cystatins. These inhibitors 
are composed of 115-120 amino acid residues having MW of about 13000. 
Cystatins contain two disulphide bonds and lack carbohydrate contents. They 
are synthesized with the singel peptide and found at a relatively high 
concentration in secretions like chicken egg white, seminal plasma and saliva. 
They originate in cell and function infracellulariy. The known members of this 
family are chicken cystatin, human cystatin C, D, S, SN, SA, E, F and M. 
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Measurements of the concentration of the cystatin In human biological fluids 
reveal that all such fluids contain Inhibitors, but the total molar ratios of 
different inhibitors vary markedly. Cystatins are found both In cells, tissues 
and secretions [Lofberg et al. (1983)]. The general pattern seems that 
secretions contain the highest concentration of family 2 cysfatins 
[Abrahamson (1994)]. Family 2 cystatin genes are clustered in multigene 
locus on chromosome 20 together vwth two pseudogenes [Abrahamson et al. 
(1990) Thiesse et al. (1994)]. The best known representatives of this class of 
cystatins are human cystatin C, chicken cystatin and cystatin S. [Fig -3] The 
pi value ranges from 4.4 to 9.3. 
Cystatin C 
Originally cystatin C was tenmed as y-trace or post y-globulln from CSF 
because of its basic natures and y-electrophoretic mobility [Barrett et al. 
(1984a) Brzin (1984)]. It was also found in urine from patients with renal 
failure [Butler and Flynn (1961)] and ascetic and pleural fluids [Hochwald and 
Thombecke (1962)]. Later, cystatin C was also detected In saliva, normal 
serum [Cejka and Fleischmann (1973)] and in seminal plasma [Collie et al. 
(1976)]. Lofberg and Grubb (1979) determined cystatin C concentration of 
5.8pg/ml In CSF [cerebrospinal fluid], 1.8mg/ml in saliva, 0.095ug/ml in nomial 
urine, 21pg/ml in urine fi'om patients with renal tubular disorders and 1.1pg/ml 
in normal plasma. Seminal plasma contains 50pg/mi that is. 36 fold higher 
concentration of inhibitor than in normal blood plasma [Grubb et al. (1983), 
Abrahamson ff990J7 found cystatin C concentration of 3,4ug/ml in saliva from 
submandibular glands and 0.9pg/ml fi'om the parotid gland. The high level of 
cystatin C in the CSF compared with blood plasma suggeste the production of 
cystatin in the central nervous system [Lofberg and Grubb (1979)]. The 
protein is able to cross blood brain banier to the vascular space and thereby 
rapidly filtered in the glomeruli and catabolised in the renal tubular cells. 
Despite widespread extracellular distribution, cystatin C has also been 
detected Intracellularly in brain cortical nerves [Lofberg et al. (1981a)], nonnal 
and neoplastic neuroendocrine cells in the adrenal medulla [Lofberg et al. 
(1982)]. A cells of pancreatic islets [Lofberg et al. (1981b)], thyroid and 
pituitary glands [Lofberg et al. (1983), Moller et al. (1985)]. Homologues of 
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human cystatin C have been found in several mammals including mouse, rat, 
cow and dog [Solan et al. (1990), Esnard et al. (1990). Hirado et al. (1985), 
Poulik et al. (1981)]. It is also found to be linked with epileptogenesis and 
epilepsy along with other neurodegenerative diseases [McGeer (1995)].Cejka 
and Fleischmann (1973) determined the isoelectric point of cystatin C to be 
9.0 although, values ranging from 8.0 to 9.5 have been reported. [Brzin et al. 
(1984)] Degradation of N-teiininal region takes place during storage which 
results in a lower pi value, N-terminal truncation of cystatin C by cathepsin L 
has been reported by Popovic et al. (1999) leading to loss in its activity and 
lowering of pi to 8,1 and 8.25 due to loss of one or more basic residues. It was 
suggested that cleavage could be of physiological significance to control the 
extent of inhibition by cathepsin B at the site of inflammation [Abrahamson el 
al. (1991)]. The truncation results in the exposure of N-terminal and loss of 
ordered structure of cystatin in solution [Ekiel et al. (1997)]. 
Chicken cystatin 
Chicken cystatin was first isolated fi^ om chicken egg white by Possum 
and Whitakerin (1968) and Sen and Whitakerin (1973) reported it as low MW 
light binding CPI of ficin and papain and of cathepsin B and C by Keilova and 
Tomasek (1974, 1975). Chicken cystatin [Fig-4] has also been detected in the 
serum of both male and female chickens at a concentration of 80pg/ml in egg 
white and 1pg/ml in the serum [Anastasi et al. (1983)].\t was found to be heat 
stable and could be boiled for 30 min without much loss of activity, but was 
unstable to freezing or freeze drying. It has also been found In chicken muscle 
cells [Wood et al. (1985)] and showed resemblance to cystatin C Mw of about 
13,000 has been determineii for chiken cystatin from its amino acid 
composition [Lindahl el at. (1988), Nicklin and Barren (1984)] resolved this 
inhibitor as two isoelectric forms I and II having pi values of 6.5 and 5.6, 
respectively. 
Cystatin D 
Frieje et al. (1991) cloned a new member of human cystatin multigene 
family from a genomic library using cystatin 0 cDNA probe.This inhibitor 
consists of 122 amino acid residues having aMwof 13,885. The deduced 
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Fig-3 Three dimensional structure of Human cystatin 
(Member of the type-I cystatin superl^ mily) 
Fig-4 Three dimensional structure of Human cystatin along 
with its inhibitory reactive sites 
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amino acid composition includes a putative signal and has 51-55% homology 
with either cystatin C or secretory gland cystatins S. SA and SN. Cystatin D is 
relatively neutral protein with PI in the range 6.8-7.0 [Frieje et al. (1991)]. It is 
expressed in parotid glands, saliva and tears [Balbin et al. (1994)]. This tissue 
restricted expression is in marked contrast with a wider distribution of all other 
family 2 cystatins. 
Cystatin S 
Human saliva contains several low MW acidic proteins which include 
CPI also [Minakata and Asano (1985)]. The first salivary inhibitor purified and 
sequenced was SAP-I (salivary acidic proteinase-l) [Isemura et al. (1984a)], 
which was renamed as 'cystatin S'. It was found to have 54 and 41% 
sequence homology with cystatin C and chicken cystatin, respectively 
[Isemura et al. (1984a and b)] This inhibitor has also been isolated from 
human submaxillary, submandibular and sublingual glands and found to be 
present in tiie serous cells of parotid and submaxillary glands [Isemura et al. 
(1984b)]. It is assumed tiiat these cells are responsible for its synthesis. The 
protein has also been found in tears, serum, urine, bile, pancreas and 
bronchus [Isemura et al. (1986)] Cystatin S contains no phosphate, in conti^st 
to otiier salivary proteins. 
Variants of cystatin S 
Several molecular variants of cystatin S have been studied by Isemura 
et al. (1986). They differ in their N-terminal sequences and pi values 
differences in PI values resulted from phosphorylation of residues Ser 3 and 
Ser 1 in salivary cystatin [Isemura et al .(1991)] 
Cystatin SN 
It was originally known as cystatin SV or SA-I [Abrahamson et al. 
(1986)] The protein consists of 121 amino acid residues and MW value of 
14,316. The pi value is in tiie range of 6.6-6.8. 
Cytatin SA 
The protein consists of 1221 amino acid residues and Mw value is 
slightly higher than SN, which is 14,351. It has acidic pi value of 4.6 [Isemura 
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et al. (1991)]. Cystatin SA isolated from saliva had N-terminal residue 
Glutamic acid [Isemura et al.(1986)]. 
Cystatin E 
Ni et al. (1997) found this type of cystatin by expression of amniotic 
fluid and fetal skin epithelial cell cDNA libraries. The mature protein is a 
polypeptide of 121 amino add residues and has 28 residue signal peptide 
having a Mw of 15,000. Cystatin E resembles family 2 cystatins structurally in 
containing two protective disulphide bridges and by being a secreted protein. 
The inhibitor has unusual characteristic of being a glycoprotein carrying an N-
linked oligosaccharide at Asn 108 [Stenmann et al. (1997)]. Cystatin E is a 
functional tight binding CPI it has amino acid sequence similarities with 
human family 2 cystatins [C.D.S, SN and SA] in the range of 26-34% , 18 and 
23% homology with family 1 { cystatin A and B) and less than 30% with 
domains 2 and 3 of the family 3 cystatins, tiiat is kininogens [Ni et al. (1997)]. 
The protein has Pro-Trp pair towards tiie C-tenninal like that of family 2 and 3 
cystatins. Cystatin E gene is localized on chromosome 11 [Stenmann et al. 
(7997j/.Cystatin E has been detected in a variety of specialized tissues and 
organs [Ni et al .(1997)]. Its high concenti^ ation is found in uterus and liver, but 
significant amounts in placenta, pancreas, heart, spleen, small intestine, and 
peripheral blood leucocytes, in brain, testis and kidney of mammals. The 
inhibitor serves a protective role during fetal development. 
Cystatin F 
Another described human member of the cystatin superfamily was 
identified as cystatin F by Ni et al. in (1998). Its sequence contained signal 
peptide and the mature protein of 126 amino acid residues has two disulphide 
bonds which resemble family 2 cystatins. Unlike other members, cystatin F 
has two additional Cys residues indicating ttie presence of an exti^ a disulphide 
linkage which stabilizes N-terminal region of tiie molecule. The mature protein 
has an extended N-terminal segment, being 6-10 residues longer than tiie 
other single domain cystatins. Cystatin F has a Mw of 14,543 as determined 
by sequence analysis [Ni et al. (1998)].Cysia^n F has two N-linked 
cariDohydrate chains at positions 36 and 88. It has 30-34% homologous 
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sequence to human family 2 cystatins, only 29% homology to cystatin E, even 
lower 22-20% identities to cyslatin A and B and 24% with domain 3 of 
kininogens [Ni et al. (1998)]Jhe distribution pattern of cystatin F is very 
different from that of cystatin C or E. Blood contains low levels of this inhibitor 
(0.9 \igJm\). The highest concenfration Is present in the spleen and peripheral 
blood leucocytes, moderate levels in thymus and small intestine. Cystatin F is 
found mainly in the immune cells. However, it could not be detected in B ceil 
lines but appreciable amounts were detected from primary dentritic cells, bone 
marrow, activated T-cells, multiple sclerosis lesions, osteoarthritic, lymph 
nodes, apoptotic T-cells, osteosarcoma cells, pancreatic islet tumour cells, 
thymus, helper T-cells and peripheral blood mononuclear cells. The function 
of cystatin F is important for specialized cells of the myeloid or T-cell lineage. 
Taken altogether the expressiion pattem, Inhibitory profile and Intracellular 
localization predispose cystatin F as possible regulator of antigen proc^sssing 
and presentation [Niet al. (1998)]. 
Cystatin M 
Cystatin M was discovered in the primary tumour ceil lines. It is 
synthesized and secreted as a precursor protein [Von Heinjie (1985)]. The 
predicted molecular mass is approximately 14.3 KDa and pi of 7.8 for tfie 
mature protein. It containes a single disulphide bond [Sotimpoulou et al. 
(1997)] An N-glycosylated form of cystatin M of 20-22KDa was 
immunoprecipitated and aax>unted for about 30-40% of total cystatin M 
protein. Botii forms of native cystatin M occurred intiacellularly.Cystatin M 
resembles other memt)ers of the family in having the three conserved 
domains. It has 40% homology to human type 2 cystatins the overall 
homology between cystatin M and other cystatins range from 30-40% for 
conserved amino acid residues and 25 to 33% for identical amino acids. 
Cystatin M shows the closest homology to cystatin C, tiiey share 33% 
identical and 38% conserved amino acid residues [Sotimpoulou et al. (1997)]. 
Cystatin M is expressed by normal mammary epitiielial cells and a variety of 
human tissues but it is not expressed in many metastatic mammary tumour 
cell lines. High levels of cystatin M are present in placenta, lung, skeletal 
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muscle, kindly and pancreas Its lower level was observed in heart tissue 
[Sotiropoulou et al. (1997)]. 
FAMILY 3 (TYPE lH): KIMINOGENS 
Kininogens are the high molecular weight thiol proteinase inhibitors 
found only in plasma .In mammals, three types of kininogens have been found 
differing in size, structure and function. The largest kinin precursor, commonly 
refen-ed to as high molecular weight (HMW) kininogen, has a Mw of 88000-
114000, depending on its species and tissue origin [Kato et al. (1981)]. 
Among the smaller kininogens, a low molecular weight (LMw) kininlogen with 
a Mw of 50000-70000 is found In throughout the mammalian lineage [Muller-
Esterl et al. (1986)]. The third type, T-kininogen of MW 68000, seems to be 
unique of rats [Okamoto and Gmenbaum (1983)]. The various types of 
kininogen have the same basic structure, a heavy chain of 50-60KD at the 
amino-terminus, Vne kinin scjgment in the core part of the molecules and a 
light chain of variable length at the carboxy-termlnus [Kitamure et al .(1985), 
Lottspeich et al. (1985)]. The primary structure of the heavy chain, kinin 
portion and a segment of 12 amino acid residues are identical in HMW and 
LMW kininogens, but the structure of their light chain diverges considerably. 
HMW kininogen has a large light chain of 45-58Da which hariDOurs unique 
histidine-rich region [Sugo et al. (1980)]. The HMw kininogen light chain 
contains the binding site or prekalllkrein and factor XI. The structure of T-
kininogen closely resembles that of LMw kininogen in its heavy and light chain 
portions but differs at the amino-termlnal flanking region of the kinin segment 
[Cole et al. (1985)].The primary site of kininogen biosynthesis is the liver with 
only minor expression in other tissues. The kininogens are secretory proteins 
synthesized with a signal peptide and undergoes glycosylation. Important 
functions of kininogens are tlie release of vasoactive peptide bradykinin, by 
acting as substrate for kallikrein, intrinsic blood coagulation, acute phase 
reactions and inhibition of cysteine proteinases [Muller-Esterl et al. (1986)]. pi 
values reported for the multiple isoelectric forms of L and H kininogens fall in 
the range 4.04.9 [Ryley (1979) , Muller-Esterl et al. (1982 , 1983)]. The 
proteins are stable to temperature in the range of 50-90°C [Taniguchi et al. 
(1981)]. 
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Plasma concentrations of kininogens have been determined by radio 
immunoassay to be 109-271 pg/ml (L-kininogens) and 69-116 |jg/ml (H-
kininogen) [Adam et at. (1985), Salvesen et al. (1985)] found that three 
cystatin like segments are present in kininogens, although the first the first 
lacks preserved sequence GIn-Val-Val-Ala-Gly. It is known that the LMW-
kininogen contain no free ttilol groups [Salvesen et al. (1985)]. Kininogens 
inhibit papain, ficin, cathepsin B, H and L [Jarvinen (1979), Gounaris et al. 
(1984)]. Table 1 summarizes the various mammalian and non mammalian 
sources from where cystatins have been isolated. 
1.3 OTHER TYPES OF CYSTEINE PROTEINASE INHIBITORS 
There are a number of other cystatin or cystatin related proteins, which 
are structurally related to cystatins with no inhibitory activity against papain 
like enzymes [Turk and Turk (2008)]. CRES (Cystatin Related Epididymal 
Spermatogenic proteln./Swffon et al. (1999)], testatin (expression restricted to 
mouse pre-Sartoli cells) [Tohonen et al. (1999)], c^tatin SC and cystatin TE-1 
(expressed In testis and epididymis, respectively) P-i et al. (2002)], and 
several other genes of cystatins with no inhibitory activity were found 
expressed specifically in the male reproductive tract [Hamil et al. (2002) , 
Xiang et al. (2005) , Shoemaker et al. (2000)] indicating the existence of a 
new subgroup in the type two cystatins [Cornwall et al. (2003) , Sutton-Walsh 
et al. (2006)]. These CRE Statins show homology to cystatins, with the 
exception of the two hairpin loops responsible for the cysteine proteinase 
inhibition Their role could be regulation of proteolysis In the reproductive tract 
as well as protection against invading pathogens, as shown by cystatin 11 
[Hamil et al. (2002)]. 
The CRES protein tend to form oligomers similar to cystatin C 
[Janowski et al. (2001), Wahlbom et al. (2007)] and stefin B [Jenko-Kokalj et 
al. (2007)]. Another type 2 cystatin, cystatin 10, expressed in cartilage, 
localized in prehypertrophic and hypertophic chondrocytes Is known to be an 
inducer of chondrocyte maturation followed by apoptosis [Koshizuka et al. 
(2003)] A novel cystatin type 2 protein namely CLM expressed widely in 
normal tissues playing role in hematopoietic differentiation or inflammation, 
different from CRES was characterized by Sun and coworkers [2003] 
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TABLE -1 CP1 FROM DIFFERENT SOURCES 
Source 
African puff 
Beef 
Bovine 
Carp 
Horse shoe 
Crab 
Human 
Rabbit 
Sheep 
Goat 
Trypanasoma 
cruzi 
Tissue 
Adder 
Spleen 
Hoof 
Muscle 
Colostrum 
Ovary 
Hemocytes 
Liver 
Placenta 
Spleen 
Liver 
Skin 
Plasma 
Kidney 
Brain 
-
Mr 
13,000 
13,000 
11,406 
14,000 
12,787 
12,000 
12,600 
12,400 
12,300 
11,400 
5000-
10,000 
12.500 
280,000 
67,000 
70,300 
12,720 
11,000 
Pl 
6.5 
4.8-7.0 
-
6.2 
10.0-10.3 
-
-
-
6.0-6.5 
-
6.6 
-
-
-
-
Reference 
Evans and Barrett, 1987 
Brzinetal, 1982 
Tsushima et ai, 1996 
Bigeetal., 1985 
Hiradotetal., 1984 
Tsaietal., 1996 
Agaiwala et ai, 1996 
Green et al,. 1984 
Warwas & Samicki, 
1985 
Rinnie et al., 1980 
Pontremoli et al., 1983 
Udaka & Hayastii, 1965 
Baba et al., 2005 
Zehra et al., 2005 
Sumbul & Bano, 2006 
Monteiro et al., 2001 
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1.4 NEW MEMBERS OF THE CYSTATIN SUPERFAMILY 
The feutins and histidine-rlch glycoproteins (HRG) comprise fourth 
family of cystetins. The feutin family insists of two tendem cysfatin domains. 
Bovine feutin was first characterized by Pedersen in (1944) and its relation to 
cysfatin superfamlly was described in 1988 [Elzanowski et al. (1988)]. Human 
feutin (a2-HS glycoprotein) was confirmed in 1987 [Dziegielewska et al. (1987, 
1990) Dziegielewska and Brown (1995)]. Since then, protein and/or cDNA 
sequences of this protein have been reported for human, cow, mouse and 
Habu snake. Almost all the feutin sequences confain 12 cysteine residues, 
showing homology to the cystatins and cysfatin domains In kiniogens 
[Dziegielewska and Brown (1995)]. 
HRG has been characterized in the plasma of man. mouse, rabbit and 
cow /Leung (1993)], sharing good sequence homotogy with human and 
bovine HMW kininogen [Koide et al. (1986)]. A large number of proteins have 
been discovered recently, which posses cysfatin domains e.g. latexin [Agaard 
et al. (2005)]. However, feutin, HRG and latexin all seem to lack CPI activity. 
Thyropins 
Constitute a new family of papaln-like CP inhibitors [Lenarcic and 
Bevec (1998)], classified as family 131 [Rawlings et al. (2004)]. The p41 
invariant chain (Ii)-fragment of the MHC class Il-Ii (X)mplex 104, 105 and 
equistatin from the seai anemone [Lenarcic et al. (1997)] are best 
characterized members of this family Thyropins show Inhibitory activity 
against CPs and also towards aspartic and mefalloproteinases [Mihelic and 
Turk (2007), Lenarcic and Turk (1999)]. 
Tick cystatins 
Syalostatin L and syalostatin L2 [Kotsyfakis et al. (2007)] have been 
characterized from salivary/ glands of the tick Ixodes seapularis. Both show 
75% sequence identity and inhibit cathepsin L with a Ki of 4.7 nM and 
cathepsin V with Ki of 57 nM. 
Statphostatins 
These are specific inhibitors of staphylococcal CPs. Three members of 
this family have been described-staphosfatins A and B fi'om Staphylococcus 
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aureus and staphostatin A from Staphylococcus epidermidis [Filipek et al. 
(2003)]. 
Clitocybin 
It is a new type of CPI from a mushroom appearing to be related to 
fungal lectins and hence a new family of CPIs is suggested for them called 
mycocypins [Brzin et al. (2000)]. Chagasin Is a cysteine proteinase inhibitor 
from Tiypanozoma cruzi inhibiting both cruapain and papain, but has no 
homology with cystains [Monteiro et al. (2001)]. 
Phytocytatins 
In plants, inhibitors of CPs are known as phytocystatins. They contain 
the QXVXG region of type 2 cystatins, but also resemble stefins in the 
absence of disulphide bonds [Aral et al. (2002)], providing a transitional link 
between type 1 and type 2 cystatins. 
There are numerous phytocystatins expressed and characterized on 
the basis of protein level from com [Abe et al. (1992)], rice [Chen et al. 
(1992)1 soyabean and sugarcane [Oliva et al. (2004)]. C-temiinal extended 
phytocystatins were found as bifunctional inhibitors of papain and iegumain 
[Martinez et al. (2007)]. In addition, a "multicystatin" containing two cystatin 
like domains were isolated from cowpea leaves [Diop et al. (2004)]. 
Also there are certain plant proteins like monellin which lack the CPI 
activity but have a cystatin like ttiree dimensional structure [Grzonka et 
al.(2001)]. Phytocystatins and other inhibitors important for plant defence 
response to insect predation may act to resist infection by some nematodes 
[Koiwa et al. (1997)]. They play a crucial role in response to various conditions 
[Diop et al. (2004), Brzin and Kidric (1995)] and show great potential tools for 
genetically engineered resistance of crop plants against pests [Aguiar et al. 
(2006)1 
VARIANT CYSTATINS 
Divergent cystatins showing significant homology to stefins, cystatins 
and kiniogens have been expressed/purified and characterized from venom of 
African puff adder (Bitis arietans) [Evans and Barrett (1987)] from perilymph of 
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flesh fly larvae [Suzuki and Natori (1985)] from Drosophlla melanogaster 
[Delbhdge and Kelly (1990)]. 
1.5 EVOLUTIONARY RELATIONSHIP 
Statistical analysis of the similarities t)etween the aligned sequences in 
Cystatins is suggestive that they have evolved from a single primitive 
sequence [Barker and Dayhoff (1972)] Difference matrix of the sequences of 
the members of the superfamily revealed that the type-l forms one family and 
type II forms a second family whereas kininogens also form a single family. 
However, members of the cystatin superfamily are closely related to each 
other. [Ffg.5] demonstrates the relationship between all known inhibitory 
active human cystatin domains according to their sequence homology and 
physicochemical properties. 
The structure of the cyst<»tin superfamily indicates that the members of 
the family involed atleast six duplications of genetic material from a single 
primordial sequence to produaj the cystatins A, B, C, S and 3 segments of 
kininogens. Gene structures of kininogens show that each of the three 
cystatin like segments of kininogens are coded by three exons for which, the 
cystatin gene was the precursor [Kitamum et al. (1985)]. Some workers 
reported that only the first two of the three exons of the primitive family 2 gene 
was represented in family I cystatin gene, the segment is acquired during the 
evolution of family 2 cystatins [Keil-Dlouha (1986)].Aj]a\ys\s of amino acid 
sequence data led to the conclusion that the differences in the length of the 
polypeptides are accounted by the insertion and deletion of the genetic 
material in small blocks. Sinc^ disulphide bonds are often acquired in the 
evolution of protein but are rarely lost, it is assumed that the primitive 
precursor of the cystatin was not unlike a modern type I cystatin. The 
evolutionary relationship among the various CPIs remained largely obscure 
until Muller-Esterl et al. (1985) suggested a common evolutionary origin of 
stefins, cystatins and kininogens. 
The superfamily of mammalian CPI is constituted by atleast three 
distinct families with stefin, cystatin and kininogens as their prototype.The 
phylogenetic dendogram depicts that the divergence between chicken cystatin 
and human cystatin C and S may have occun-ed 300 million years ago, the 
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Fig-5 Schematic illustration of evolutionary relationship of 
cystatins of type I ,n, I I I 
The Figure shows evolutionary relation ship between ail known 
inhibitory active human cystatin femilies 
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Cystatin A 
Cystatin B 
Cystatin S 
Cystatin SA 
Cystatin SN 
Cystatin C 
Cystatin D 
Cystatin E/M 
Cystatin F 
Kininogen 03 
Kininogen 02 
Type I 
Type li 
Type ill 
time of appearance of first reptile. The divergence of cystatin A and B appears 
to be about 230 million years ago, before the appearance of true mammals 
[Muller-Esterl (1985)]. 
1.6 PRIMARY STRUCTURE 
Most of the member of cystatin super family are polypeptides of 98-126 
amino acids residues with Mr values falling in the range of 11000-14000 it 
can be seen that (^statin A and a are devoid of cysteine residues where as 
cystatin B and p contain one and two residues respectively. 
Cystatin F Is reported to have two or more cysteine residues apart from 
the usual four cysteine resides although tryptophan is absent from type I 
cystatin it is reported to be present in stefin C. An interesting feature of the 
stefins B is the conserved QWAG region in tiie stefins of mammalian 
origin.Val 54 is replaced with Leu 54.[Grubb et al. (1984)] The disulphide 
linked peptides have been identified from human cystatin C and chiken 
cystatin between cys 71- cys81 and cys 95 -cys 115. Anastasi et al. (1983) 
found that cystatin type I contains no free thiol groups .cystatin E apart from 
other usual conserved sequences characteristic of family 2 cystatins has a 
five residues insertion between amino acid 76 and 77 and a deletion of 
residues 91 (cystatin C numbering).M et al. (1998) deciphered the presence 
of a second trp residues, in addition to the conserved trp-106 in cystatin F. 
1.7 SECONDARY STRUCTURE 
The secondary structure of chicken cystatin and human cystatin C has 
been studied extensively. One line of evidence from analysis of amino acid 
sequence for the disfributlon of hydrophilic and hydrophobic residues, has 
predicted that hydrophilic residues are on the surface whereas hydrophobic 
regions are in the interior of the protein inhibitors like other compact globular 
proteins.Each sequence poss;es a large N-tenninal hydrophilic region (15-42 
residues) and a prominent cenfral hydrophobic region (55-70 residues) 
followed by another large hydrophilic region at C-tenninus. The secondary 
sfructure of human cystatin 0 in solution is very similar to that reported for 
chicken cystatin [Dieckmann et al. (1992)]. The crystalline form of chicken 
cystatin has been reported by [Bode et al (1988)].Both human cystatin C and 
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chicken cystatin as well as the family 1 cystatlns (A and B) consist of five 
stranded antiparallel p-pleated sheets [Martin etal. (1995) ]v/h\ch is wrapped 
around a straight five turn ci-helix. X-ray diffraction analysis showed an 
appending segment of partial a - helical in chicken cystatin [Saxena and 
Tayyab (1997)] which is not found in human cystatin C The confirmation of 
this region seems to be closer to that found in chicken cystatin pieckmann et 
al. (1993)1 
The N-terminal segment upto Val 10 seems to be flexible similar to that 
of otiier cystatins [Martin et al. (1995)]. Trp was found only in the second 
hairpin loop of cystatins [Bode et al (1988)].C\rcu\ar dichroism and computer 
prediction of secondary structtire from tfie sequence indicate that the chicken 
cystatin has about 20% a-helix, 42% p-stiiicture, 24% p-turn and 12% random 
coil structure. Janowski et al. (2001) proposed that the human cystatin C 
undergoes dimerizati'on under mild denaturing conditions. NMR studies 
revealed that the majority of the proteins are not affected by dimerization 
however, the CP binding site is significantly affected whidi accounts for ttie 
activity loss [Ekiel et al. (1997)]. 
Hence, it is concluded that hydrophobic CP binding site is involved in 
the monomer-monomer contact. The dimerization may be required for 
regulation of cystatin C inhibitory activity in vivo [Abrahamson (2001)]. Three 
dimensional swapping studies indicated the dimerization of human cystatin C 
to be a step towards protein oligomerization [Janowski et al. (2001)]. 
1.8 INHIBillON OF PROTEASES 
Specificity 
All the enzymes known to be inhibited by tiie cystatins are proteases 
with cysteine at the active sites. No example of serine, aspartic or 
metalloproteinase or non proteolytic enzymes being inhibited by cystatins is 
available. Results tiiat have been reported include tiiose on cystatin A and B 
with ti7psin, chymotiraypsin, pancreatic elastase, catiiepsin G and thermolysin 
[Fraki (1976), Green et al. (1984)]. The available data indicates that all 
cystatins Inhibit CP of papain superfamlly including papain, chymopapain, 
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papaya, proteinase II I , ficin, actinidin and the lysosomal CP and cathepsisn 
B, H and L. 
Of the t^>e I I cystatins, chicken cystatin has been shown to inhibit 
papain, ficin, chymopapain, papaya proteinase III, actinidin and cathepsin 
B,H, L and N [Possum and Whitaker (1968), Keilova and Tomasek (1974 , 
1975) Barrett (1985), Ettierigton (1976)] cystatin S inhibits papain and ficin 
[Isemum etal.(1984b)], beef colostrums cystatin inhibits papain and cathepsin 
B and H [Hirado et al. (1984)]. 
Cystatin M Inhibits papain [Sotiropoulou et al. (1997)] Cathepsin B and 
papain are inhibited by cystatin E [Ni et al. (1997)] Cystatin F inhibits papain 
and cathepsin L but not cathepsin B [Ni et al. (1998)]. Cystatin D inhibits 
cathepsin L, H and S but not cathepsin B [Balbin et al. ff994)7-Ironically, 
papain homologue bromelain from pineapple stem or fruit is not inhibited by 
cystatin. The low Mw cystatin B do not inhibit calpains, chicken cystatin 
[Johnson et al. (1984)] and human amniotic fluid [Rohrlich et al (1985)] 
Human (^statin A and chicken cystatin partially Inhibit ciostripain and 
show no inhibition of streptococcal cysteine proteinase [Green et al. (1984)] 
Ciostripain was also not inhibited by cystatin S [Isemura et al. (1984b)] 
Keilova and Tomasek (1975) showed that chicken cystatin inhibits dipeptidyl 
peptidase I, this proteinase is also known to be inhibited by human cystatin A, 
B, C, and S [Green et al (1984), Isemura et al. (1986)] cystatin a [Jarvinen 
and Hopsu-Havu (1975)] and cystatin p. He also reported Inhibition of 
lysosomal carboxypeptidase B by cystatin p 
Kinetic Behaviour 
The cystatins are the firjjt group of protein inhibitors of CP for which the 
mechanism of inhibition has been investigated, cystatins are a group of 
potent, non covalent and reversible inhibitors of CP of papain superfamily 
[Ban-ett (1987), Ekiel et al. (1997)]. Some of the reported values of Ki are 
presented in Table-2. It can be seen that the inhibition constants extend down 
to a value of 5 x 10"^ .^ Inhibition of cathepsin B tends to be weaker than that of 
papain and cathepsin H and L, except with cystatin C which is a strong 
inhibitor of cathepsin B. 
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TABLE-2 Ki VALUES FOR INHIBITION OF CYSTEINE 
PROTEASE BY LOW MW CYSTATINS 
Enzyme 
Papain 
Cath. B 
Cath. H 
Cath. L 
Dipeptidyl 
Cath. S 
A» 
0.019 
8.2 
0.31 
1.3 
33 
nd 
B' 
0.12 
73 
0.58 
0.23 
0.23 
nd 
C" 
0.005 
0.25 
0.28 
0.005 
3.5 
nd 
0.9 
1000 
8.5 
25 
nd 
0.24 
1.1 
-
0.31 
nd 
nd 
E" 
0.39 
32 
nd 
nd 
nd 
0.35 
Chicken 
cystatin 
0.005 
1.7 
0.064 
0.019 
nd 
nd 
Bovine 
stefin 
0.18 
>100 
nd 
0.0065 
nd 
nd 
Puff 
adder 
0.1 
2.7 
nd 
nd 
0.23 
nd 
Values are given in nanomolar concentration. 
nd - not determined 
a Barrett et al. (1984) Gounaris et al. (1984) and Mactileidt et al. (1986). 
h Balbin et al. (1994) 
c M et al. (1998) and d Ni et al. (1997). 
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Reactive site 
The reactive site of the folded, native cystatin molecule could obviously 
involve parts of the molecule well separated In primary sequence. The 
elucidation of the crystallographic stnjcture of cystatin / enzyme complexes 
classified the precise location of the reactive site [Fig 6 a & b]. The central 
region of the sequence contains the highly conserved block, usually Gln-Val-
Ala-Gly at 53-57, Gin 57 are common to all cystatins and inhibitory kininogen 
segments The neighbouring residues also show strong tendency to conserve 
this type of sequence. In chicken cystatin the sequence is QLVSG instead of 
QWAG [Barrett et al. (1986), Barrett (1987)]. Residues 60-62 are all 
uncharged generally with large hydrophobic side chains in small cystatins. 
The C-terminal part of the sequence tends to be very varied, although 
Cys 71 and Tyr 100 are conserved in the large majority of sequences. There 
also appear to be deletions and insertions in the C-tenninal segments that 
suggest variability in structure but the disulphide bonds presumably stabilize 
the folding of these segments in type I cystatins and kininogens. Chicken 
ystatin has Trp 104 as the reactive group during the interaction with Cp. All 
other type II cystatins also contain the conserved se<x)nd hairpin loop around 
Trp 104. Estrada et al. (1998) emphasized the role Gly4 on human stefin A 
(cystatin A) in the binding of target proteinases. Even the smallest 
replacement in this protein by site directed mutagenesis by Ala resulted 
approximately 1000, 10 and 6000-fokl decreased affinities for papain, 
cathepsin L and cathepsin B, respectively. 
As the side chain of the substituted amino acid residue became more 
bulky, the inhibitory activity of the variant decreased markedly [Shibuya et al. 
(1995)], the single cysteine residue, Cys 3 of human and bovine cystatin B 
has appreciable importance for inhibition of CP, particular for cathepsin B [Pol 
and Bjork (2001)].Jhe contact residues in the hairpin loop. Leu 73 and His 75 
when replaced by Gly it resulted in appreciably reduced affinities for papain, 
cathepsins H and B. These hvo residues contribute 20-30% of the free energy 
of binding of cystatin B. 
Replacement of the contact residue in the C-terminal end, Tyr-97, with 
Ala resulted in the loss in affinities for papain, cathepsins H and L. All affinity 
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Fig-6 Proposed model for the structure of papain and papain 
inhibitor complex 
Part a and b of the figures give a diagrammatic representation of the 
3D structure of papain and its interaction with proteases inhibitor 
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decreases were due to increased dissociation rate constants [Pol and Bjork 
(2001)]. Cystatins form tight equimolar complexes with CP Nicklin and Barrett 
(1984)]. The binding ratio between cystatin p and rat cathepsin H is found to 
be 1:1 on the basis of titration of the active site of proteinase. Abrahamson et 
al. (1987) also reported the rapid fonnation of 1:1 complex between cystatin C 
and papain. Previous studies of chicken cystatin revealed that about two 
molecules of the inhibitor are required for the inhibition of each molecule of 
papain. Nicklin and Barrett (1984) Found that dipeptidyl peptidase and papain 
competed for binding site of cystatin [Bjork et al. (1989)] contrary to previous 
report in a separate experiment cathepsin B was shown to compete for 
binding to the same site too [Nicklin and Barrett (1984)]. 
1.9 MECHANISM OF INTERACTION OF CYSTATINS WITH 
PROTEASES 
It has been established that no disulphide bond is formed between the 
active site cysteine and thie inhibitor because complexes dissociate when 
denatured without reduction as was found in chicken cystatin and kininogens 
[Gounaris et al. (1984)]. Carboxymethylation of enzyme and inhibitor does not 
prevent complex formation [Anastasi et al. (1983)]. It became clear that 
complex formation is reversible competitive and non-covalent with enzyme. 
The nature of interaction resembles the standard mechanism of 
inhibition described by Laskowski and Kato (1980). The active site of papain 
In complex with chicken cystatin is unreactive with 5,5'-dithlo-bis-(2-
nitrobenzoic acid) at pH 8, 2,2 '-dipyridyl disulphlte and f^C] iodo acetate at 
pH 4 [Nicklin and Barrett (1984)]. It has also been reported that the complex 
formation is accompanied by pronounced spectroscopic changes, most likely 
reflecting local perturbation of the environment of aromatic residues in both 
enzyme and inhibitor [Bjork et al. (1989)]. 
The mechanism of inhibition of papain by chicken egg white cystatin 
has been extensively studied. Bode et al. (1988) proposed a model for the 
interaction of cystatin with CP based on X-ray crystal structure of chicken 
cystatin and subsequent situdies based on docking experiments indicate tfiat 
three parte of the inhibitor are in close contact with the active site cleft of 
papain, the amino acid terminus with conserved Gly-9, a first hairpin loop from 
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residues 53-57, containing the prototype sequence, Q\A/AG [Barrett et al. 
(1986) , Barrett (1987)] and a second loop (residues 102-107) containing 
conserved Trp 104. Bode et al. (1988) demonstrated that the major 
contribution formed the first hairpin loop containing the QWAG sequence 
[Turk (1985), Ohkubo et al. (1984)] .According to the model of N-temiinal 
segment of cystatin which is more flexible bridges over the active site Cys 25 
residue of papain without completely burying it and additionally the side chain 
of Leu 8 binds to the S2 subsite of papain which detemiines the substrate 
specificity of papain [Drentti et al. (1976) Asboth et al. (1988)]. The side chain 
groups of QLVSG segment makes the most intimate contact with putative Si 
subsite of papain [Fig. 7J. This explains the presence of Gly 9 in close vicinity 
of Cys 25 of papain but not in direct contact with it. Removal of Leu 7 and Leu 
8 leads to approximately 5000 fold lower affinity of papain. This was 
supported by Brzin et al. (1984) who demonstrated that the truncated form of 
human cystatin C starting with Leu-Val before Gly-11 (corresponding to Gly-9 
of chicken cystatin) has virtually the same affinity for papain as the full length 
form whereas the truncated form starling with Gly 12 has been reported to be 
1000 fold weaker inhibitor [Abrahamson et al. (1987)]. However, Nycander 
and Bjork (1990) emphasized the role of trp-104 in the inhibition of CP. 
According to his model, Trp 104 of cystatin interacts primarily with two 
tryptophan side chains (Trp 177 and Trp 181) in the active site cleft of papain 
in such a manner that the indole ring of Trp 104 stacks on the side chain of 
Trp 177 and its edge lies on tile indole ring of Trp 181. 
A two step mechanism of inhibition of the lysosomal CP, cathepsin B 
by its endogenous inhibitor, cystatin C was observed by Nycarider et al. 
(1998). An initial weak interaction in which N-terminal of the inhibitor binds to 
the proteinase is followed by a conformational change. Subsequently, the 
occluding loop of the proteinase that partially obscures the active site is 
displaced by the inhibitor, bringing about another conformational change. The 
presence of occluding loop of cathepsin renders It much more susceptible to 
inhibition by cystatins as compared to other proteinases. A similar two step 
binding of cystatin A to the CP was suggested by Estrada and Bjork (2000) 
which shows tiiat the flexible N-terminal region of ttie cystatin binds 
independenfly to the target proteinases after hairpin loops. 
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Fig-7 Scheme of proposed model for the interaction of 
chicken cystatin with papain 
Interaction of chicken cystatin with papain has been illustrated 
33 
/ " : 
VI2 
I ' l l 
o 
, w 
R52 
fl-
K59 S 
o 
CYSTATIN 
1102 
Qn6 
QI07 
H 
v/\ 
Nil 
wr- wm 
PAPAIN 
/ <m5 
y 
(j«>5 
; > / \ . / 
HNH F207 S20X 1204 
1.10 PHYSIOLOGICAL FUNCTIONS OF CYSTATINS 
The present knowledge of serine proteinases and their endogenous 
inhibitors at the molecular level is much more detailed than our understanding 
of the structure and functions of thiol proteinases. Since, cystatins constitute a 
powerful regulatory system for endogenous cysteine proteinases, which are 
often secreted or leaking fi'om the lysosomes of dying or diseased cells [Ekiel 
et al. (1997)] which otherwise may cause uncontrolled proteolysis and tissue 
damage. It is established that imbalance between these endogenous 
inhibitors and thiol proteinases have been associated with various diseases. 
The activity of thiol proteinases cannot nomially be measured in body fluids, 
but can be detected extracellularty in conditions like endotoxin induced sepsis 
[Abrahamson (1994)], metastasizing cancer [Koppel et al. (1994) , Lee et al. 
(2008)] and local inflammatory processes such as rheumatoid arthritis 
[Trabandt et al. (1991)] , purulent bronchiectasis, [Buttle et al. (1990)] 
peridontitis and renal failure [Kabanda et al. (1995), Servais (2008)] 
Alzheimer's disease [Nakamura) et al. (1991), Levy (2008)] multiple sclerosis 
[Bever et al. (1995)] and muscular dystrophy [Sohar et al(1998)] which 
indicates that a tight enzyme regulation by cystatins is a necessity in the 
normal state.ln general, cyst<itin concentrations are elevated in patients 
suffering from inflammatory diseases and autoimmunity [(Barrett (1986) , 
Hansen et al. (2000), Mangge et ai (2000)] Cystatin B (p) serves a general 
protective role. The abundance of cystatin A selectively in squamous epithelial 
cells and in PMN leucocytes contrasts strongly with the general distribution of 
cystatin B and suggests a specific function connected with these types of cells 
[Kotyza and Krepla (2002)] These cells are in the front line defense against 
invading pathogens and parasite, many of which use OP for entering in the 
body. A cysteine proteinase produced by Leishmania spp. is inhibited by 
human cystatin A, B 0 and kiniinogens. [North (1982)]. 
Apart from defensive role, it is possible tiiat cystatin A is Involved 
directly in the physiology and pathology of the skin. Jarvinen et al. (1978) 
suggested that tiie inhibitor may contiibute to the keratinisation process and 
Hibino et al. (1980) demonstrated production of cystatin a in the upper 
spinous or granular cells that became keratinized. Fukuyama et al. (1982) 
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have also suggested that cystatin a is involved in the differentiation of 
epidermis on the basis of electron microscope immunolocalization work. 
Hopsu-Havu et al. (1981) demonstrated antibodies to cystatin A in patients 
witti a wide variety of dermatologicai conditions like dermatitis and psoriasis. 
Auto antibodies may be produced when tiie inhibitor leaks into the blood 
sti-eam following damage to tiie epidennis and dermis. Cystatins have also 
been implicated in other inflammatory reactions in tiie skin [Udaka and 
Hayashi et al. (1965)]. 
Alaviakko et al. (1985) reported tiiat one or two cases of AIDS showed 
profound alterations of dendritic reticulum cells revealed by localization of 
cystatin A. A role of type I cystatins has also been considered in connection 
with the control and turnover of myofibrils in the cytoplasm of muscle cells it is 
probably mediated by CP and can be modified by low MW inhibitors. Spanier 
and Bird (1982) Indicated that levels of cystatins decrease in the guinea pigs 
with a nub'itional muscular dysti-ophy induced by vitamin E deficiency. 
Cystatin A level increases in patients witii cardiovascular disease, 
sarcoidosis and hepatic cirrhosis [Hopsu-Havu et al. (1983b)]. The 
concentration of cystatin B increases in patients suffering from inflammatory 
diseases and kidney failure. 
Some reports tend to implicate the role of lysosomal CP in the 
malignancy suggesting that they may contiibute to the nutrition of tumour 
cells, to the destruction of connective tissue elements, in the invasion and 
sloughing off the metastatic cells into the circulation [Straull et al. (1990), 
Sloane and Honn (1984)] F-urthermore tiie role of cathepsins and their 
inhibitors in various types of cancers has been investigated [Sloane et al. 
(1994), Mirtii et al. (2003)] Nishida et al. (1984) have reported that cells of one 
human melanoma cell line released cystatin like inhibitor into their culture 
medium. On the contrary, a deficiency state in which the levels of the 
inti-acellular cystatin B are lowered due to mutations has been shown to 
segregate witii a form of progressive myeclonus epilepsy [Pennacchio et al. 
(1996)]. Recent observations indicate that some patiiogens produce proteins 
homologous to cystatins tiiat are capable of suppressing the host immune 
response against the pathogens through interference with the MHC class II -
restricted antigen processing In the antigen present cells of Infected host. This 
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type of pathogen induced immune suppression Is exemplified by Bm-CPI-2 
protein, a cystatin homologue secreted by filarial parasite Bnigia malayi, 
which inhibits the MHC class Il-restricted antigen processing via direct 
inhibition of multiple lysosomal cysteine proteases including cathepsins S, L, 
B and Legumain. The concentration of cystatin C may be elevated In the 
serum of patients suffering from autoimmune diseases, lupus erythematosus 
and glomerulonephritis [Brzin et al. (1984)]. 
Certain genetic disorders are linked to mutation in cystatin gene. In 
Icelandic hereditary cystatin C amyloid angiopatt^ y, a mutation in the cystatin 
C gene (CSTC) causing a single substitution (L68Q) In cystatin C gene is 
coupled to decreased concenti'ation of tills major CPI In CSF, and leads to its 
amyloid deposition in almost all tissues Including tiie cerebral arteries 
[Pennacchio et al. (1998), Grubb (1990)]. 
This deposition results In fata! cerebral haemorrhages in young non-
hypertensiveadulte. Anotiier patiiologlcal condition has been Implicated due to 
a decrease in CSF cystatin C level. That Is Guilain-Barr syndrome, chronic 
inflammatory demyellnating poly-neuropatiiy and muscular sclerosis. In these 
groups of patients, high cathepsin B activity but not cathepsin H was observed 
in CSF [Nagai et al. (2000)] Kos et al. (1997) pointed out that cystatin C level 
in the sera of advanced melanoma patients increases owing to higher levels 
of cathepsin B and H in tiiese patients. Differentiy tiuncated forms of cystatin 
C are found in tiie urine of patients with nephrological diseases [Popovic et al. 
(1990)1 
Moreover, cystatins play additional roles in human defence by being 
the members of non-immune defence system of the body against microbial 
invasion. Cell culture shows tiiat chicken cystatin C and D Inhibit tiie 
replication of polio [Korant et al. (1985)] herpes simplex virus [Bjork et al. 
(1990)] and coma virus [Collins and Gnibbs (1991)], respectively. 
Antibacterial activity of peptidyl derivative like cyclopeptides structurally based 
upon the inhibitory centre of human cystatin C were reported by 
Kasprzykowshi et al. (2000) against Streptococcus pyogenes and 
Staphylococcus aureus. Takahashi et al. (1994) also reported the inhibition of 
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staphylococcus aureus V8 by phosphorylated cystatin a in the skin cornified 
envelop of Staphylococcus aureus. 
However, the results obtained by Blankenvoorde et al. (1998) 
suggested that the growO-i of porphyromonas gingivalls Is due to the 
antibacterial sequences present in chicken cystatin and cystatin S and that it 
does not depend on the inhibition of P. gingivalls CP. Antifungal role of 
cystatin from plant sources has also been reported [Soares-costa et al. 
(2002)1 Cystatin 11 was also found to have antimicrobial activity against 
Escherichia coli. Different reports suggest possible clinical application of these 
proteins for prediction of prognosis puffy et al. (1996)]. Serum cystatin C can 
be used as a marker of GFR in patients with various renal diseases 
[Newmann etal. (1995), Servais (2008)]. 
1.11 FUTURE SCOPE 
Cysteine proteinases inhibitors of the cystatin super family are ubiquitous 
in the mammalian system. Uncontrolled proteolysis and damage are avoided 
by regulating tiie activities of endogenous proteinases. Thus they play a 
protective role.Enormous amount of progress has been made in tiie efforts to 
understand tiie stiucture, functions and evolutionary relationship of cystatin 
and tiieir target enzymes. There is rapidly growing infonnation about the 
importance of these biologically active substances in many pathological 
events. Serum cystatin C concentration has been reported to independentiy 
predict brain and cardiovascular diseases, heart failure, peripheral arterial 
disease and mortality [Shiipak et al. (2005), Samak et al.(2005), O Haire et al. 
(2005), Shipaketal. (2006)]. 
Cystatin are crucial for proper brain functioning. Alzheimer's disease is 
one of the most prevalent diseases of tiie ageing population which is 
characterized by amyloid plaques. It has been investigated ttiat lysosomal 
proteinase (cathepsins) and their endogenous inhibitors (cystatins) have been 
closely associated with senile plaques, cerebrovascular amyloid deposits and 
neurofibrillary tangles in Alzheimer's disease [Bernstein (1996), Levy (2008)] 
Cystatin C is also found to be linked witii epileptogenesis and epilepsy along 
with other neurodegenerative diseases [Mc Geer (1995)]. Thus a detailed 
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investigation of cystatins will help in understanding about the mechanisism of 
these diseases 
1.12 BRAIN 
Brain is the most important organ of the mammalian body. It is a large 
soft mass of nerve tissue contained within the cranium. The brain consists of 
five parts: the cerebrum, cerebellum, pons varilii, medulla oblongata and 
the midbrain. It is the center for regulating and coordinating body activities 
[Fig-8]. A review of the existing literature showed that Cystatins from 
mammalian sources have species as well as organ differences, ttiey differ not 
only in size but in several other properties. Therefore, in view of the reported 
differences in molecular and fuinctional properties of cystatin from various 
species and organs it was thought desirable to isolate and purify cystatin from 
a hitherto uninvestigated source and to characterize it on physicochemical 
basis. The current study has be(sn focused on identification and purification of 
cystatin from animal source Bubalus bubalis (buffalo) in a multlstep procedure 
including alkaline treatment, ammonium sulphate fractionation and gel 
filtration chromatography. The procedure has been found to be efficient and 
simple with a high percent yield and fold purification as compared to previous 
studies. The woric has involved characterization of the isolated protein. 
Studies on the isolated cystatin include molecular mass determination, 
kinetics pH and temperature stability studies, cartDohydrate content and 
sulphydryl group determination, fluorescence and UV spectral analysis. The 
work gives comprehensive information about tiie properties of a new animal 
thiol proteinases inhibitor and its characterization on the basis of its interaction 
of free radicals and neurological drugs. Confomiational studies of isolated 
cystatin have also been done, this study therefore might be Insfrumental in 
finding the relevance of the various pathophysiological associations made 
with the thiol proteinase inhibitor cystatins. 
1.13 INTERACTION OF FREE RADICALS WITH BRAIN CYSTATIN 
Oxidation and production of free radicals are an integral part of human 
metabolism. Oxygen is the ultimate electron acceptor in a closely linked 
electron flow system that produces energy in the fomi of ATP. Under certain 
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conditions, the electron flow become uncoupled, leading to production of free 
radicals, which are molecules with unpaired electrons and thus show high 
reactivity.They oxidize other molecules to gain electrons and stabilize 
themselves. The reaction produces another free radical, initiating a domino 
effect of free radical stabilization and formation [MacNin and Bendich (1987), 
Uddin and Ahmad (1995)]. The oxidative damage created by free radicals is 
referred to as oxidative stress, and has been associated with several 
degenerative diseases, including cardiovascular and inflammatory diseases, 
cancer, aging, and stroke [Machlin and Bendich (1987), Uddin and Ahmad 
(1995)]. Free radicals are produced in the cells and in the their environment 
as normal product of cellular metat>olisim Examples of free radicals include 
superoxide (O'a), hydroxyl (OH*), peroxyl (RO'2), alcoxyl radical (RO*), 
oxides of nitrogen(NO', N0*2) and thiyi (RS*) [Halliwell et al. (1995), Andrens 
(1996)1 'n addition, free radicals may be induced by reactive oxygen species 
generated in biological systems such as phagocyte activation, lipid oxidation, 
the arachidonate pathway, autoxidation of catiiecolamines, reduced flavins, 
hemoprotein and iron mediated reaction [Halliwell et al. (1995), Thomas 
(1995),] Moreover otiier molecules like H2O2 and hypochlorous acid altiiough 
not themselves free radical t:an lead to generation of free radical . It is well 
known that free radicals cause cell damage through mechanisms of covalent 
binding and lipid peroxidation with subsequent tissue injury [(Albina (1998). 
The highly reactive species refered to as ROS causes cellular damage by 
oxidizing proteins, membrane lipids, and DNA. 
Mitochondria are an important source of ROS (reactive oxygen 
species) within most mammalian cells [Andreyev et al. (2005), Adam and 
Chinopoulos (2006),]. The ROS production contiibutes to mitochondrial 
damage in a range of patfiologies [Balaban et al. (2005),]. Consequentiy, 
knowledge of how mitochondria produce ROS is vital to understand a range of 
currently important biomedical problems [Fig-9]. 
The first report that the respiratory chain produced ROS came in 1966 
[Jensen (1966)], followed by tiie pioneering work of Chance and colleagues 
who showed that isolated mitochondria produces H2O2 [Chance et al. 
(1979)].LaieT, it was confinned that this H2O2 arose from the dismutation of 
superoxide (O2—) generated within mitochondria [Loschen et al. (1974)] 
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Fig-9 Overview of mitochondrial ROS production 
ROS production by mitochondria can lead to oxidative damage to 
mitochondrial proteins, membranes and DNA, impairing the ability 
of mitochondria to synthesize ATP and to carry out their wide range 
of metabolic functions, Mitod i^ondrial oxidative damage can also 
increase the tendency of mitctchondria to release intermembrane 
space proteins such as cytochrome c (cyt c) to ttie cytosol by 
mitochondrial outer membrane permeabilization (MOMP). 
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Antioxidant agents of natural origin have attracted special interest 
because they can protect human body from free radicals [Osawa et at (1990), 
Houghton et al (1995 ]. The production of these reactive species in healthy 
organisms is approximately balanced by antioxidant defense systems. 
However, an organism may be suffering from so-called 'oxidative stress' 
while experiencing disturbance in the pro-oxidant-antioxidant balance in favor 
of the former, leading to potential damage [(Halliwell and Gulteridge, 1999)]. 
When an excessive amount of oxygen free radicals are produced or defense 
mechanisms are impaired, oxidative damage may occur and this appears to 
be important in contributing to several pathological conditions like aging, 
carcinogenesis and stroke. Oxidative damage to membrane lipids causes 
changes in the structure of the membrane which usually result in a more rigid 
membrane that will cause changes in the activity of essential membrane 
proteins such as Na/K-APTase enhanced oxidative stress seems to have an 
important contribution to brain aging in general and neurodegenerative 
diseases in specific. Therefore it becomes more and more important to 
develop neutraceuticals dmgs that possibly are neuroprotective.The brain is 
the most susceptible organ to oxidative damage due to its high oxygen 
demand [Commenges et a!. (2000), Elevated oxygen consumption may lead 
to oxidative stress. The pathology of aging-associated neurodegeneration is 
Increasingly linked to oxidjatlve and nitrosative stress {Eckert et al (2003), 
Barja (2004)]. 
Cystatins the natural inhibitor of cystiene proteases have received 
much attention in the last two decades due to their potential In regulating the 
function of cystiene proteinases. Alteration in proteinases to their inhibitor 
ratio contribute to the progression of several pathological conditions for 
example Cystatins are involved In Alzheimer disease, inflammation tumor 
growth and metastasis these are typical examples of pathological processes 
that are the result of imbalance between enzymes and their physiological 
inhibitors [(Blankenvoorde et al. .2000)] There Is now good evidence that 
proteins are major targets for oxidants and the protein oxidation plays a very 
important role In several pathological conditions. Thus In view of this present 
study was canied out to see the effects of oxidative stress produced by 
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photosensitized riboflavin, hydrogen peroxide nitric oxide radicals and 
hypochlorous acid on purified brain cystatin. 
NITRIC OXIDE INDUCED MODIFICATIONS OF BC 
Nitric oxide is a gas synthesized by a family of enzymes present in the 
cells of the body. NO is a molecule with pleiotropic effects in different tissue. 
Nitric oxide ( NO) in biological tissues is catalysed by specific enzymes nitric 
oxide synthases (NOS) in a reaction leading to the oxidation of L -arginine to 
L-citrulline via five electron oxidative reaction [Ghafourifar and Cadenas 
(2005), and Virginia et al. (2003)] NO synthases (NOS), Is a family of 
enzymes vwth four major types: endothelial, neuronal, inducible and 
mitochondrial. They can be found in almost ail the tissues and they can even 
coexist in the same tissue. NO is a good vasorelaxant agent, it works as a 
neurotransmitter when produced by neurons [Bredt and Snyder (1994)]. it is 
also involved in defence when produced by immune and glial cells [Guix et al. 
(2005)] NO is themnodynamically unstable molecule and tends to react with 
other molecules especially proteins resulting in their oxidation, nitration and 
nitrosylation, witii the concomitant effects on many cellular mechanisms. 
However, under pathophysiological conditions NO has damaging effects 
[Fig.lOJ. NO is found to be involved in neural disorders involving oxidative 
stress such as Alzheimer's disease [Tran et al. (2003)] ischemia 
jThiyagarajan et al (2004)] Parkinson's disease [ToiTeilles et al. (1999)] 
Huntington's disease [ButterTied et al (2001)] and multiple sclerosis [Khal et al. 
(2003)] over production of resactive niti"ogen species (RNS) is called nitrosative 
stress [Klat and Lamas (2000) and Ridnour et al. (2004)]. 
This may occur when the generation of reactive niti'ogen species in a 
system exceeds tiie system's ability to neutralize and eliminate tiiem. 
Nitrosative sti-ess may lead to niti"osylation reactions that can alter tiie 
structure of proteins [Fig-11] and so inhibit tiieir normal function.Reactive 
nitrogen intennediates, such as nitric oxide (NO.), peroxynitrite (ONOO) and 
nitrogen dioxide {N02)has also been shown to play an important role In tiie 
Inflammatory processes [Clancy and Abramson (1995)]. 
Peroxyniti'ite (ONOO) is a powerful oxidant species, which can 
be formed in vivo by the non enzymatic reactions of nitiic oxide (NO) and 
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Fig-10 Formation of NO in the vasculature and the effects of 
SOD 
The (shear stress) activates endothelial NOS in endothelial cells 
(EC), resulting in the synthesis of NO from arginine. The NO is 
freely diffusible and enters vascular smooth muscle cells (VSMC), 
where it binds reversibly to soluble guanylate cyclase (sGC), 
resulting in the formation of cGMP and ultimately vessel relaxation. 
In competition with the binding to NO is the reaction of NO with 
O2*" which is inhibited by SOD or results in the formation of 
peroxynitrite (0N00-). 
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Fig-11 Comparison of the oxidation reactions mediated by 
the Fenton reaction and ONOOH 
Before the proposal that ONOOH (peroxynitrous acid) was produced 
biologically, the predominant mechanism thought to cause oxidation 
and hydroxyiation was the Fenton reaction. This is shown In this 
simplified scheme in which H2O2 is shown to be the source of the 
powerful OH" radical which had been shown to mediate many 
oxidative reactions, including thiol oxidation and phenol 
hydroxyiation. NO and O2*" react together to form ONOOH .which is 
then capable of mediating oxidation and hydroxyiation reactions 
which do not require the participation of transition metals, and is 
inhibited by SOD but not caitalase. A reaction which is not mediated 
by the Fenton reaction, but is catalysed by ONOOH, is nitration of 
tyrosine residues. 
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superoxide anion at an eirtremely rapid rate limited only by diffusion. At 
physiological pH ONOO is protonated form peroxynitrous acid which rapidly 
decomposes forming highly reactive oxidant species especially in the 
presence of carlwn dioxide. [Ferdinandy (2006) Beckman et al. (1990) Saren 
etal. (1990)1 
N0*+02- • ONOO-
ONOO+H* • ONOOH 
ONCK)H • OH +N02" 
HYPOCHLOROUS ACID [HOCQ 
It Is a chlorinating agent and potent oxidant generated In neutrophiles 
by the reaction of chloride ion witti hydrogen peroxide catalyzed by 
myeloperoxidase (MPO) [Foote et al. (1983)] 
H2O2+CI -??^ HOCI+OH* 
HOCI is believed to be the major oxidant produced by neutrophils 
under physiological conditions [Kettle and Winterboum (1997)] It reacte with a 
wide variety of biological molecules and is known to cause tissue damage 
[Winterboum (1985)] Reaction of HOCI with amino adds, peptides and 
proteins has been the subject of extensive sbjdy, and it has been 
demonstrated that such processes are Important in both bacterial cell killing 
and human disease [Hazel et al. (1994), Yang et al. (1997)] Active 
myeloperoxidase has been identified in human atherosclerotic plaque tissue 
[Daughertyet al. (1994]), as have HOCI-modified apollpoprotein B-100 [from 
low-densjty lipoproteins (LDLs)] and other proteins [Hazel et al. (1996)]. 
Treatment of proteins with HOCI results in direct oxidative damage to 
the protein (alteration of amino acid side-chains, protein fragmentation and 
dimerization) and renders the protein more susceptible to degradation by 
proteolytic enzymes [Davis et al. (1993) .Hazel et al. (1994), Yang et al. 
(1997),Hazel et al. (1996), Vissers and Winterboum (1991)] For example, 
exposure of fibronectin to HOCI results in changes to both the primary and 
tertiary structure of the protein and increases the susceptibility of the protein 
to degradation by elastase [Vissers and Winterboum (1991)]. 
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Certain amino acids are particulariy susceptible to modification by 
HOC!. Tyr and Phe (free amino acids or in proteins) undergo ring chlorination, 
and these materials have been employed as markers of HOCI-induced 
damage [Kettle (1996), Leeuwenburgh (1997)]. 
Protein aggregation by HOCI could contribute to Inflammatory tissue 
injury, including the eariy stages of atherosclerosis.The mechanism of HOCI-
mediated protein aggregation, and the properties that make some proteins 
more susceptible than othei's. 
HYDROGEN PEROXIDE [H2O2] 
Hydrogen peroxide (H2O2) is a very pale blue liquid, which appears 
colouriess in dilute solution. It is a weak acid, has strong oxidizing properties, 
and is a powerful bleaching agent. It is used as a disinfectant, antiseptic, 
oxidizer, in organisms hydrogen peroxide is naturally produced as a byproduct 
of oxygen metabolism, virtually all enzymes catalyzing this reaction are called 
as peroxidases, which harmlessly and catalytically decompose low 
concentrations of hydrogen peroxide to water and oxygen. Scientists found 
that hydrogen peroxide is released after tissues are damaged .Antimicrobial 
levels of ROS are produced by the mammalian host defense to kill invading 
bacteria and limit bacterial colonization thiol proteins are the main target of 
H2O2 upon oxidative stress. 
Oxidatively modified thiol groups appear to be specifically sensitive to 
either hydrogen peroxide or NaOCI stress. These results indicate that 
individual oxidants targets distinct proteins in vivo. H2O2 can freely cross 
membrane and in the presence of iron or copper it is prone to participate in 
fenton reaction. 
H2O2 is able to induce oxidative stress and it can cause, oxidative 
damage to proteins relatively small concentration of hydrogen peroxide 
fractions of (mM) are sufficient to carry out the reactions [Germat (1982)] 
H2O2 in addition produces highly reactive molecules through hydroxyl radical 
or peroxidase action can exert a number of direct effect on cell organelles and 
enzymes [Ramasarma (1990)] Wide range of free radical are generated in 
the living system [Table -3] 
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TABLE -3 FREE RADICALS OF THE LIVING SYSTEM 
S.No 
1 
2 
3 
4 
5 
Name 
Hydrogen 
atom 
Superoxide 
Hydroxy! 
Peroxyl, 
alkoxyl 
Oxides of 
nitrogen 
Formula 
H* 
02 -
OH* 
RO2' , 
RO* 
NO*, 
N02* 
Comments 
The simplest free radical 
An oxygen centered radical 
An oxygen centered radical :the most 
highly reactive oxygen radical 
An oxygen centered radicals formed 
during the break down of organic 
peroxidase 
Both are free radicals NO* is fonned in 
vivo from the Amino acid L -arginine, 
NO2* is made when NO* reacts with 
O2 and is found in polluted air and 
smoke from burning organic materials 
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EFFECT OF RIBOFLAVIN ON CYSTATIN 
Riboflavin also known as vitamin B2 is an easily absorbed 
micronutrient with a key role in maintaining health in humans and animals.lt is 
the central component of the cofactors FAD and FMN, and is therefore 
required by all flavoproteins. Riboflavin is yellow or yellow-orange in color and 
in addition to being used as a food coloring it is also used to fortify some 
foods. [Yang and Mccomick (1965)]. some substrate (typically amines amino 
acids and some aromatic compounds) are apparency oxidized [ Frisell 
Chung and Mackenzie (1959)] photosensitized destruction of amino acids 
and nucleotide bases has been used to induce chemical modification in 
protein and nucleic acids [Simon (1967)]. 
SUPEROXIDE 
Superoxide may serve important biological function such as 
intracellular signaling and cell growth regulation. Auto oxidation reactions in 
which compounds such as catecholamine ascorbic add are alleged to react 
directly with O2 to form O2*". Extra cellular O2* is produced in vivo by several 
cell types other than phagocytes including lymphocytes fibroblast Generation 
of O2'" ,HOCI and H2O2 by phagocytes is known to play important part in the 
killing of several bacterial cciil and fungal strains. 
O2*- combines with NO* the resulting peroxynitiite may be directly 
cytotoxic examples by oxidizing essential - SH groups on proteins [Radi at al. 
(1990)]. Peroxynitiite can also decomposes to generate a range of toxic 
species including OH*, NO2 * and NO2* [Beckman etal. (1990)] 
02* +NO* • ONOO-
ONOO" + H* • OH •+ NOz* 
Because NO* is a vasodilator agent tiie ability of O2* to remove It can produce 
vasoconstiictor effects [Moncada et al. (1989)]. 
FLAVONOIDS 
Flavonoids are natural antioxidants derived from plants and commonly 
found in foods, such as fruils and vegetables. They are the most commonly 
known compounds for their antioxidant activity. Flavonoids are commonly 
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referred to as bioflavonoid. They are biological in origin. There are several 
subclasses of flavonoids; flavanols, flavanones, flavones, isoflavones, 
anthocyanidins, and flavonols [Hollman and Katan (1997)J.The divisions in 
flavonoid subclasses are based on structural properties. The flavanols are 
found in red grapes and red wine, flavanones are in citrus foods, flavones are 
in green leafy spices, isoflavones are found in soy foods, anthocyanidins are 
in hemes, and flavonols are found in almost all foods [Beecher (2003)]. 
Flavonoids have been refen-ed to as natural biological response modifier 
because of their inherent ability to modify the body reactions. They show anti 
allergic, anti-Inflammatory, anti microbial and anticancer activity [Yamammoto 
and Gaynor (1989)]. 
EFFECT OF CURCUMIN AS SCAVENGER 
The rhizome of tutineric Is widely used in indigenous medicine. 
[Nadkami (1954)] A paste made from powdered rhizome of Curcuma longa 
Linn, mixed with slaked lime applied locally, an ancient household remedy for 
sprains, muscular pain and inflamed joints. It is also applied in poultices to 
relieve pain and inflammation. Curcumin is yellow colored phenolic pigment, 
[Fig-12a]. [Cooper et al. (1994)] obtained from powdered rhizome of 0. longa 
Linn. (Family-Zingiberaceae). 
It is extensively usetj in the traditional Indian medicine and used to 
treat a wide variety of diseases. Its therapeutic effects well studied, anti-
inflammatory, [Arora et al. (1971)] antibacterial, [Negi et al. (1999)] antiviral, 
[Bourne et al. (1999)] antifungal, [Apisariyakul et al. (1995)] antitumor, 
[Kawamori et al. (1999)] antispasmodic [Itthipanichpong (2003)] and 
hepatoprotective./" Park et al.(2000)] Recently, its potential utility in 
autoimmune deficiency syndrome (AIDS) has been demonstrated./" Mazi//nc/er 
et al. (1996), James (1993)] Curcumin acts as a free radical scavenger and 
antioxidant, inhibiting lipid peroxidation. Curcuminoids are potent inhibitors of 
cytochrome P450 [ShukIa (2003)] Curcumin was found to be a very potent 
antioxidant./ Sharma (1976), Iqbal et al. (2003)] It was found to generate 
hydroxyl radicals through the Fenton reaction by reducing Fe3+ to 
fe2+.[Elizabetti, Rao (1989)]. 
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SCAVENGING EFFECT OF QUERECITIN ON BC DAMAGE 
Quercetin, a major representative of the flavonol subclass, has received 
considerable attention. Dietary Sources : Fruits and vegetables - particularly 
citrus fruits, apples, onions, parsley, tea, and red wine - are the primary 
dietary sources of quercetin /Fig-f2f»/.Quercetin and its glucosylated forms 
represent 60-75% of flavonoid intake [Bouktaib et al. (2002)]. Quercetin has 
displayed the ability to prevent tihe oxidation of low-density lipoproteins (LDL) 
by scavenging free radicals and chelating transition metal ions. As a result, 
quercetin may aid in the prevention of certain diseases, such as cancer, 
atherosclerosis and chronic inflammation and brain disease. [Murota and 
Terao (2003)]. The oxidation of low-density lipoproteins (LDL) can result in the 
fonnation of atherosclerotic plaques, leading to cardiovascular disease 
[Hollman and Katan (1997)]. However, several studies have illustrated 
quercetin's ability to inhibit LDL oxidation. The vulnerability of brain lipid 
membranes to lipid peroxidation thought to lead neurodegenerative disease, 
such as Alzheimer's and Parkinson's disease [Balazs and Leon (1994)]. 
Balazs and Leon (1994) found that oxidative stress occurring in the brain 
membrane lipids is associated with the extracellular accumulation of amyloid 
beta-peptide, which precedes neural losses in Alzheimer's patients. Yet, 
formation of amyloid plaques can be prevented by taking antioxidants [Ansari 
etal. (2008), Harmanetal. (1976)]. 
In this situation, quercetin does not only stop the propagation of lipid 
peroxidation, but also increases glutathione (GSH) levels [Ansari et al. 
(2008)] GSH is part of the neuron's defense against oxidative damage. 
When the superoxide radical is formed, the radical can be converted to 
the hydrogen peroxide radical by superoxide dismutase; however, GSH can 
convert hydrogen peroxide to oxygen and water, preventing tiie formation of 
free radicals [Balazs and Leon (1994)]. 
Quercetin can also reduce inflammation by scavenging free radicals. 
Quercetins, and otiier flavonoids, have tiie structure to act as powerful 
antioxidants, and have often proven so in vitro. Quercetin, being a major 
constituent of ttie flavonoid intake, could be key in fighting several chronic 
degenerative diseases [Bouktaib et al. (2002)]. 
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0% 
GLUCOSE: 
It is found in considerable concentration in the fruits and in honey. 
Glucose is very important for the body especially for the brain and red blood 
cells. Glucose act as scavenger of OH. In physiological concentration and 
therefore may serve an antioxidant role in the biological systems [Sagone 
(1983)]. 
Mannitol: 
Sodium azide: 
Thiourea: 
Potassium iodide: 
Sodium benzoate: 
scavenger of hydroxyl radical 
scavenger of singlet oxygen 
scavenger of hydroxyl radical 
scavenger of flavin triplet 
scavenger of hydroxyl radical 
1.14 ANTIDEPRESSANT DRUG 
An antidepressant is a psychiatric medication used to alleviate mood 
disorders, such as major depression. Drugs including the monoamine oxidase 
inhibitors (MAOIs), tricyclic antidepressants (TCAs). tetracyclic antidepressants 
(TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs) are most commonly associated 
with the term. Despite the name, antidepressants are often used to treat other 
conditions, such as anxiety disorders, obsessive compulsive disorder, eating 
disorders and chronic pain. 
AIVIITRIPTYLINE HYDROCHLORIDE: 
Amitriptyline Hydrochloride is a tricyclic antidepressant drug. It is a 
white, odoriess, crystalline compound which is freely soluble In water; it is 
usually dispensed In tablest form. In terms of Its mechanism of action, 
amitriptyline inhibits serotonin and noradrenaline reuptake almost equally. 
Amitriptyline is approved most commonly for the treatment of major 
depression. It is used to treat various forms of depressions like pain 
associated with the nerves (neuropathic pain), and to prevent migraine 
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headaches. [Fig-13a] Amitiiptyline may be prescribed for other conditions 
also sudi as insomnia [Endep Consumer Medicine Information (2005)], 
rebound headache, chronic pain, chronic cough, postherpetic neuralgia 
(persistent pain following a shingles attack), diabetic peripheral neuropathy, 
and neurological pain Typically lower dosageslO to 50 mg daily are required 
for pain control [MedlinePlus Drug Infomiation (2008)]. 
Common side effects of using amitriptyline are mostly due to its 
anticholinergic activity, including weight gain, dry mouth, loss of appetite, 
drowsiness, muscle stiffness, nausea, constipation, nervousness, dizziness, 
blurred vision and urinary retention and insomnia. Some rare side effects 
include tinnitus, lip and mouth ulcers and hepatic toxicity. 
FLUOXETINE: 
Fluoxetine (b^ ade name Prozac) is an antidepressant of the selective 
serotonin reuptake inhibitor (SSRI) class. [Fig-13b] Fluoxetine is approved for 
tiie treatment of major depression (including pediatric depression), obsessive-
compulsive disorder (in both Adult and pediatric populations), anorexia 
nervosa, panic disorder and premenstiual dysphoric disorder./Prozac 
Phanvacology, Phamnacoldnetics, Studies, Metabolism (2007)]. The 
bioavailability of fluoxetine is relatively high (72%), and peak plasma 
concentrations are reached in 6 to 8 hours. It significantiy binds to plasma 
proteins, mostiy albumin. Fluoxetine is metabolized in the liver by isoenzymes 
of the cytochrome P450 system, only one metabolite of fluoxetine, 
norfluoxetine (demethylated fluoxetine), is biologically active. The extremely 
slow elimination of fluoxetine and its active metabolite norfluoxetine from the 
body distinguishes it from otiier antidepressants. Fluoxetine has been 
associated with related movement disorders p.eo (1996)i Gerber, Lynd 
(1998); Caley (1997)] Fluoxetine taken during pregnancy also increases rate 
of poor neonatal adaptation. [Expert Panel Report on Reproductive and 
Developmental Toxicity of fluoxetine (2004)]. 
Fluoxetine and norfluoxetine if taken in higher doses inhibit many 
isozymes of ttie cytochrome P450 system that makes dmg metabolism 
possible [Sandson et al (2005) Joy, Adams, Lawrie (2006)] The simultaneous 
use of fluoxetine witii serotonergic agents biptans and ti^amadol can result in 
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rare, but potentially life-threatening adverse drug reaction called serotonin 
syndrome. 
HALOPERIDOL 
Haloperidol is a typical antipsychotic drug./Fig-f3c/.lt is an older 
antipsychotic drug used in the treatment of schizophrenia and more acutely, in 
the treatment of acute psychotic states and delirium. Due to its strong central 
antidopaminergic action, it is classified as a highly potent neuroleptic drug and 
possesses a strong activity against delusions and hallucinations, ttie 
peripheral antidopaminergic effects of haloperidol account for its strong 
antiemetic activity. 
The drug is rapidly absort)ed. Plasma-levels readi their maximum 
within 20 minutes after injection. The bioavailability is 100% and the very rapid 
onset of action is seen within about ten minutes. The duration of action is 3 to 
6 hours. Plasma levels of 4 micrograms per liter to 20 micrograms per liter are 
required for therapeutic action. A comprehensive review of haloperidol has 
found it to be an effective agent in ti^eatinent of symptoms associated with 
schizophrenia. [Joy, Adams, Lawrie (2006)] Haloperidol is also used in the 
control of tiie symptoms of acute psychosis, hyperactivity and aggression. The 
risk of tile facial disfiguring is around 4% per year in younger patients. [Joy, 
Adams, Lawrie (2006)]. 
DONEPEZIL 
Donepezil, mari<eted under tiie ti-ade name Aricept,ls a reversible 
acetylcholinesterase inhibitor./ Birks, Harvey (2006)]. Its main therapeutic use 
is in the treatinent of Alzheimer drug where it is used to increase cortical 
acetylcholine, it has an oral bioavailability of 100% and easily crosses tiie 
blood-brain bamer. It has a half life of about 70 hours. Alzheimer disease is 
the most common cause of dementia and is a primary degenerative disease 
of the brain of unknown cause. Onset is usually late in life with increasing 
impairment of memory, developing gradually into a global impairment of 
cognition, orientation, linguistic ability and judgement. Acetylcholine is an 
important neurotransmitter associated witti memory, and abnonnalities in 
cholinergic neurones (including cell loss) are among the many neurological 
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and neurochemical abnormalities that develop in Alzheimer disease. One 
approach to lessening the impact of these abnomnalities is to inhibit the 
breakdown of acetylcholine by blocking the relevant enzyme. Tacrine (another 
Alzheimer drug) was the first compound approved as a treatment for 
Alzheimer disease (AD) in the US and worked for the disease, but caused 
severe side effects, donepezil, is a second generation cholinesterase inhibitor 
and appears to be highly specific, with relatively few side effects [Birks , 
Melzer (2000)].Donepez:\\. [Fig-13d] and tacrine can bind proteins, donepezil 
is metabolized by CYP3A4 and CYP2D6. [Jann et al. (2002)]. 
Even small structural differences in protein conformation can lead to 
drastic changes in functional parameters. [ Sneppen, Zocchi, (2006)] Addition 
of small molecules such as substrates, coenzymes, inhibitors and activators 
that bind especially to the native state and can alters the delicate balance of 
various interaction in protein. In this regard, many drugs, particularly those 
with local anesthetic, tranquillizer, and antidepressants exert their activity by 
interaction with biological membranes. These drugs are carried to their sites 
of action by means of protein carriers at which they bind with different 
affinities. Accumulation of drug molecules at certain sites in the body causing 
a localized high concentration, Adverse drug reactions [Wen, Ye (1993)] and 
ligand induced protein structure conformational changes [Takeda et al (1988)] 
are major problems complicating drug medical therapy. Therefore, studies 
which combine the study of the conformational changes in proteins through 
variations of extemal parameters such as pH, temperature and the analysis of 
the binding mechanism between proteins and antidepressant drugs and the 
stmcture of the resulting complexes are of particular interest. These studies 
enable to elucidate how ligand affinity is regulated and how the protein 
conformation is altered upon omplexations [Sneppen, Zocchi (2006)] ivhich 
are of crucial importance in a vast range of important biochemical 
phenomena. 
1.15 NEUROTRANSMITTERS 
Neuroti-ansmitters are endogenous chemicals which relay, amplify, and 
modulate signals between a neuron and another cell. [ Di Chiara, Loddo, 
Tanda (1999)] They are packaged into synaptic vesides that cluster beneath 
56 
o 9 
UJ 
Q. O 
< 
X 
N 
m 
OL 
UJ 
z 
o 
Q 
UJ 
z 
m 
>-
Q. 
< 
z 
H-
UJ 
X 
o 
D 
the membrane on the presynaptic side of a synapse, and are released into the 
synaptic cleft, where they bind to receptors in the membrane on the 
postsynaptic side of the synapse. Release of neurob'ansmitters usually follows 
arrival of an action potential at the synapse, but may follow graded electrical 
potentials. Low level "baseline" release also occurs without electrical 
stimulation. Amino acids, peptides, and monoamines are Included into 
neurotransmitters. Major neurotransmitters are amino acids and peptides 
glutamate, aspartate, serine, glycine and y-amino butyric acid (GABA), 
Monoamines like Dopamine (DA), Norepinephrine (noradrenalin) epinephrine 
(Adrenaline), serotonin, melatonin. Others neurotransmitters Include 
acetylcholine (ACh), adenosine and histamine 
AMINO ACIDS NEUROTRANSMITTER 
An amino acid neurotransmitter is a chemical substance which is able 
to transmit a nerve message across a synapse. Neurotransmitters (chemicals) 
are packaged into vesicles that cluster beneath the axon tenninal membrane 
on the presynaptic side of a synapse in a process called endocytosls. Amino 
acid neurotransmitter are released by the mechanism of exocytosis is 
dependent upon calcium (Ca^*) concentration and Is a presynaptic response. 
There are inhibitory amino acids (lAA) and excitatory amino acids (EAA). The 
lAA include GABA, Glycine, P-Alanine, and Taurine. The lAA depresses the 
activity of post-synaptic cells. [Hugo (2002)]. The EAA are L-Glutamate, L-
Aspartate, L-Cysteine, and L-Homocysteine. These neurotransmitter systems 
will activate post-synaptic cells. 
MONOAMINE NEUROTRANSMITTER (DOPAMINE) 
Dopamine, the Monoamine neurotransmlttersare neurotransmitters and 
neuromodulators that contain one amino group that is connected to an 
aromatic ring by a two-carbon chain (-CH2-CH2-). All monoamines are derived 
from aromatic amino acids like phenylalanine, tyrosine and tryptophan. 
Among organic compounds, there are six monoamines classified as 
neurotransmitters in addition to non-monoamines such as acetylcholine, 
purines, certain fatty acids, and around fifty peptides including some 
hormones The six monoamine neurotransmitters include: 
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Dopamine, produced from phenylalanine and tyrosine, Norepinephrine or 
noradrenaline, Epinephrine or adrenaline. Serotonin, also known as 5-
hydroxytryptamine or 5HT, Melatonin .Histamine, produced from histidine 
Monoamines are moved into or out of cells \na a class of proteins 
called monoamine transporters.After release into the synaptic cleft, 
monoamine neurotransmitter action is ended by reuptake into the presynaptic 
terminal. There, they can be repackaged into synaptic vesicles or degraded 
by the enzyme monoamine oxidase (MAO), which is a target of monoamine 
oxidase inhibitors, a class of antidepressants. 
Antidepressants and psychoactive drugs often affect the monoamine 
transporters rather than the monoamine itself. A monoamine neurotransmitter 
relays, amplifies, and modulates electrical signals between two neurons. 
MAOIs [Monoamine oxidase inhibitors or antidepressants] prevent breakdown 
of monoamine neurotransmitters, therefore increasing the concentrations of 
neurotransmitters in the brain. In the present study two most important 
neurotransmitters that is dopamine and serotonin have been investigated for 
their interaction with cystatin. 
DOPAMINE 
Dopamine abbreviated is "DA.". [Fig-14a] has the chemical formula 
C6H3(OH)rCH2-CH2-NH2. Itsi chemical name is "4-(2-aminoethyl) benzene-
1,2-diol" They are formed in the brain by the decarboxylation of dopa and 
essential for the normal functioning of the central nervous system. A reduction 
in its concentration within the brain is associated with Parkinson's disease and 
its high concentration leads to schizophrenia. Dopamine is manufactured 
inside dopamine neurons in a controlled manner from the amino acid 
precursor L-tyrosine, which mammals obtain through the normal diet. 
Dopamine is then stored in vesicles within the nerve terminals, which may 
fuse with the cell membrane to release dopamine into the synapse. [Fig-15]. 
Dopamine has many functions In the brain, including important roles in 
behavior and cognition, voluntary movement, motivation, inhibition of prolactin 
production (involved in lactation), sleep, mood, attention, and learning. 
Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is 
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dopamine) are present chiefly in the ventral tegmental area (VTA) of the 
midbrain. [Fig-16] 
SEROTONIN 
Serotonin (5-hydroxytryptamine or Serotonin). [Fig-14b] is a 
monoamine neurotransmitter. It is found extensively in the gastrointestinal 
tract of animals, and about 80 to 90 percent of the human body's total 
serotonin is located in the gut, where it is used to regulate intestinal 
movements. [Berger et al. (2009)] The remainder is synthesized In 
serotonergic neurons in the central nervous system (CNS) where it has 
various functions, including control of appetite, mood and anger. 
Serotonin is not only found in animals, but also in fungi and 
plants,/KaA7fif et al. (2009)] Including fruits and vegetables. Serotonergic action 
Is terminated primarily via uptake of Serotonin from the synapse. This is 
through the specific monoamine transporter for Serotonin, SERT, on the 
presynaptic neuron. This chemical is found in very low amounts In people 
diagnosed with depression compared to normal individuals. Serotonin works 
as a neurotransmitter and helps with the modulation of things such as anger, 
appetite, sleep, and mood. People with depression often have impaired 
serotonin genes. Selective serotonin (Serotonin) reuptake inhibitors (SSRIs) 
are efficacious in depression because of their ability to Increase Serotonin 
neurotransmission. The MAOIs (Antidepressants) prevent the breakdown of 
monoamine neurotransmitters (including serotonin), and therefore increase 
concentrations of the neurotransmitter in the brain. The tricyclic antidepressants 
(TCAs) inhibit the re-uptake of botfi serotonin and Dopamine. Amytriptyline, 
flouxetine and Haloperidol have fewer side-effects and fewer interactions with 
other drugs. Therefore these antidepressants have been chosen to 
Investigate their effect on cystatin. If neurons that make serotonin -
(serotonergic neurons) - are abnomial in infants, there is a risk of sudden 
Infant death syndrome (SIDS). [Paterson et al. (2006)] Low levels of serotonin 
may also be associated with intense spiritual ejqjeriences. [Lars and 
Jacqueline (2003)] 
It is known that the distribution, free concentration and the metabolism 
of various drugs are strongly affected by dmg-protein Interactions in the blood 
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FIG-14 CHEMICAL STRUCTURE OF NEUROTRANSMITTERS 
a) DOPAMINE 
b) SEROTONIN 
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DOPAMINE 
SEROTONIN 
Fig-15 Illustration of the major elements in a prototypical 
synapse. 
Synapses are gaps between nerve ceils. These cells convert their 
electrical impulses into bursts of chemical relayers, called 
neurotransmitters, which travel across the synapses to receptors on 
adjacent cells, triggering electrical Impulses to travel down the latter 
cells. 
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DOPAMINE SYSTEM. 
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effectiveness carries \he risl< of side effects and an increase of therapeutic 
action of free fractions of drugs. This can be dangerous when exhibiting toxic 
effect [Hu et al. (2005)]. Regulation of cysteine proteinases and their inhibitors 
are of utmost importance in neurodegenerative diseases like Alzheimer and 
Parkinsons. Protease - antiprotease imbalance accelerates disease 
progresssion. In the present study, the effects of antidepressants and 
neurotransmitters have been studied to explore the drug induced protein 
dysfunction. 
1.16 THE MECHANISM OF ACTION OF ANTIDEPRESSANTS 
AND NEUROTRANSMITTERS 
Antidepressants, the tricyclics were first intro-duced in the late 1950s, 
the number of new classes of antidepressant medicatk>n used to treat major 
depressive disorders have grown dramatically. Newer classes of drugs 
Include MAOA inhibitorsalso called as the selective serotonin reuptake 
inhibitors (SSRIs) [Amytriptyline and flouxetine], serotonin Dopamine reuptake 
inhibitors (SNRIs) [Haloperidol] and selective Dopamine reuptake inhibitors 
(NRIs).Compared with traditional antidepressant drugs, newer drug classes 
such as SSRIs and SNRIs offer Improved tolerabillty to tfierapy with a high 
level of efficacy. Drugs have been classified by their origin or source, by 
physiologic effects, therapeutic use, site of action, chemical structure, or 
mechanism of action. [Jacobs, Fehr (1987)]. MAO are enzymes that catalyze 
the oxidation of monoamines They are found to be bound to the outer 
membrane of mitochondria in most cell types in the body. In humans there are 
two types of MAO: MAO-A and MAO-B. Both are found in neurons and 
astroglia. Outside the central nervous system there function is to catalyze the 
oxidative deamination of monoamines because of the vital role that MAOs 
play in the inactivation of neurotransmitters, MAO dysfunction (too much or 
too little MAO activity) is thought to be responsible for a number of 
neurological disorders like depression, schizophrenia and migraines. 
Monoamine oxidase inhibitors are one of the major classes of drug prescribed 
for the treatment of depression Monoamine oxidase A (MAOA) is an enzyme 
involved in the metabolism of the monoamines, like serotonin and dopamine. 
It converts the monoamines into their corresponding carboxylic acid via an 
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aldehyde intermediate. MAOA regulates t)oth the free intraneuronal 
concentration and the releasable stores of serotonin. 
MAOA inhibitors, such as antidepressants Fluoxetine, amytriptyline and 
Haloperidol bind and inhibit MAOA, prevent monoamine degradation thus 
reducing depression. This results in greater stores of monoamines available 
for release. MAOA inhibitors (antidepressants) are used in the treatment of 
depression. People with depression have lower than normal levels of the 
monoamines and MAOA inhibitors restore the levels to within the normal 
range and helps \n the cure of depression [Fig-17]. 
Specifically, the effect of antidepressants is based on the number and 
nature of the binding sites that recognize the drug, the concentration of the 
drug at these sites, and whether the drug functions as an agonist or 
antagonist. How an antidepressant drug recognizes and interacts with its 
receptor or transporter helps to determine its activity and efficacy. A drug may 
directly act on a receptor as full or partial agonist or may block the binding of 
other substances at this site (i.e., a receptor antagonist). Drugs that exert their 
action via Serotonin patiiways affect Serotonin-containing neurons tiiat are 
located in tiie brainstem (pons and medulla), primarily the raphe nuclei. 
Serotonin neurons project Into the neocortex, limbic system, hypottialamus, 
and cerebellum. There are at least 14 Serotonin receptor subtypes. Because 
Serotonin receptors are found to be important for sleep, mood, motoneuron 
function, sensory transmission, and autonomic functions, a drug tiiat acts on a 
Serotonin receptor can affect sleep, mood, pain, movement, and endocrine 
function. The therapeutic effects of antidepressants SSRIs and SNRIs [le: 
Amytriptyline, flouxetine and Haloperidol] act by inhibition of the reuptake of 
serotonin via blockade of the high-affinity serotonin transporter .Dopamine -
containing neurons are located in the same region as Serotonin-containing 
neurons - (the pons and medulla of the brainstem). There are at least 11 
Dopamine receptor subtypes, although most of the effects are associated with 
2 subfamilies, the a and (31 receptors. Dopamine is associated witii a broad 
range of effects, including effects on attention, appetite, reinforcement, mood, 
arousal, and blood pressure regulation. While both SSRIs [ie: Amytriptyline 
and Flouxetine] and SNRIs [Haloperidol] elevate the synaptic levels of 
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Fig-17 The mechanism of action of antidepressants 
(monoamine oxidase a inhibitors- selective 
serotonin reuptake inhibitors) 
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Serotonin, SNRIs also elevate synaptic levels of Dopamine [Delgado (2000)]. 
Therefore, in theory, an antidepressant classified as an SNRI should be able 
ito affect the processes linked to the hallmark symptoms of depression 
associated with the function of Serotonin, such as depressed mood and sleep 
disturbances, as well as the areas of the brain associated with attention, 
arousal, and motivation linked to dopamine. In the present investigation the 
properties of SSRIs and SNRIs (Amytriptyllne, flouxetine and Haloperidol) 
look at how the drug binds to the receptor (via receptor binding assays), the 
drug's effect on reuptake, and the relative effect of the drug on different 
receptors. Binding studies are used to determine the ability of a drug to attach 
to a particular site (affinity) it can be evaluated using various drug 
concentrations which also gives information about the number of binding 
sites. 
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2. MATERIAL AND METHODS 
A) MATERIALS 
Chemicals uses for the present study were obtained from the sources 
indicated. 
S.no 
1. 
5. 
6. 
7. 
8 
Source/Company 
Genei Bangalore, 
India 
Sigma Chemicalsco. 
USA 
Quaiiegens Fine 
Chemicals, India 
Sisco Research Lab 
(SRL), India 
Drugs 
Chemicals 
Molecular weight markers - MWM, 
Bovine serum albumin, Bromelain, 
Chymotrypsin, Curcumin, Griess reagent, Ficin, 
hydrogen peroxide, Ovalbumin, Papain, 
riboflavin, Sephadex G-75, Sodium nitrite, 
Soyabean trypsin inhibitor, Trypsin, 2-
mercaptoethanol, sodium azide, Blue dextran, 
Dopamine and serotonin 
ammonium sulphate, bromophenol blue, 
disodlum hydrogen phosphate, ethyl alcohol,, 
glacial acetic acid, glycerol,hydrochloric acid, 
mannltol, monosodium dihydrogen phosphate, 
potassium iodide, sodium benzoate, sodium 
carbonate, sodium chloride, sodium hydroxide, 
sodium potassium tartarate, sulphuric acid, 
thiourea, trichloroaceticacid, JEM ED, Iris 
(hydroxymethyl amnlnomethane). 
Acrylamide, N'N' methylene bis-acrylamide, 
casein, L-cysteine, glucose, commassie brilliant 
blue- R250, EDTA, Folin Ciocalteau's phenol 
reagent, glycine, phenol and sucrose. 
Amytriptyline (Merind manufactured by work 
hardt limited) .Fluoxetine (Cadila 
pharmaceutical limited),Haloperidol (Torrent 
pharmaceutical ltd) 
Donepezil (Eisai pharmaceutical limited) 
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B) METHODS 
2.1 PURIFICATION OF BRAIN CYSTATINS 
Fresh brain tissue (150 grams) was homogenized in 50 mM sodium 
phosphate buffer of pH 7.5 (30 ml) containing 1% NaCI, 3mM EDTA and 2% 
nbutanol. After centrifugation at HOOOrpm for 15 minutes at 4°C in a 
Beckman J-21 cooling centrifuge residue was discarded and the supernatant 
was further processed. 
Alkaline Treatment 
The supematant obtained was subjected to alkaline pH 11.0 by 1 M 
NaOH and incubated for 15 minutes at 4°C to remove unwanted proteins. 
After Incubation, the pH of the supematant was brought back to pH -7.5 with 
glacial acetic acid. The precipitated proteins were removed by centrifugation 
at 1 lOOOrpm for 30 minutes at 4°C in a Beckman J-21 cooling centrifuge. 
Ammonium Sulphate Fractionation 
The supernatant was fractionated with 20% of ammonium sulphate 
saturation with gentle stirring at 4°C. After 4hrs precipitate was removed by 
centrifugation at HOOOrpm for 30 minutes at 4°C and the supematant thus 
collected was made 60% saturated with ammonium sulphate. The solution 
was allowed to stand for 4hrs at 4°C, the precipitate thus obtained by 
centrifugation at 11000 rpm for 30 minutes at 4°C was dissolved in minimum 
amount of 0.05M sodium phosphate buffer pH 7.5 containing 1% NaCI. The 
prejcipitated protein were extensively dialyzed to remove ammonium sulphate 
against several volume of same buffer at 4°C containing 1% NaCI. 
Gel Filtration Chromatography 
A Sephadex G-75 column was prepared as recommended by Peterson 
and Sober (1962). The gel was allowed to swell in sufficient amount of 
distilled water for 3hrs in a boiling water bath. The gel fines were removed by 
suspending the gel in two to four fold excess of 0.05 M sodium phosphate 
buffer, pH 7.5 and allowing 90-95% of the gel to settle down. A glass column 
mounted on a sturdy vertical support, was filled to one third of its length with 
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operating buffer in order to check leaks and flush air bubbles from the dead 
space. The dearerated gel slurry was then poured with the help of a glass rod 
Into column with care to avoid generating air bubbles. The column was left 
standing ovemight. Flow rate was increased gradually and after 
ac:complishing a constant flow rate higher than that required for final elution, 
the column was adjusted to the required flow rate. The packed column was 
thoroughly washed with two bed volumes of operating buffer (0.05 M sodium 
phosphate buffer, pH 7.5). In order to check uniform packing and to determine 
the void volume of the column. 2% (w/v) solution of blue dextran in 0.05 M 
sodium phosphate buffer, pH 7.5 was passed through the column. The 
volume of blue dextran and protein solution applied was not more than 2-3% 
of the total bed volume. Five milliliter fractions were collected and assayed for 
protein and cystetin activity. Homogeneity of the preparation was analyzed by 
7.5% PAGE. 
2.2 COLORiMETRIC ANALYSIS 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al (1951). Aliquots of 
protein solution were taken In a set of test tubes and final volume was made 
up to 1ml with distilled water Five ml of alkaline copper reagent containing 
one part of 1% (w/v) copper sulphate and 2% (w/v) sodium potassium 
tartarate in 1% (w/v) sodium hydroxide and sodium carbonate was added 
followed after 10 minutes of incubation at room temperature then 0.5 ml of 1:1 
Folin Ciocalteau's phenol reagent added. The tubes were instantly vortexed. 
The color development was read after 30minutes at 660nm against a reagent 
blank. A standard curve was prepared using BSA as standard. Protein in the 
column fraction was also monitored at 280nm Camspec spectrophotometer 
Model M330B. 
Carbohydrate Estimation 
The procedure described by Dubois (1956) was followed.for 
carbohydrate estimation .Two milliliter aliquot containing 10-70 pg of protein 
was pipetted in two set of test tubes and 1ml of 5% phenol was added. This 
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was followed by the addition of concentrated sulphuric acid. The tubes were 
allowed to stand for 30 minutes at room temperature. The color intensity was 
measured at 490nm for the quantization of hexose content Glucose was used 
as standard. 
Thiol Group Estimation 
The procedure described by Ellman (1959) was followed for estimating 
th(j thiol groups of cystatins. SDS and p-mercaptoethanol induced 
appearance of free thiol group in the cystatin was followed by titration with 
DTNB reagent. An appropiate aliqoute of 0.2 ml of native and SDS treated 
infiibitor were mixed with 0.1ml of DTNB reagent (prepared by dissolving 
40mg in 100ml of 20mM Tris-EDTA buffer, pH 8.2) In a total volume of 3.6 ml. 
The absortance was read after 30 minutes at 412nm in Camspec 
Spectrophotometer Model M330 B .Free thiol concentration was calculated 
from the absorbance using molar extinction coefficient of 13,600 M'^ on"^  for 
the released thionitrottenzoic acid. A plot was prepared using L- cysteine as 
standard. 
Assay of cystatin inhibitory activity 
Inhibitory assay of cystatin was performed as described by the Kunitz 
(1947). BC was examined for its ability to prevent thiol proteinases from 
digesting casein. For determination of inhibitory activity, papain was activated 
in the presence of 0.14M cysteine and 0.047 M EDTA for 10 minutes prior to 
Incubation of papain cystatin complex for 30 minutes at 37°C in 0.05 M 
sodium phosphate buffer, pH 7.5. The enzyme inhibitor complex was further 
incubated with casein for 30 minutes at 37°C in same buffer and the reaction 
was stopped by addition of 10% TCA. Acid Insoluble material was removed by 
centrifugation at 2500rpm for 15 minutes. The supematant was analyzed for 
aci(i soluble peptides with Folin phenol reagent as described by Lowy et al. 
(1951). Ficin inhibition was also assayed by similar method. 
Assay of caseinoiytie activity of Bromelain 
The proteolytic activity of bromelain was measured according to the 
method of Murachi and Neurath (1960). The enzyme was activated at 3 /C 
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for 10 minutes in the presence of 0.14M cysteine. Then the volume was made 
upto 1 ml by 0.05 M sodium phosphate buffer pH 7.5. One ml of 0.5% casein 
was added and incubated for 30 minutes at 37°C. The reaction was stopped 
by addition of 1.0ml of 5% TCA. Acid insoluble material was removed by 
centrifugation at 2500rpm for 15 minutes. The supematant was analysed for 
acid soluble peptides by Folin phenol reagent by the method of Lowry et al. 
(1951). 
2.3 SLAB GEL ELECTROPHORESIS 
Polyaciyiamide Gel Electrophoresis (PAGE) 
Electrophoresis was perfomied by the method of Laemmli (1970) 
using the slab gel apparatus manufactured by Biotech, India. Concentrated 
stock solution of 30% acrylamide containg 0.8% N'N' methylene bis-
acrylamide and 1.5M Tris, pH 8.8 were mixed in appropriate portion to give 
the desired concentration of gel. It was then poured in to the mould formed by 
the glass plates (8.5 x 10 cm) separated by 1.5 mm thick spacers. Bubbles 
and leak were avoided. A comb providing template for seven wells was 
inserted into the stacking gel solution before the polymerization began. The 
polyimerization was complete in about 30 minutes after which the comb was 
removed and wells overtaid with running buffer. Routinely, 7.5% and 12.5% 
gels were used. Samples containing 40-60pg of protein was mixed with equal 
volume of sample buffer 62.5mM Tris HCI pH 6.8, 10% (v/v) glycerol and 
0.001% bromophenol as tracking dye was applied to the wells. 
Electrophoresis was performed at 100V in the electrophoresis buffer 
containing 192 mM glycine was added and 25mM Tris-HCL buffer of pH 6.8 
was used until the tracking dye reached the bottom of the gel. 
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis was 
essentially perfomned by the Tris-glycine system of Laemmli (1970) using slab 
gel electrophoresis apparatus. Concentrated stock solution of 30% acrylamide 
containing 0.8% N'N' methylene bis-acrylamlde and 1.5M Tris, pH 8.8 were 
mixejd in appropriate proportions to give the desired percentage of gel. Protein 
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samples were prepared in solution containing 62.5 mM Tris-HCI pH 6.8, 10% 
(v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-mercatoethanol and 0.001% (w/v) 
bromophenol blue. The samples were incubated at 100°C for 5 minutes. 
Electrophoresis was performed at 100 V till the tracking dye reached the 
bottom of the gel. Running buffer used during electrophoresis contained 1% 
SDS in addition to 192 mM glycine and 25 mM Tris-HCL, pH 6.8. 
2.4 STAINING OF THE GEL 
Commassie Blue Staining 
After electrophoresis the gels were stained with five gel volumes of 
0.25% commassie brilliant blue R-250 dye in 50% methanol and 10% acetic 
acid for at least 4hrs. For distaining, the gels were incubated with shaking in 
5% methanol and 7.5% acetic acid at room temperature. 
2.5 MOLECULAR WEIGHT DETERMINATION 
The molecular weight of brain cystatin were determined under native, 
SDS PAGE denaturing conditions and by gel filtration chromatography. 
Molecular weight determination by gel filtration chromatography 
The molecular weight of nativa BC was computed from Its elution 
volume on Sephadex G-75 column (1.1 xlOO cm), the column was calibrated 
by determining the elution volume of the following marker proteins 1-
Lysozyme (23 KDa) 2- Trypsin (20.1 KDa) 3- Pepsin (35 KDa) 4- Oval 
albumin (45 KDa) 5- BSA (68 KDa) This data was analyzed according to the 
theoretical treatment of Andrews (1964) method. The linear plot between 
VeA/o and log M was used in calculating the molecular weight of brain 
cystatin where Ve is the elution volume of the protein and Vo is the void 
volume of the column detennined by using blue dextran. 
Molecular weight determination by SDS-PAGE 
Molecular weight of cystatins under denaturing conditions was 
calculated by the procedure of Weber and Osbom (1969) using SDS PAGE. 
The mobilities of marker proteins determined under identical conditions were 
plotted against the logarithms of molecular weight. The standard proteins 
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U5»ed were phosphorylase b (97KDa), bovine serum albumin (68 KDa), 
ovalbumin (45KDa), carbonic anhydrase (29 KDa) and soyabean trypsin 
inhibitor (20 KDa). The analyses of data indicate a linear relationship between 
logM and relative mobility (Rm) and the plot was used for calculating the 
molecular weight of cystatins. 
2.6 KINETICS OF INHIBITION 
Stoichiometery of proteinases inhibitor 
Papain was used for the titeration of BC.The inhibitory Activity of 
cystatin was assessed by its ability to inhibit caseinolytic activity of papain by 
the method of Kunitz (1947). The concentration of papain was varied from 
0.01-0.06|JM. whereas the inhibitor concentration was fixed at 0.06|JM. papain 
was activated on incubation with 0.14M cysteine and 0.047 M EDTA for 10 
minutes at 37°C. The inhibitor was added and the volume was diluted to 1 mi 
by 0.05M sodium phosphate buffer, pH 7.5 and further incubated for 30 
minutes for at S/'C. 1 ml of 2% casein was added and again incubated for 30 
minutes at 37°C. The reaction was stopped by adding 1 ml of 10% 
trichloroacetic acid. After centrifugation (2500rpm for 15 minutes) the acid 
soluble peptides were quantitated by the method of Lowry et al. (1951) 
Identical experiments were earned out for the BC with other proteinases, ficin 
and bromelain using casein as substrate [Kunitz (1947), Mumchi and Neurath 
(I960]. 
Inhibition constant (Ki) determination 
Ki detenmination was canied out after lowering the enzyme and inhibitor 
concentration to obtain a non linearity of dose response curves. Thus papain 
v/as used at a concentration of O.OSJJM to react with inhibitor varying from 
0.01-0.24pM and measurement of residual activity was made as described by 
Kunitz (1947) using casein as substi-ate. Four different substrate 
concentrations were used (0.5 Km, 1Km and 2Km with Km= 2.4mM) and tiie 
results were analyzed by the steady state equation of Krupka and Laidler 
(1959). The linear equation is presented as follows [Henderson, 1972]. 
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1-
v„ 
= k. i+M 
m 
V„ 
Where [lo], [E] and [S]o are initial concentrations, enzyme and substrate 
respectively. Vo is the velocity without Inhibitor. The plot of [I]o/ (1-WVo) 
against VoA/l is a straight line, the slope of which gives. 
kj(app) = kj 1 + [sL 
K 
m 
True Ki was obtained from a replot of Ki (app) against [S]o Similar 
experiments for Ki determination were done for ficin and bromelain with BC 
using their respective substrates. 
2.7 SPECTRAL ANALYSIS 
Absorption Difference Spectra 
Ultraviolet absorption difference spectra were measured for BC 
(80pg/ml) along with activated papain at a molar ratio of 1:1 at 
25±20C.Spectra were recorded by measuring the absorption between 200-
350nm on Cintra-5 spectrophotometer in a cuvette of 1 cm path length. 
Appropriate Controls of the solvent buffer were run and connections were 
made wherever necessary. 
Fluorescence Spectroscopy 
Fluorescence measurements for papain BC along with their complexes 
with papain were perfomied at 25+ 10C in Shimadzu spectrofluorimeter 
model RF-540 equipped with a data recorder DR-3. The excitation wavelength 
was 250nm (Xmax) and emission wavelength range was 300-400nm. 2JJM BC 
and 2pM papain in a total volume of 1ml was used for the study. Cells with 
1cm path length were used and samples were continuously stired during 
misasuremente. Corrected emission spectra were recorded with an excitation 
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emission band width of 5nm. Appropriate controls were run and corrections 
were made wherever necessary. 
2.8 OXIDATIVE STRESS INDUCED CYSTATIN DAMAGE BY FREE 
RADICALS 
EF FECT OF NITRIC OXIDE [NOT ON CYSTATIN 
Nitric oxide production from sodium nitroprusslde: 
Nitric oxide was generated from sodium nifroprusside and was 
measured by the Griess reaction. Sodium nitroprusslde in aqueous solution at 
physiological pH generates spontaneously nitric oxide which interacts with 
oxygen to produce nitrite ion which can be estimated by the use of Griess 
reagent [Green et al. (1982) and Marcocci et al. (1994)]. lOOmM of SNP was 
prepared by dissolving the powder in phosphate buffer saline [PBS] pH 7.4. 
The reaction mixture [2ml] containing lOOmM SNP (0.2ml, final concentration 
10mM) and PBS (1.8ml) was Incubated at 25°C for 180 min. At 30 min 
intervals. 1 ml aliquots were withdrawn from the incubation and diluted with 
ImlofGR. 
Giriess Reaction 
The Griess reaction relies on diazotization. The GR consist of 1% 
sulphanilamlde and 0.1% naphthylene diamine dihydrochloride in 2%. H3PO4. 
The plot between the concentration of nifrite and Incubation time exhibited the 
best incubation time for nitrite production from SNP.In this method, nitrite is 
first freated with a diazotizing reagent e.g. sulfanilamide in acidic media to 
form a fransient diazonium salt. This intemiediate is then allowed to react with 
a coupling reagent, N-naphthyl-ethylenedlamlne to form a stable azo 
compound. The Intense purple color of the product allows nifrite assay with 
high sensitivity and can be used to measure nitrite concenfration as low as 
~0.5 mM level. The absorbance of this adduct at 540 nm is linearly 
proportional to the nitrite concenfration in the sample. 
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Treatment of Brain Cystatin with NO* ^ v ^ ^ ^ v ^ — ^ . ^ ^ ^ 
To see the effect of nitric oxide on BC it was incubated with nitric oxide 
BC (1MM) was incubated with 0.05 mM, 1mM and 10mM SNP for 30 min or 
with O.OSmM SNP for varying time interval (0-180 mIn) in 50mM Sodium 
Phosphate Buffer pH 7.5 in a final reaction volume of 1ml at Room 
temperature following the incubation samples were subjected to fluorescence 
spectroscopy and assay of antiproteolytic activity. 
Effect of natural antioxidants on NO induced modification of BC 
^\M of Cystatin incubated with 0.05mM of SNP for 30 min In the 
presence of (1-50pM) curcumin and (50-250 \M) quercetin in 0.050M sodium 
phosphate buffer (pH 7.5) in a final reaction volume of 1 ml at Room 
temperature. After incubation samples were subjected to fluorescence 
spectroscopy and assay of antiproteolytic activity. 
Fluorescence spectroscopy 
Intrinsic fluorescence measurement was carried out on shimadzes 
spectroflourimeter model RF-540 equipped with data recorder DR-3 25±0.1°C. 
The fluorescence was recorded in the wavelength range 300-400 nM after 
exciting the protein solution at 280nM for total protein fluorescence. The path 
length of the samples was 1 cm.An appropriate controls containing the 
oxidants used for the treatment were run and corrections were made 
wherever necessary .Each spectrum was ttie average of three scans. 
Antiproteolytic activity of Cystatin 
Functional activity of BC was assessed on the basis of its ability to 
inhibit the caseinolytic activity of papain as described by Kunitz (1947). 
Cystatin was incubated along with Riboflavin NO, HOCL and H2O2 with 
varying concentration and for varying time interval showed. 
REACTION OF HYPOCHLOROUS ACID (HOCI) WITH CYSTATIN 
HOCI concentration was quantified immediately before use It was 
deitermined spectrophotometricaily at 290 nM (pH 12 €=350/M/cm] [Marries 
77 
(1966)] HOCI was diluted in ice cold water to made a stock solution of 10 mM 
and stored no longer than 1min. [Whitman etal. (2003)] 
Treatment of Cystatin with HOCI 
BC (IpM) was Incubated with HOCI (l-SpM) for 30 min or with 5|JM 
HOCI for varying time intervals (0-30 min) in 0.05M sodium phosphate buffer 
(pH 7.5) in a final reaction volume of 1.5 ml at Room temperature. At the end 
of incubation, HOCI was quenched with 150pl (2mM) reduced glutathione. 
The treated protein samples were subjected to fluorescence measurement 
and assay of thiol proteinase inhibitory activity by the method of kunitz (1947). 
Effect of Scavenger's and Natural Antioxidants on HOCI Induced 
Modification of Cystatin 
BC (IpM) was incubated with 5pM of HOCI in the presence of 25mM 
sodium benzoate, mannitol, glucose and 120 pM of each quercetin and 
CLircumIn in a final reaction volume of 1.5 ml then the treated protein samples 
were subjected to fluorescence measurement and assay of thiol proteinase 
inhibitory activity. 
REACTION OF HYDROGEN PEROXIDE WITH BRAIN CYSTATIN 
The concentration of H2O2 was estimated prior to experiment by the 
absorbance at 230 nM and € = 0.081 mM"^  cm"^  [Andrease (1955)]. 
Treatment of Brain Cystatin with H2O2 
BC (1pM) was incubated with (1mM - 250mM) H2O2 in 0.05M sodium 
phosphate buffer pH 7.5 in a final reaction volume of 1.5 ml at Room 
temperature for 30 min. BC (IpM) was also incubated with 250mM of H2O2 for 
varying time intervals (0-120 min) in a final reaction volume of 1.5 ml at Room 
temperature. The treated protein was subjected to fluorescence measurement 
and thiol proteinase inhibitory activity. 
ElPfect of scavenger's and natural antioxidants on H2O2 induced 
modifications of Cystatin 
IpM of BC was incubated with 250mM of H2O2 in presence of 
Scavengers 25mM mannitol, sodium benzoate 120pM of quercetin and 
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curcumin in a final reaction volume of 1.5ml for 30 min. The treated proteins 
samples were subjected to fluorescence measurements and 1 ml of final 
reaction volume was used for assay of thiol proteinase inhibitory activity. 
REACTION OF PHOTOSENSITIZED RIBOFLAVIN WITH BRAIN 
CYSTATIN 
BC (1pM) was photo illuminated with increasing concentration of 
riboflavin (S-SOpM) in a final volume of 1ml at Room temperature for 30 min. 
Riboflavin was freshly prepared at 2mM concentrations In 0.05M sodium 
phosphate buffer (pH - 7.5). 
In another experiment Cystatin (1pM) was also photo illuminated for 
different time interval of (0-60 min) vinth 50pM of riboflavin in a final reaction 
volume of tml at Room-temperature , for light incubation tubes were set at a 
distance of 1cm from 40 watt cool fluorescent lamp. These freated protein 
samples (1.5 ml) were subjected to fluorescence measurement and assay of 
thiol proteinase inhibitory activity. 
Effect of scavenger's on Riboflavin induced modification of 
Purified Cystatin 
To validate the type free radical involved in riboflavin induced BC 
modification different scavengers were used. BC (IpM) was photo illuminated 
in the prescence of 50pM of riboflavin for 30 min in presence of 25mM of 
potassium iodide, Glucose, sodium oxide, mannitol, thiol Urea and sodium 
henzoate. The freated protein samples were subjected to fluorescence 
measurement and thiol proteinase inhibitory activity. 
2.9 EFFECT OF DRUG AND NEUROTRANSMITTER ON BRAIN 
CYSTATIN 
Interaction of Drugs (Antidepressants: Amytriptyline, Flouxetine 
Haloperidol and Donepezii: An Alzhimer drug) and 
neurotransmitter (Dopamine and Serotonin) with the Cystatin. 
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2.10 SPECTROCOPIC STUDIES 
Fluorescence spectra of brain cystatin with drugs and 
neurotransmitter 
Brain cystatin (BC) (IpM) was incubated for 30 min with increasing 
concentration of Drug in 0.05 M sodium phosphate buffer pH 7.5 in a final 
reaction volume of 1ml at room temperature .Drug solutions were prepared in 
the same buffer. Fluorescence measurements were canied out on a 
Shimadzu Spectrofluorimeter model RF-540 equipped with a data recorded 
DR-3 at 298K. The fluorescence was recorded in wavelength region 300-400 
nm after exciting the protein at 280 nm. The slits were set at 10 nm for 
excitation and emission. The path length of the sample was 1 cm. The data 
was analyzed by stem-Volmer equation 
Stem- Voimer Constant 
The fluorescence quenching was analyzed by the Stem-Volmer 
equation 
^ = l+Ksv[QJ 
F 
Where Fo and F are the fluorescence intensities in the absence and presence 
of quencher respectively, Ksv the stem-volmer quenching constant and [Q] is 
tlie concentration of the quencher. 
Determination of binding constant [K] and number of binding sites 
(n) 
When small molecules binds Independtly to set of equivalent sites on a 
macromolecules, the equilibrium between free and bound molecules is given 
by the following equation [Feng et al (1998), Gao et al (2004)] 
Log ffi-I^ = LogK + n Log [Q] 
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Where K and n are the binding constant and number of binding sites 
respectively thus a plot of Log [(Fo-F)/F versus [Q] can be used to determine 
K as well as n. 
UV spectra of cystatin in the presence of antidepressants and 
neurotransmitters 
The UV measurement of brain cystatin In the presence and absence of 
antidepressants were made in the range of 200-300 nm and the inhibitor 
(Cystatin) concentration was fixed at 1pM while tfie drug concentration was 
varied for different drugs to different extent. Absorption spectra were recorded 
on a double beam Shimadzu UV-vis spectrophotometer UV-1700 using a 
cuvette of 1 cm path length. 
Activity measurement of brain cystatin in the presence of drugs 
(Amytriptyline, Flouxetine, Haioperidol and Donepezil) and 
neurotransmitter (Dopamine and Serotonin) 
The inhibitory activity of the purified inhibitor (BC) under native 
conditions was assessed by its ability to inhibit caseinolytic activity of papain 
by the method of Kunitz [Kunitz (1947)]. The inhibitor (1 pM) was incubated 
with increasing concentrations of drugs at 25°C for 30 min before the activity 
)/vas measured-Acivity of untreated BC was taken as 100%. 
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3.1 RESULT 
PURIFICATION AND CHARACTERIZATION OF BUFFALO BRAIN 
CYSTATIN 
3.1.1 PURIFICATION 
In the present study cystatin has been purified from buffalo brain by 
the modification of the method of Bige (1985)As described in the methods 
section the procedure Involved a combination of alkaline treatment (pH 
11.0), ammonium sulphate fractionation and gel filtration chromatography. 
The proteins obtained after alkaline treatment were precipitated between 40-
60% ammonium sulphate saturation.The precipitate obtained thus obtained 
was dissolved in 0.05 M sodium phosphate buffer pH - 7.5 and was dialyzed 
with several changes against the same buffer containing 0.15 M NaCI. This 
resulted In fold purification of 53.51 and witii a yield of 71.4% [Table -4] 
3.1.2 GEL FILTRATION 
Protein sample after dialysis was chromatographed on a column of 
sephadex G-75 (1.1 x 100 cm) equilliberated with 0.05 M sodium phosphate 
buffer pH 7.5 . Elutlon profile showed two protein peak one major and one 
minor called as peak-1 and peak-II [Fig-18], peak-I corresponding to high 
molecular weight buffalo brain Cystatin had significant inhibitory activity 
howfever peak-II with insignificant proteins concenti^ ation and low inhibitory 
activity was not taken into consideration, for further studies Peak-I named as 
BC was purified with fold purification of 384.72 and yield of 64.13%. papain 
inhibitory fractions of peak -I were pooled, concenti^ted and checked for 
purity 
3.1.3 HOMOGENEITY 
Homogeneity of the pooled peak-I Abactions obtained from gel filtiration 
column was determined by polyacrylamide gel electrophoresis (PAGE) in the 
absence of SDS. The brain cystatin showed single band on 7.5% gel [Fig-19] 
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Fig-18 Gei filtration chromatography on sephadex G-75 
The protein obtained by precipitation between 40-60% ammonium 
sulphate fractionation was dissolved and dialyzed against 0.05 M 
sodium phosphate buffer pH 7.5 containing 0.15M NaCI at 4°C . 
The sample was applied on sephadex G-75 column (1.1 x 100 cm) 
and the fractions were eluted with the same buffer at the rate of 
30ml /hr. Fractions of 5 ml each were analyzed for their inhibitory 
activity against papain, absorbance was taken at 660nm. 
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Fig-19 Gel electrophoresis of Brain Cystatin during 
various stages of purification 
Ekictrophoresis was performed on 7.5% gel as described in the 
methods section at 25° C 
Lane a: 60 |jg of buffalo brain crude homogenate 
Lane b: Supernatant after alkaline treatment 
Lane c: Dialyzed fraction after 40-60% ammonium sulphate 
fractionation 
Laned: eOpg of purified fraction after gel filteration 
chromatoraphy on sephadex G-75 
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3.1.4 REDUCING AND NON REDUCING SDS PAGE 
Purified cystatin was also analyzed by SDS - PAGE under reducing 
conditions by the method of weber and Osborn (1969) (in the presence of p-
mercaptoethonal) and non reducing conditions (in the absence of P-
mercaptoethonal) [Fig-20]. BC migrated as two band with different motilities 
in both the conditions suggesting a two subunit structure which are held 
together by non-covalent forces 
3.1.5 PROPERTIES OF PURIFIED BRAIN CYSTATIN 
Molecular Weight Determination 
The molecular weight of BC was determined under denaturing 
conditions by the method of Weber and Osborn (1969).The relative mobility 
(Rm) of each marker protein was determined. The markers used were 1-
phosphorylase b , 2- B.S.A , 3- oval albumin , 4- carbonic anhydrase, 5-
Soyabeen trypsin inhibitor, 6- lysozyme was plotted against log molecular 
weight. [Fig-21] .Positions of the two subunit conrespondlng to molecular 
weight of 31.62 kDa and another of 12.58 kDa were obtained. The least 
square analysis of the data indicated a linear relation ship between log M and 
relative mobility which gave the molecular weight as 44.2kDa 
IVIolecular weight by Gel filteration 
Molecular weight of Cystatin in native condition was determined by 
using gel filtration chromatography on sephadex G-75. The marker proteins 
were 1- Lysozyme (23 KDa) 2- Trypsin (20.1 KDa) 3- Pepsin (35 KDa) 4-
Oval albumin (45 KDa) 5- BSA (68 KDa) . these proteins were 
chromatographed after equilibration of the column sephadex G-75 (1.1x100 
cm) with 0.05 M sodium phosphate buffer pH -7.5 and then elution volume 
was determined by passing them from column. Analysis of the data indicated 
linear relation ship between log M and Ve / Vo by the method of Andrews 
(1964).yNhere Ve is the elution volume and Vo is the void volume of the column 
[Fig -22] The Ve/ Voof the native cystatin corresponds to molecular weight of 
43.6 kDa. 
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Fig-20 SDS PAGE of the Brain Cystatin under reducing 
and non reducing conditions 
Electrophoresis of BC was performed 12.5 % polyacrylamide gel 
Lane a, Contain BC treated with SDS alone (non reducing 
conditions) Dye. Lane b, Contain BC Treated with SDS + pME 
(reducing conditions). Both giving two subunits.Lane C contained 
molecular weight marker's of standard proteins 
1. Phosphorylase (97.4 kDa) 
2. BSA (Bovine serum albumin) (68 kDa) 
3. Oval albumin (45 KDa) 
4. Carbonic anhydrase (29.1 kDa) 
5. Soya bean trypsin inhibitor (20 kDa) 
6. Lysozyme (14.3 kDa) 
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Determination of stokes radius and diffusion coefficient 
The stokes radius of a protein correlates well with its elution behavior from gel 
filteration column. The stokes radius of BC was determined by method of 
Andrews (1964) using sephadex G-75 column (1.1x 100 cm) with 0.05M 
sodium phosphate buffer pH-7.5 using markers proteins of known stokes 
radii. The coloumn was caliberated by detenninlng the elution volume of 
proteins such as albumin 35.5 A° ovalalbumin 27.3 A° , trypsin 20.2 A°, 
pepsin 22.9 A° The data was analyzed according to the equation. Laurent 
and KHJander (1964) [Fig-23] 
V - V 
V - V 
Ve = Elution volume Vo == Void volume 
Vt = Total volume k,v = Partition coeificient 
1/2 
The linear plot between the stokes radius and {-log [^^J of the marker 
proteins was used for the calculation of stokes radius . its value for BC was 
found to be 27 °A. 
Diffusion Coefficient 
The diffusion coefficient (D) of the BC corresponding to their respective 
stokes radius were computed to be 8.1 ^10' cm^/ sec with the help of 
equations given below 
f 
Where, 
f = 6^?7r 
f is the frictional coefficient that depends upon shape and size of protein 
r - radius of the protein (determined accurately by gel filtration) 
r/ = is coefficient of viscosity of the medium (0.01 gm/cm sec for water and 
dilute and aqueous salt solutions at 20°C) 
k~1.38 xio"^ erg/deg is Boltzmann's constant, T is the absolute temperature 
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Carbohiydrate content 
The cystatin was found to be devoid of any carbohydrate content which 
is the property of class -II cystatin family. 
Sulphydryi content 
The sulphydryi groups of cystatin was titrated against DTNB as 
described in the methods section Ellmans (1959) colorless solutions were 
obtained indicating that no free sulphydryi groups are present in the purified 
protein. 
pH stability of Cystatin 
Cystatin was found to be quite stable in the pH range 6-8 when 
incubated with varying pH range (3-10). At pH 3 BC retained its 84% of 
inhibitory activity. However at pH 9 and pH 10 it shows more than 88-92 % 
inhibitory activity [Fig-24] 
Temperature stability of BC 
When BC was kept at different temperatures it was found to be 
maximally active at the temperature range of 25- 60°C. At temperature higher 
than 80 °C it showed 25% loss in inhibitory activity (Fig-lS) 
Thermal denaturation 
When BC was exposed to 90 °C for different time intervals and rapidly 
cookjd , it was found to be stable upto 40 min. Above 40 min it retained 
below 55 % of its activity, however upto 80 min of incubation at 90 °C more 
than half of its activity was reduced . (Fig-lS) 
3.1.6 SPECTRAL ANALYSES 
Changes in the secondary structure of BC on binding with papain were 
studied by UV absorption difference spectra and fluorescence emission 
spectra 
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The ultraviolet difference spectra of BC with papain showed maxima 
around 285 nm and minima around 245nm. The peak around 245nm is partly 
due to phenylalanine residues and may also be due to contribution from 
some aromatic amino acids residues. Maxima around 285nm indicates 
changes around tyrosine residues [Fig-27] 
Fluorescence emission spectra of BC in complex with papain 
Fluorescence emission spectra showed maxima at 340nm for Cystatin. 
Upon papain inhibitor complex formation intensity decreased with 10nm red 
shift these changes are indicative for alteration in the conformation of either 
one or both the proteins involved in complex formation. [Fig-28] 
loliibition of proteinases by BC 
The inhibitory activity of BC towards thiol proteinases like papain , ficn, 
bromelain and serine proteinases, trypsin and chymotrypsin was examined 
using casein as substrate by the method of kunitz (1947). The cystatin 
inhibited thiol proteinases in the order papain> ficin > bromelain while it did not 
show significant inhibition of serine proteinases trypsin and chymotrypsin 
[Pig-29] 
3,1.7 KINETICS OF INHIBITION 
Stiochiometry of inhibition 
Purified cystatin was found to be highly specific for thiol proteases with 
no specificity for serine proteinase.The inhibition of proteinase was also 
studied by varying the molar concentration of proteinase at a fixed molar 
concentration of cystatin .The remaining activity of proteinase showed that as 
the concentration of proteinase was increased from 00.1-0.06pM it is 
progressively inhibited by the cystatin.concentration of BC (0.06 pM) results 
showed the stiochiometric ratio of 1:1 showing that one molecule of BC 
inhibits 1 molecule of active papain. 
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CONCENTRATION OF BC IN ng 
Ki determination 
Ki values have been determined after lowering the papain and inhibitor 
conoentration, which fevour the dissociation of the complex. Ki values were 
determined using the steady state equation derived by krupka and laidler 
(1959) 
k_ 
i--=k, 
1 
V„ 
Vo 
Where /Q, EQ and So are the initial concentrations of inhibitor, enzyme and 
Substrate, respectively 
Vo is the velocity without inhibitor 
Vj is the velocity in the presence of inhibitor 
I V 
The plot of —TT-against —^ is a straight line 
The slop of which gives 
ki(aap)=k. 
True Ki was obtained from a replot of Ki (aap) against [sj, 
Ki (aap) increase as a function of the substrate concentration. The true Ki 
value may be obtained from replot of Ki (aap) against [S]. 
The Ki values obtained from the plot were 1 nm for papain, ficin 1.85nm and 
for bromelain 2.25nm (Fig: 30-32) hence papain showing highest specificity 
for BC from other proteinase results summerised in Table-S 
ICso values 
IC50 is the concentration of the inhibitor at which 50% of the enzyme is 
inhibited. The ICso value obtained with various thiol proteinases have been 
summarized in the Table -5 the value obtained with various thiol proteinases 
papain ficin and bromelain showed that papain (0.09 iM) has maximum affinity 
foir BC while fidn (0.12 i^M) and bromelain (0.15 ^M) showed the less affinity 
towards BC 
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TABILE-5 KINETICS CONSTANT FOR INTERACTION OF BC 
WITH DIFFERENT PROTEINASES 
Proteinases 
Papain 
Ficin 
Bromelain 
Ki values 
1.0 nM 
1.85 nM 
2.25 nM 
10 50 
0.09 MM 
0.12 |JM 
0.15 MM 
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DISCUSSION 
Endogenous thiol proteinase inhibitors cystatins constitute the powerful 
regulatory system for overall cellular activity of cysteine proteinases 
[Sotiropoulou et al.(1997)]A proteinase inhibitor is of physiological importance 
because inhibition is achieved at physiological concentration of the inhibitor in 
a sulficiently short time with negligible dissociation of the complex. 
Cystatins are ubiquitously found in organisms, ranging from bacteria to 
mammals. They are classified into three distinct families based on their 
sequence homology, presence of disulphide bonds and molecular mass. 
Beaiuse of the various important physiological roles of cystatins they demand 
significant attention. Moreover they are assodated with several 
neui'odegenerative diseseas and pathological conditions including rheumatoid 
arthritis [Trabandt et al. (1991)], osteoporosis [Delaisse et al. (1991)], renal 
failure , cardiovascular and cancer diseases [Kabanda et a! (1995), Servais 
(2008)1 resulting due to imbalance of endogenous cysteine proteinases and 
their inhibitors. 
Extensive woric has been earned out for the purification and 
characterization of these inhibitors using various isolation procedures. 
Cysrtatins have been purified and characterized from various sources 
including bovine muscle [Bige et al. (1985)], goat kidney [Zehra et al. (2005)], 
human spleen [(Jarvinen M (1982)] human liver [Green et al. (1984)], amyloid 
fibrils [Cohen et al. (1983)] human placenta [Rashid et al. (2006)] and sheep 
plasma [Baba et al. (2005)], The CPIs have been isolated in multiple forms 
from several organs. However, brain being the key organ of the mammalian 
system was chosen for the present study as lacunas exist in the purification 
and physic-chemical characterization of cystatin from buffalo brain. Thus, it 
was envisaged that a thorough and systematic study of CPI from this source 
will be helpful in understanding in-deptti about the cystatins of mammalian 
system and to compare its properties with other known mammalian cystatins. 
The progress of a typical purification is summarized in /Tab/e-4/. The 
procedure adopted for purification of cystatin from buffalo brain is slightly 
modified from that reported by Bige (1985).\n the present wori^  purification of 
buffalo brain cystatin was achieved using a three step procedure including 
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alkaline treatment at pH 11.0, ammonium sulphate fractionation and gel 
filteiration chromatography The precipitated protein obtained after 40-60 % 
ammonium sulphate fractionation was diaiyzed and loaded on sephadex G-75 
column. A major protein peak with significant papain inhibitory activity was 
obtained [Fig-18] 
The fractions con'esponding to the peak-I with significant inhibitory 
activity were pooled and lyophilized for further analyses. The procedure is 
efficient and simple with a fold purification of 384.72 and percent yield of 
64.13. Purification of CPIs from ottier sources has been reported using a 
combination of several techniques like affinity chromatography, 
chromatofocussing, gel filtration and ion exchange chromatography [Anastasi 
et al. (1983) , Evans and Banrett (1987) , Rashid et ai (2006) Baba et al. 
(2005)]. Our simple procedure has given better yield and fold purification as 
compared to the values reported in literature for some other species [Bige et 
al. (1985)1 [Table-1] 
The inhibitor protein migrated as single band on native PAGE 7.5 % 
gel , however in reducing and non reducing SDS PAGE (12.5% gel) it 
showed two bands , indicating that the two subunits are joined by non 
covalent forces [Fig-20]. The molecular weigth obtained by SDS PAGE as 
shown in Fig-21 .The relative mobility of each marker protein was plotted 
against their log molecular weight .The molecular weight obtained by SDS 
PAGE for two the subunits were 31.62 kDa and 12.58 kDa which is equivalent 
to was 44.2 kDa.lt was further determined by gel filteration under native 
condition by passing marker proteins through Sephadex G-75 column. The 
VfiA/o ratio for each protein obtained from gel filteration was plotted against 
Log M of marker proteins [Fig-22]. Molecular weight obtained from gel 
filteration chromatograghy was found to be 43 .6 kDa.Cystatins from tissues 
are usually small inhibitors having Mr in the range of 11 to 25 KDa [Rashid et 
al. (2006), Green et al. (1984), Zabari et al. (1993), Turk et al. (1995)]. Now 
contrasted with these reports on low molecular mass. Ylonen et al. [1999] 
isolated and purified high molecular mass thiol proteinase inhibitors (of 43 
kDa and -52 kDa) from the skin of Atlantic salmon. Cystatin isolated from 
goat kidney was reported to have a molecular mass of 67 kDa [Zehra et al. 
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(2005)]. Recently, the work from our lab, has reported the purification of a 
high molecular mass cystatins from goat lung jKhan and Bano (2009)] and a 
cystatin of 70.8 kDa isolated from goat brain [Sumbul and Bano (2006)] 
Gesnerally type I and type II cystatins isolated from tissues lack carbohydrate 
content. However.the presence of carbohydrate content has been reported in 
some type n cystatins like rat cystatin C isolated from urine is slightly 
gfycosylated [Esnard et al. (1990)] and cystatin isolated from goat kidney has 
also been found to be slightly glycosylated [Zehra et al. (2005)]. Ni et al. 
(1997) found cart)ohydrate attachments in cystatin E. Glycosylation has also 
been demonstrated in cystatin F from the immune cells and in cystatin M 
isolated from primary tumor cell lines [Ni et al. (1998), Sotimpoulou et al. 
(1997)]. Presence of carbohydrate chains is a distinguishing feature of type III 
c/statins, the kininogens [Salvesen et al. (1985) , Gounaris et al. (1984) , 
Baba et al. (2005)].Ana\ys\s of all the results showed BC possessed high 
molecular weight negligible amount of CHO content and no suiphydryl groups. 
Hydrodynamic parameter for BC as detemiined firom gel filtration behavior 
SLiggested a stokes radius 27.3 A° [Fig-23] and diffusion coefficient of 8.1 
x10'^  cm /^ sec. The values of stokes radius and Smax/S ratio can be used to 
predict the shape of the protein molecule [Schurmann et al (2001)] Globular 
proteins typically have Smax/S ratio of 1.2-1.3 (for example catalase and 
serum albumin have Smax/S of 1.20 and 1.29), and the ratio increases to 1.6-
2.0 or more for elongated proteins [Ehckson (1982)]. For BC Smax/S ratio was 
calculated to be 1.2. The values of stokes radius and Smaj^ S ratio for BC are 
in close agreement with those of ovalbumin, suggesting that BC is a globular 
in shape. 
Effect of pH on BC activity was examined at various pH values [Fig-24] 
results show ttiat the purified inhibitor Is stable in the pH range 3-10. Stability 
of BC was also investigated as a function of temperature in the range of 30-
90°C in 0.05M sodium phosphate buffer of pH- 7.5 by monitoring its papain 
inhibitory activity [Fig-25] .BC when incubated at constant temperature of 90 
°(^  for varying time interval where it retained almost 65% of its activity upto 20 
miin and had 45% activity till 80 minutes [Fig-26] .These properties are in 
accordance witii other reported cystatins like that from bovine Muscle , 
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chicken cystatins , stefin A and stefin B. [Barwtt et al. (1984), Machleidt 
(1986))] it is also in accordance with high molecular weight cystatins 
reF>orted from goat kidney and human placenta [Zehm ( 2005) , Sumbul 
(2006) , Rashid et al. (2006)]. BC showed maximum emission at 340nm 
when excited at 280 nm. However on complexation with papain the 
fluorescence of BC was enhanced and maxima shifted to 350nm [Fig-28]. 
These changes suggest that the environment of tryptophan residue is 
pnjdominantly perturbed either by exposure of aromatic residue to the solvent 
or it may originate from local interactions affecting chromophoric groups of ttie 
two proteins. Difference spectrum of Cystatin papain complex showed ti^ench 
at 245 nm and positive peak at 285 nm [Fig-27] These spectroscopic 
changes indicate ttiat tiie environment of several aromatic amino acid 
residues in protein have been altered upon interaction of the inhibitor witii 
paipain, such changes are consistent with earlier reported results for 
interaction of low and high molecular weight Kininogen's [Baba et al. (2005)], 
cystatin from human placental [Rashid (2006)] and rat cystatin witti papain 
[Takeda (1988)] Studies were also done for inhibition of various cystiene 
proteinases by cystatin. BC was found to be potent inhibitors of thiol 
proteinases. [Fig-29] It is evident by tiieir Ki values. It was readily apparent 
tiiat tiie degree of inhibition varied wrtii absolute concenfration of tiie inhibitor 
as expected for tight binding reversible inhibition. The brain cystatins 
exhibited a Ki value for papain as InM [Fig-30], for ficin it was 1.85 nM 
[Fig-31] and for bromelain the value was found to be 2.25 nM respectively 
[F'ig-32], as shown in Table-5. A comparison of Ki (app) values indicates that 
this cystatin has highest affinity for papain, then ficin and least witii bromelain. 
It has been reported that cystatin isolated from other sources generally do not 
inhibit bromelain but in our present shJdy bromelain is found to be inhibited by 
cystatin as reported eariier for goat kidney [Zehm et al. (2005)], human 
placental cystatin [Warwas and Sawicki (1985) Rashid et al. (2006)] and 
human spleen CPI [Jarvinen and Rinnie (1982)].The values are in good 
comparison witti other proteinase inhibitors. The Inhibition constant (Ki) for 
chicken cystatin and is reported to be 5 x 10"^ ^ M for botii with papain. Ki 
values of nanomolar range has been given for cathepsin B, H and L witii 
cystatin A, Barrett et al. (1984), cystatin C, Machleidt et al. (1986), chicken 
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cysjtatin and cystatin D, Balbin et al. (1994). The Ki values of various cystatins 
have been summarized in Table-5. 
The increasing value of KI for BC with an increase in the substrate 
concentration suggests the inhibition to be competitive. This finding Is 
supported by the apparent results of Nicklin and Barrett (1984) for the 
inhiibition of human cathepsin B by chicken cystatin. KI (app) values for 
chicken cystatin with papain and cathepsin B was reported as 0.05 and 
0 39nM and 1.85 and 3.68nM respectively. 
The results of the chapter gave comprehensive Information about the 
purity molecular weight, shape, specificity and kinetics of inhibition of BC with 
papain, ficin and bromelain. The overall comparison showed that BC has 
compact In shape and inhibited papain more effectively as compared to other 
two proteinases. 
The binding stoichiometry of BC with papain is found to be 1:1 
A(X)urate K, values were detenmlned by woridng at lower enzymes 
ccmcentrations and using equation derived by [Krupa and Laidler (1959), 
Henderson (1972)]. IC50 is the concentration of inhibitor at which 50 % of the 
enzyme is inhibited IC50 value of BC for the three proteinases papain , ficin 
and bromelain were 0.09 pM , 0.12 pM and 0.15 pM respectively .Low IC50 
VciJue for papain suggests a greater affinity for the inhibitor towards the 
enzyme. Hence, the lowest value for papain further justifies the higher affinity 
of the purified cystatins for papain. These value indicate that the affinity of BC 
for these proteinases are in order of papain > flcin> bromelain. Katunuma and 
Kominami (1985) isolated Cystatin from rat liver have found the IC50 value 
0.16pg for papain and 0.046pg for ficin and IC50 value of 4.2pg was obtained 
for cathepsin B and 0.14pg for cathepsin H. 
Owing to the absence of caribohydrate content, disulphide linkages and 
all other results obtained for BC, It can be placed In type I cystatins, the 
Stefins class of cystatin superfamlly. BC however resembles cystatin purified 
from goat kidney [Zetira (2005)] and other cystatins with respect to high 
molecular weigth hence, it is more appropriate to conclude that BC is a 
variant of class I and class II of cystatin superfamily. Furthermore, it can also 
be concluded that all tissue cystatin are not same because of the specific 
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physiological function they perfbmi in the mammalian body. Owing to tfie 
importance and myriad of crucial functions cystatins perform in the 
mammalian txxiy, tfie sfojdy is of great significance as it sheds light on the 
pihysicochemical properties of cystatins of one of the most important 
mammalian organ, the brain. 
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3.2 RESULT 
3.2.1 NITRIC OXIDE (NO) INDUCED FUNTIONAL AND 
STRUCTURAL MODIFICATION OF BRAIN CYSTATIN 
Functional inactivation of Cystatin by nitric oxide [NO] 
When Cystatin was incubated with NO, generated by the reaction of 
SNP at varying concentrations there was 54% loss in antiproleolytic activity at 
50pM of SNP for 30 min of incubation. This loss in antiproleolytic activity 
increased to 84% at 2mM concentration.However increase in length of 
e}cposure upto 2 hrs at 50 pM concentration did not show any significant 
dejcrease in antiproteolytic activity, 59% loss was noted after after 1 hrs of 
incubation which increase to 66% after 2!4 hrs of incubation [Table-6 and 7]. 
Structural modification of BC by nitric oxide [NO] 
Nitric oxide when generated from 50pM of SNP resulted in the major 
loss of tryptophan fluorescence (38%), it was observed that when BC 
incubated with NO generating SNP, as the concentration increases 
fluorescence intensity decreases upto 97% at 2mM [Fig-33] this 
concentration when varied with time causes 48% loss in tryptophan 
fluorescence after 1 hrs of incubation, decrease in tryptophan fluorescence 
increased upto 59% at 2:30 hrs of incubation [Fig-34]. 
Prevention of structural and functional modification of BC by 
curcumin 
Curcumin (0-50 pM) was used to validate its scavenging capacity for 
NO and protection of Cystatin against the NO damage. The results indicated 
that when Cystatin was incubated with SNP, in the prescence of curcumin it 
was able to deplete SNP induced damage to BC, this damage is maximally 
rejduced by 50\iM of curcumin , the loss in tryptophan fluorescence when 
incubated with SNP for 30 min was 38%. This loss decrease to 27% when 
incubated along with 30pM of curcumin when this concentration increases 
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TABLE-6 EFFECT OF VARYING CONCENTRATION OF SNP 
ON ANTIPROTEOLYTIC ACTIVITY OF CYSTATIN 
Cystatin (1pM) was incubated for 30 min with different SNP 
concentrations taking native Cystatin inhibitory activity as 100%. 
was measured by caseinolytic method ofkunitz(1947) 
S.NO 
1 
2 
3 
4 
5 
6 
' 
Different Concentrations of SNP 
incubated along with BC(IMM) 
BC alone 
BC +0.05 Mm SNP 
BC + 0.1 mM SNP 
BC + 0.2 mM SNP 
BC + 0.5mMSNP 
BC +1 mM SNP 
BC + 2 mM SNP 
% Remaining 
inhibitory 
Activity 
100 
46 ± 0.59 
40 ± 0.91 
32 ± 0.92 
25 ±0.77 
19 ±0.91 
16 ± 0.51 
All data are expressed as mean ± S.E for four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
piobability level of 0.05 was selected showing results are significant. 
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TABLE-7 EFFECT OF VARYING TIME INTERVALS ON 
ANTIPROTEOLYTIC ACTIVITY OF SNP TREATED 
CYSTATIN. 
BC was incubated with SNP (O.OSMm) for varying time interval 
taking native inhibitory activity as 100%. Inhibitory activity was 
measured by caseinolytic method of kunitz (1947) 
S.NO 
1 
2 
3 
4 
5 
6 
7 
8 
Time of Incubation of 
SNP (0.05mM)with BC(IMM) 
BC alone 
Omin 
ISmin 
30mln 
60min 
90min 
120 min 
150 min 
% remaining 
Inhibitory Activity 
100 
51 ± 0.93 
49 ± 0.87 
46 ± 0.59 
41 ± 0.64 
39 ± 0.62 
35 ± 0.91 
34 ±0.71 
All data are expressed as mean ± S.E for four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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further, loss in tryptophan fluorescence decreased to 8% at 50pM of curcumin 
concentration. [Fig-35]. The similar results are obtained when caseinolytic 
activity was assessed, showing maximum protection at 50pM of curcumin 
[Table-8]. 
IF r^eventive effect of Querecitin on structural and functional 
inactivation of BC 
With varying concentration of querecitin (50-250 [iM) there is 
prevention of degradation of BC by NO. The functional damage is reduced to 
20% at 150|JM of querecitin while this damage was further condensed as the 
concentration of querecitin increase to 250[JM , showing only 11% decrease 
in antlproteolytic activity. /Taft/e -9/. When SNP was incubated with Cystatin 
the decline in tryptophan fluorescence was 38% , this loss in tryptophan 
fluorescence reduced to 25% at 150pM of quercetin. [Fig-36] which was 
further reduced to 13% at 250pM of quercetin. Showing maximum protection 
by 250 jjM of quercetin , the measurement of antlproteolytic activity and 
fluorescence along with quercetin shows protective effect by reducing the 
damage caused by SNP at 50|JM 
3.2.2 HYPOCHLOROUS ACID (HOCI) INDUCED STRUCTURAL AND 
FUNCTIONAL MODIFICATION OF CYSTATIN 
Structural modication of Cystatin by hypochlorous acid (HOC!) 
When IpM of BC was incubated with increasing concentration of HOCI. 
The samples were analyzed for impact on structural Integrity of BC by the 
t.(£jchnlque of fluorescence [Fig-37] Significant loss In native protein was 
observed (73%) when Cystatin was incubated with IpM of HOCI. very low 
fluorescence intensity was observed beyond 5|JM of HOCI , while emission 
maximum remained unaffected at all concentration of HOCI. 
Functional modification of BC in the prescence of HOCI 
The exposure of IpM of Cystatin to varying concentration of HOCI 
njsulted in remarkable loss In antlproleolytic activity as determined by the 
method of Kunitz (1947) at concentrations as low as luM of HOCI [Table-10] 
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TABLE-8 EFFECT OF VARYING CONCENTRATION OF 
CURCUMIN ON ANTIPROTEOLYTIC ACTIVITY OF 
NITRIC OXIDE TREATED BRAIN CYSTATIN. 
Cystatin (I^JM) was incubated with SNP (O.OSMm) in the 
presence and absence ofcurcumin taking native Inhibitory 
activity as 100%. It was measured by caseinolytic method of 
kunit2(1947). 
S.NO 
1 
2 
3 
4 
5 
6 
7 
Different Concentrations of 
Curcumin incubated with 1 pM of 
BC along with SNP 
BC( native with out SNP) 
SNP + Brain Cystatin 
BC+ SNP+10 [M Curcumin 
BC+ SNP+20 MM Curcumin 
BC+ SNP+30 |iM Curcumin 
BC+ SNP+40 MM Curcumin 
BC+ SNP+50 MM Curcumin 
% Remaining in 
inhibitory Activity 
100 
46 ± 0.59 
72 ±0.93 
80 ± 0.77 
85 ± 0.90 
88 ± 0.77 
90 ± 0.63 
All data are expressed as mean ± S.E for three different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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TABLE-9 EFFECT OF DIFFERENT CONCENTRATIONS OF 
QUERECITIN ON ANTIPROTEOLYTIC ACTIVITY OF 
NO TREATED CYSTATIN. 
BC (IpM) was incubated with SNP (O.OSMm) for 30 min in the 
presence and absence of querecitin taking native as 100%. 
Inhibitory activity was measured by caseinolytic method of 
Kunitz (1947) 
S.NO 
1 
2 
3 
4 
5 
6 
7 
BC with different concentration of 
Querecitin along SNP 
BC alone 
SNP+Cystatin 
BC+ SNP +50 MM Querecitin 
BC+ SNP +100 |JM Querecitin 
BC+ SNP +150 MM Querecitin 
BC+ SNP +200 \iM Querecitin 
BC+ SNP +250 |iM Querecitin 
% Remaining 
inhibitory Activity 
100 
46 + 0.59 
48 ±0.93 
77 + 0.51 
80 ± 0.77 
83 + 0.75 
89 ±0.92 
All (iata are expressed as mean ± S.E for three different sets of experiments 
sitatical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant 
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TABLE-10 EFFECT OF VARYING CONCENTRATrONS OF 
HOCL ON ANTIPROTEOLYTIC ACTIVITY 
OF CYSTATIN. 
Cystatin (IpM) was incubated with different concentrations of 
HOC!. For 30 min Inhibitory activity was measured by the 
caseinolytic method of kunitz (1947). 
S.NO 
1 
2 
3 
4 
Different Concentrations of HOC! 
incubated along with BC(1|JM) 
BC alone 
BC +1 pM HOCI 
BC +3 MM HOCI 
BC +5 MM HOCI 
% Remaining 
Inhibitory Activity 
100 
68 ±0.88 
50 ±0.71 
18 ±0.77 
AW (iata are expressed as mean ± S.E for three different sets of experiments 
sitatiica! significance was conducted employing ONE WAY ANOVA .a 
Firot)ability level of 0.05 was selected showing results are significant 
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which lead to 32% loss in activity of BC. The inhibitor was only 18% active at 
J)MM of HOC! showing 82% loss in activity. Beyond this HOCI concentration 
no papain activity was detected. 
I^ rc»tective effect of different scavengers on the damage of BC by 
HOCI 
Flavonoids have been exclusively studied for their anti oxidant 
projperties against free radicals damage [Fig-SB] however their effect on 
hypochlorous acid mediated damage is less known. 
Thus present work was also aimed for exploring the potential of these 
compounds curcumin, quercetin, Glucose, sodium benzoate and Mannitol for 
their effect on BC diminished the extent of loss of antiproteolytic activity and 
lluorescence intensity, causing the inhibitory potential as well as fluorescence 
of cystatin close to native. 
Glucose was found to be most effective as it caused only 47% 
(Jecrease in fluorescence of BC in the presence of HOCI as compared to 55-
77 % queching in the prescence of other scavengers These results are 
supported by the inhibitory activity detenninations in the presence of 
scavengers listed in Table-ll ,which shows these coumpunds are effective 
ior protection in the order of glucose > querecitin > curcumin > mannitol > 
sodium benzoate 
3.2.3 HYDROGEN PEROXIDE INDUCED FUNTIONAL AND 
STRUCTURAL MODIFICATION OF CYSTATIN 
Hydroperoxidase such as H2O2 and lipid hydroperoxidase have been 
implicated as mediator of cellular injuries in a variety of clinical conditions 
including cancer etc [Pryor et al 2006]. 
Thus deleterious effects of H2O2 and protective effect of polyphenols 
and other compounds were assessed on BC. 
To directly quantitate the effects of exposure of oxidant [H2O2I on BC, the 
antiproteolytic activity of BC was measured in the presence of the component 
t)y the method of Kunitz (1947) using casein as substrate as described in the 
methods section. 
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TABLE-11 EFFECT OF DIFFERENT SCAVENGERS ON 
ANTIPROTEOLYTIC ACTIVITY OF HOCI TREATED 
CYSTATIN. 
BC (1M|j) was incubated with different scavengers (25mM) in 
the presence of HOCI (5|JM) for 30 min .Inhibitory activity was 
measured by caseinolytic method of kunitz (1947). 
S.NO 
1 
2 
3 
i 4 
5 
6 
7 
BC (1|JM )incubated with HOCI in 
the prescence of each scavengers 
25mM 
BC aione 
BC+HOCI (5 pM) 
BC+HOCI (5 pM)+Curcumin 
BC+iHOCI (5 pM)+QueFecitin 
BC+HOCI (5 pM)+Sodium benzoate 
BC+HOCI (5 pMHMannitol 
BC+HOCI (5 pM)+Glucose 
% Remaining 
inhibitory Activity 
100 
18 ± 0.77 
68 ± 0.93 
66 ± 0.60 
55 ± 0.90 
35 + 0.75 
47 ± 0.51 
All data are expressed as mean ± S.E for four different sets of experiments 
sitatical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant 
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Functional inactivation of BC by H2O2 
H2O2 caused only modest inactivation of cystatin. Even at high 
concentration of H2O2 (250mM) 40% of antiproleolytic activity of BC was 
retained P'able-12] To study the impact of H2O2 on activity of BC as a 
function of time IpM of BC was incubated with 250mM H2O2 in dark for 
vairying time interval [0-60 min] and activity of Cystatin was determined by the 
mejthod of [Kunitz (1947)]. A gradual decline in activity of BC was observed 
showing 60% loss after 30 min of incubation with H2O2 (250 mM). 
Structural modification of BC In the prescence H2O2 
1 pM of Cystatin was exposed to {1-250pM) H2O2 in dark for 30 min and 
the! samples were analyzed by fluorescence spectra, significant changes were 
observed [Fig-39], the results obtained showed emission maxima at 340nm 
with H2O2 incubation, showing no shift in X^ax. At 1 mM of H2O2 showing no 
significant decline in fluorescence intensity while at higher concentration of 
H2O2 {250pM) the fluorescence intensity decreased to 82% as compared to 
native. 
The fluorescence result of BC under native conditions at 1mM of H2O2 
not showed significant decline in fluorescence intensity. When Cystatin was 
incubated with H2O2 at 250pM and studied as a function of time, with in 10 
min the antiproteolytic activity decreased 77 % with fluorescence intensity 
dec;rease to 82%. fTable -13 and Fig-.40] 
PROTECTIVE EFFECT OF DIFFERENT SCAVENGER'S ON 
STRUCTURAL AND FUNCTIONAL DAMAGE OF CYSTATIN 
CAUSED BY H2O2 
The effect of various scavengers on H2O2 induced Cystatin inactivation 
was studied using sodium benzoate, querecitin, curcumin and mannitol. 
A/lannitol did not show protection infact offered 27% enhancement in 
fluorescence intensity of treated BC since mannitol and sodium benzoate are 
specific hydroxyl scavengers.This suggest only partial involvement of these 
radicals in H2O2 mediated BC damage. Among antioxidants and polyphenols 
curcumin {120pM) and Quercetin offered significant (80%) protection 250mM 
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TABLE-12 EFFECT OF VARYING CONCENTRATIONS OF H2O2 
ON ANTIPROTEOLYTIC ACTIVITY OF CYSTATIN 
BC(1MM) was incubated with different concentration of H2O2. I 
nhibitory activity was measured by caseinolytic method of 
kunitz (1947) taking native as 100%. 
S.NO 
1 
2 
3 
4 
5 
6 
Different Concentrations of H2O2 
incubated along with BC(IMM) 
BC alone 
BC + 1 mM H2O2 
BC + 10 mM H2O2 
BC + 50 mM H2O2 
BC + 100 mM H2O2 
BC + 250 mM H2O2 
% Remaining 
Inhibitory Activity 
100 
88 + 1.2 
76 ± 2.1 
52 ± 0.98 
45 ±1.1 
40 ± 0.98 
All data are expressed as mean ± S.E for three different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
lprot)ability level of 0.05 was selected showing results are significant. 
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TABLE-13 EFFECT OF H2O2ON ANTIPROTEOLYTIC ACTIVITY 
OF CYSTATIN INCUBATED FOR VARYING 
TIME INTERVAL. 
BC (1MM) was incubated with H2O2 (250mM) for varying time 
interval.The Inhibitory activity was measured by caseinolytic 
method of kunitz (1947) taking native as 100% 
S.NO 
1 
2 
3 
4 
5 
6 
r 
7 
8 
Time of Incubation of 
H2O2(250mM)with BC(IMM) 
BC alone 
Omin 
10min 
20min 
30min 
40min 
SOmin 
eOmin 
% Remainng 
inhibitory 
Activity 
100 
82 ± 0.93 
77 ±1.22 
56 ±0.60 
40 ± 0.98 
12 ±0.93 
8.5 ± 0.62 
6 ± 0.62 
All data expressed as mean ± S.E for four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA a 
probability level of 0.05 was selected showing results are significant. 
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of H2O2 incubated with I^JM of Cystatin The samples when analyzed for 
ajseinolytic activity of papain [Kunitz (1947)] In the prescence of H2O2, BC 
shov/ed mediated decline in activity P'able-14]. However at 120pM of 
curcumin and Quercetin prompted restoration of lost activity near to native 
Thesie natural antioxidant also neutralize the loss in tryptophan fluorescence 
and retrieved the native like fluorescence pattern In cystatin, with curcumin 
and querecitin showing maximum protection. [Fig-41] 
3.2.4 RIBOFLAVIN INDUCED STRUCTURAL AND FUNCTIONAL 
MODIFICATION OF BRAIN CYSTATIN 
Riboflavin upon mediation with fluorescent light generates reactive 
oixygien species like superoxide anion (O2) and triplet oxygen (^ 02), flavin 
radicals and substantial amount of hydroxyl radical [Husain et al 2005]. 
Functional inactivation of brain Cystatin by Riboflavin 
Effect of riboflavin on BC function was assessed by monitoring 
changes in its antiproleolytic activity by caseinolytic assay of papain [Kunitz 
1947] 1pM of BC was incubated with increasing concentration of 
photoilluminated riboflavin (5-50pM) or with 50pM of riboflavin for varying time 
intervals. The results obtained are summarized in [Table-15] Exposure of BC 
to increasing concentration of riboflavin resulted in rapid dedine of 
antiproteolytic activity at 50 pM concentration 76 % activity was lost with more 
tfian half of its inactivation taking place at concentration as low as 20|JM 
similariy increase in length of exposure (0-60 min) [Table-16] of BC with 
riboflavin causes loss of inhibitory activity towards papain, with more than 
50% inhibition taking place after 10 min of incubation. 
Structural modification of Cystatin by riboflavin 
Treatment of Brain Cystatin with photo illuminated riboflavin drastically 
altered its intiinsic fluorescence properties. The fluorescence emission 
specti^ a of native BC gave an emission maximum at 340nm when excited at 
280nm. BC (1pM) was incubated wth increasing concenti-ation of photo 
illuminated riboflavin [5-50pM] and was analyzed by fluorescence 
speciti-oscopy [Fig-42] to assess tfie effect on tiie conformation of protein. 
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TABLE-14 EFFECT OF DIFFERENT SCAVENGERS ON 
ANTIPROTEOLYTIC ACTIVITY OF H2O2 TREATED 
BRAIN CYSTATIN. 
BC (1 MM) was incubated with H2O2 (250mM) in the presence 
of different scavengers (25mM).inhibitory activity was 
measured by caseinolytic method of l<unitz(1947). 
S.NO 
1 
2 
3 
4 
5 
6 
BC Incubated with H2O2 
along different scavengers 
BC alone 
BC4- H2O2 (250mM) 
BC+ H2O2 (250mM) 
+ Querecitin (120fiM) 
BC+ H2O2 (250mM) 
+ Curcumin(120)xM) 
BC+ H2O2 (250mM) 
+ Sodium benzoate 
BC-i- H2O2 (250mM) 
+ Mannitol 
% Remainng 
Inhibitory Activity 
100 
40 + 0.98 
83 ± 0.94 
82 ± 0.92 
72 + 0.92 
75 ± 0.75 
All data are expressed as mean ± S.E for three different sets of experiments 
static^ al significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
132 
250-, 
—•—Cystatin 
H^O^+Cystatin 
HjOj+Cystatin+Scavengers 
curcumin 
@ querecitin 
^ sodium benzoate 
< mannitol 
350 
WAVELENGTH 
Percent Decrease in Tryptophan Fluorescence 
in the presence of Scavenger 
Cystatin 
alone 
flliioiescence 
100 
H2O2+BC 
82 
curcumin 
20 
querecitin 
21 
S.benzoate 
93 
mannitol 
-
TABLE-15 EFFECT OF VARYING CONCENTRATIONS OF 
PHOTOILLUMINATED RIBOFLAVIN ON 
ANTIPROTEOLYTICACTIVITY OF BRAIN CYSTATIN 
Cystatin (1 pM) was incubated for 30 min with different 
Riboflavin concentration. Inhibitory activity was measured by 
caseinolytic method of Kunitz (1947) taking native as 100%. 
S.NO 
1 
2 
3 
4 
5 
6 
7 
Different Concentrations of 
Riboflavin incubated along with 
BC(IMM) 
BC alone 
BC + 5 MM Riboflavin 
BC -f-10 (JM Riboflavin 
BC -i- 20 |JM Riboflavin 
BC + 30 |JM Riboflavin 
BC + 40 |JM Riboflavin 
BC + 50 |iM Riboflavin 
Percent Inhibitory 
Activity 
100 
62 + 0.77 
57 ± 0.88 
40 ±1.08 
38 ± 0.92 
30 ±0.77 
24 ±0.55 
All data are expressed as mean ± S.E for three different sets of experiments 
static;al significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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TAIBLE-16 EFFECT OF RfBOFLAVIN ON ANTIPROTEOLYTIC 
ACTIVITY OF CYSTATIN INCUBATED FOR 
VARYING TIME INTERVAL. 
BC {1|JM) was incubated with (50|JM) for varying time interval. 
Inhibitory activity was measured by caseinolytic method of 
Kunitz (1947) taking native as 100%. 
S.NO 
1 
2 
3 
4 
5 
6 
7 
8 
Time of incubation 
Riboflavin(50MlM)with BBC(1|JM) 
BBC 
0 
10min 
20min 
30mln 
40min 
SOmin 
60min 
% Remaining 
Inhibitory 
Activity 
100 
45 ± 0.62 
38 ± 0.93 
29 ± 0.92 
24 ± 0.55 
18 ±0.78 
12 + 0.77 
9 ± 0.88 
All data are expressed as mean ± S.E for three different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA a 
probability level of 0.05 was selected showing results are significant 
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Samples were excited at 280nm and emission range was 300-400nm. 
At lOpM of riboflavin no change in emission Xmax however 29% decline in 
fluorescence intensity was observed. Beyond this concentration (20|JM) lOnm 
of t>lu€j shift in fluorescence intensity for native was observed with profound 
decline in tryptophan fluorescence (45%). Effect of 50pM of riboflavin on 
intrinsic fluorescence with 1pM of BC was also studied for various time 
periods of (0-60 min) .A time dependent gradual loss in fluorescence intensity 
with similar blue shift of 10nm was observed after 10 min of incubation [Fig-
43]. 
PROTECTIVE EFFECT OF SCAVENGERS AND ANTIOXIDANTS 
To detect the type of ROS involved in Cystatin inactivation various free 
radical scavengers were used. The results obtained showed that maximum 
suppression of BC inactivation was caused by potassium Iodide (40%) closely 
followed by sodium azide, sodium azide Is a scavenger of singlet oxygen and 
potassium iodide is a scavenger of flavin triplet state sodium benzoate, 
mannitol and thio urea eliminates hydroxyl radicals [Khan and Khan (2004), 
Martinez Cayucia (1995)]. These hydroxyl radical scavenger also offered 
some protection showing moderate role of this radicals in riboflavin mediated 
BC inactivation Biological antioxidant Glucose was analyzed for suppression 
of cystatin inactivation by riboflavin and it was found to be the most effective 
among natural antioxidants (57% protection) paWe-.f 77 
To ascertain the effect of various scavengers to defeat the unfavorable 
consequences of photodynamic action of riboflavin on structure of BC, 
fluorescence spectra of treated cystatin in the presence of scavengers was 
obtained and percent retention of tryptophan fluorescence was determined. 
[Fig-'U] Treated BC retained only 32% of native tryptophan fluorescence in. 
reaffirming the involvement of flavin triplet state and singlet oxygen in 
photodynamic modification of BC by riboflavin in the prescence of different 
scavengers, maximum retention of tryptophan fluorescence was shown by 
potassium iodide and sodium azide showed only 10 and 49 % decrease 
respectively Mannitol, Thio Urea and sodium benzoate exhibited only 10-15 % 
retention implicating only faint involvement of hydroxyl radical among 
biological antioxidant. Glucose again showed good protection. 
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TABLE-17 EFFECT OF DIFFERENT SCAVENGERS ON 
ANTIPROTEOLYTICACTIVITYOF RIBOFLAVIN 
TREATED CYSTATIN. 
BC (1 pM) was incubated with Riboflavin (50 |JM) for 30 min in 
the presence of different scavengers (25mM).lnhibitory activity 
was measured by caseinolytic method of Kunitz (1947). 
S.NO 
1 
2 
3 
4 
5 
6 
6 
7 
BC (1 MM) incubated with Riboflavin 
In the prescence of different 
scavengers 
BC alone 
BC + 50 MM Riboflavin 
BC •*- 50 \iM Riboflavin + Glucose 
BC + 50 MM Riboflavin + Potassium 
iodide 
BC + 50 MM Riboflavin + Sodium 
azide 
BC + 50 |JM Riboflavin Thiourea 
BC + 50 MM Riboflavin + Mannitol 
BC 4- 50 MM Riboflavin + Sodium 
benzoate 
% Remaining 
inhibitory 
Activity of BC 
100 
24 ±0.55 
57 ± 0.77 
40 ± 0.88 
37 ±0.91 
27 ±0.93 
20 ± 0.76 
10 ±0.68 
All (iata are expressed as mean ± S.E for three different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
pirol)ability level of 0.05 was selected showing results are significant. 
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DISCUSSION 
Reactive oxygen and nitrogen species (ROS/RNS) like superoxide anions, 
hyclroxyl radicals, hydrogen peroxide, and nitric oxide are the intermediates of 
regular pathway of aerobic metatx)llsm and processes. These reactive 
spc^ cies generated from nomnal metabolism or exogenous insults lead to 
pef oxidation of membrane lipids and damages to cellular macromolecules like 
DNA and proteins. Proteins are major targets for ROS as a result of their 
abundance in biological systems. Oxidants react rapidly with protein 
backbone and side chain residues causing various deleterious consequences 
like; protein damage and degradation [Davies et al. (1987a)], modification of 
amino acids [Davies et al. (1987b)l and changes in secondary and tertiary 
structures of proteins. 
NITRIC OXIDE (NO) is a pieitropic molecule that is needed for 
physiological function. It induces vasodilatation and inhibits apoptosis and 
plays a significant role in memory processes, making it a putatively valuable 
therapeutic agent in ageing associated diseases. However, NO can be 
harmful under oxidative stress conditions, due to oxidation of functional 
IDrotein especially In the brain. Thus, when NO is produced in excessive 
amounts in the brain. It changes from a physiological neuromodulator to a 
neurotoxic ^ctor. NO also act as a highly reactive free radical gas. It can 
participate as a cytotoxic effector molecule and pathogenic mediator when 
|}roiJuced at high rates by inflammatory stimuli induced nitric oxide synthase 
or over stimulation of constitutive fomis of enzyme [Radi (2004)]. In contrast 
to the protective action of low levels of NO, its excess has injurious outcomes 
due to worse oxidative damage [Pryor (2006)] 
Free radical NO leads to extensive loss of BC function. [Fig-6 and 7] 
There are number of reports for protein inactivation by NO through amino add 
modification e.g. goat lung cystatin [Khan et al. (2009)], and catalase [Sigfiid 
et al. (2003).Jhe results showed that nitric oxide free radical leads to 
functional and structural damage of BC. The functional inactivation of BC may 
be due to oxidation of tryptophan residues as shown by the intrinsic 
fluorescence studies. 
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The damage of cystatins by NO was further investigated, in the 
|)rei5ence of antioxidants .Use of curcumin and quercetin showed that these 
(X)mpounds can prevents. This damage to a very significant level fJable-B 
and Fig-35]. It was found that 50\iM concentration of curcumin and 250 \iM of 
(^ erecitin exhibited remarkable protection of BC against the functional P'able -
9] cind structural damage [Fig-36] by NO. 
Oxidative stress plays a major role in the pathogensis of various 
diseases including cerebral Ischemia- reperfusion injury, hemorrahage 
neuronal cell injury, hypoxia and cancer [vaiko (2007)]. It was reported that 
curcumin exhibits strong anti oxidant properties comparable to vitamin E and 
C [roda et al. (1985)] Dietary supplemantation of curcumin was also found to 
be beneficial in neurodegenative diseases such as Alzheimer, s diseases 
[Calabrese (2003), Yang (2005)] 
The present study is of great significance showing that purified Cystatin 
(x>uld be damage by reactive oxygen species which are generated during 
\/arious neural diseases. As cystatins play significant role in controlling the 
unv/anted proteolysis in mammalian system, thus btecause of their important 
functions they are involved in various pathophysiological conditions including 
[Beimtein et al. (1996)1 cerebral amyloid aniopathy [Jensson (1990)] and 
other neurodegenerative diseases [Shannon (2002)], their inactivation needs 
to be prevented.to maintain protease - antiprotease imbalance. 
HypochloFous Acid (HOCI) The reactive species like HOCI and H2O2 
have been recognized as characteristic components causing inflammation 
[Martinez-Cayuela 1995] Macrophages and neutrophils reduce molecular 
oxygen to superoxide anion, as a part of host defence system to neutralize 
the invading pathogens [Mamett et al. (2003)] The superoxide produced Is 
rapidly dismutated to hydrogen peroxide. Activated neutrophils release the 
esnz/me myeloperoxidase that reacts with H2O2 and chloride ions present to 
fomi HOCI [Mamett et al. (2003)] a reactive oxygen metabolite, that can 
nfioclify amino acid residues, induce confonnational changes in proteins and 
inactivate enzyme and enzyme inhibitors [ Wasil ei al.; Dean et al. (1997)] 
HOCI, a strong oxidant, is known to oxidize many other important 
biomolecules such as DNA, enzymes and antiproteinases [Jerlich et al. 
(2000), Whiteman et al. (2003), Szuchman-Sapir et al (2008)] The results 
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reveal that BC, in the presence of HOCI lost its antiproteolytic activity rapidly 
(within 30 min, 82% loss occurred at SpM HOCI). [Table-10] 
Inactivation of proteins like 02 M, by HOCI has been reported earlier. 
Whiteman et al. (2003) reported a 90% loss in activity of isolated oi and a 2 
macroglobulin in the presence of 7pM HOCI. HOCI usually causes 
aggregation of proteins as has been shown for fibronection [Vissers and 
Winterboum (1991)], caprine 02 M [Khan and Khan (2004)], ovalbumin 
[Olszowski et al. (1996)], apohaemoglobin and apomyoglobin [Chapman et al. 
(2003)]. HOCI reacts with amide groups of protein backbone and also with 
lTe€j amino groups of lysine residues of proteins yielding chloramines. These 
chloramines can than effectuate protein fragmentation. 
At low HOCI concentrations preferably lysines are modified limiting the 
rapiid backbone fragmentation [Hwakins and Davies (1998)]. The fluorescence 
|)rofile of HOCI-treated BC reveals complete loss of intensity at concentrations 
above 5pM without any change in Amax of emission. [Fig-37] Also, HOCI is 
prejudiced to modify tyrosine, phenylalanine (by chlorination and by 
sulphoxidation and oxy-acid formation) that to oxidize tryptophan [Stadtman 
and Levine (2003)].li)\s might also explain the unchanged Amax of BC mainly 
attributable to tryptophan. Curcumin (120 pM) was able to deplete HOCI 
induced damage to some extent [Fig-38], followed closely by querecitin. 
Diminution of hypochlorite induced damage on human serum albumin by 
f lavonoids has been reported by Flmzi et al. (2004). 
Hydrogen peroxidase (H202).lt was observed that H2O2 lead to 
inac;tivation of BC towards papain [Table-12] owing to destiuction of active 
site tryptophan residues. Major loss of tryptophan fluorescence intensity was 
observed in BC on incubation with 250 mM H2O2. [Fig-38] 
Quenching of Intrinsic fluorescence of BC witfi increasing H2O2 
concentration occurs probably due to oxidation of tryptophan residues leading 
to oonfomiational change as reported earlier [Khan and Khan (2004)]. H2O2 
wras found to be a mild inactivator of BC relative to HOCI (and other radicals 
studied). The ti-eated inhibitor lost only 40% of its antiproteolytic activity in 
presence of 250mM H2O2 .Use of scavengers showed prevention of H2O2 
mediated damage. [Table-14]. 
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The utilization of scavengers, quenchers and enhancers is the method 
used to investigate the role of ROS involved In the photosensitization reaction 
[R)fwkin et al. (1992)] and radical mediated damage. In order to investigate 
the type of ROS involved in inactivation of BC various scavengers like sodium 
benzoate mannitol, bioflavonoids, curcumin and querecitin were used. It was 
found that mannitol known to eliminate hydroxyl radicals have shown no 
preventive effect on H2O2 induced damage of BC. [Fig-41] While In case of 
sodium benzoate H2O2 showed marked red shift of 35nM, indicating changes 
in the microenvironment of tryptophan residues and the loss of native folded 
state of BC. 
Riboflavin on photoillumination generates singlet oxygen, hydroxyl 
radicals and flavin triplet state [Dahl and Richardson (1980)] .The results 
reveal the loss BC functional activity on exposure to photosensitized 
liboflavin. [Fig^2] This bears similarity to sheep plasma high molecular 
weight kininogen (HMWK) [Baba et al. (2004)], membrane proteins [Ali et al. 
(1991)], BSA, invertase, lysozyme and trypsin [Hasan et al. (2006)] damage 
cauised by photosensitized riboflavin. 
So free radical scavengers were used for detection of the type of ROS 
involved. /Tab/e-f 7/ shows the scavenging effect of sodium azide, potassium 
iodide, mannitol, and thiourea. Sodium azide is a scavenger of singlet oxygen, 
potassium iodide scavenges triplet state and thiourea and mannitol scavenge 
hydroxyl radicals [Martinez and Caycula (1995)]. Photoactivated riboflavin 
damage of BC showed the involvement of flavin triplet state in the damage. 
F^ otassium iodide protects 40% of inhibitory activity of BC caused by riboflavin 
inactivation. Retention of inhibitory activity in treated BC was also found in the 
presence of glucose, which is a known biological antioxidant [Arad et al. 
(1980)]. These findings indicate that BC inactivation and degradation 
piroc:eeds via hydroxyl pathway. 
Thus from the data obtained for riboflavin induced damage on BC, it can 
be conclude that hydroxyl radicals leads to extensive structural and functional 
modification of purified Cystatin. [Fig- 44 i,Table-17]. It was also found that 
potassium iodide also inhibits BC inactivation by riboflavin indicating 
involvement of flavin triplet state. Among biological antioxidants only glucose 
was found to have significant efl^ ect on BC inactivation. Thus results obtained 
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witli specific ROS scavengers suggested that singlet oxygen and flavin triplet 
state were predominantly responsible for BC damage. Same results are 
reported for sheep HMWK and catalase [Baba et al. (2004 ) ; Cardoso et al. 
(2006)1 and goat brain cystatin [Sumbul and Banc ^ 2008;;. Damaging effects 
lof riboflavin have been documented in various other proteins also . [Ali et al. 
(1991) . Hasan et al (2006)]. Among the various forms of ROS generated, 
singlet oxygen is of particular physiological significance because of its 
selectively long life in aqueous solution, its ability to cross cell membrane 
barrier and high reactivity towards biomolecules [Joshi (1998)]. 
Curcumin (Cur) and Querctin (QE) These bioflavonoid are known for 
exerting pleiotropic health benefit through their antioxidant and anti-
inflammatory, anti-inflammatory, antimicrobial anticancer and antidiabetic 
activities [Agganval et al. (2007) , Takahama et al. (2009) , Sreejayan and 
Rao (1997)]. 
In the light of this work and the previously reported results it can be 
esaid that curcumin and querecitin exhibits very beneficial effects against the 
damage caused by nitrogen free radicals and ROS .Efficacy of these natural 
antioxidants against the detrimental effects of NO, HOCI, H2O2 and 
photosensitized riboflavin studied on BC showed concentration dependent 
protective effect for all the four reactive species [Huang et al. (1988)]. 
The protective effects of curcumin may be attributed mainly to its 
aintioxidants properties. The study of the effects of curcumin and querecitin on 
inflammatory and other oxidative stress conditions may help to develop some 
novel drugs. 
Photodynamic effects of various sensitizers have long been applied to 
delineate stiuctural and functional properties of large number of enzymes and 
otiieir biologically active proteins p-lopkins and Spikes (1969)]. In tfie present 
study, it has been shown that BC is susceptible to reactive oxygen species 
generated by various oxidants ,which mimics biological exposure to oxygen 
radicals [Spike (1977)]. 
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3.3 RESULTS 
ANTIDEPRESSANTS 
Interaction of four drugs Amytriptyline, Fluoxetine, Haloperidol and 
Ooriepezil with cystatin 
3.3.1 INTERACTION OF AMYTRIPTYLINE WITH CYSTATIN 
For macromolecules, the fluorescence measurements can give some 
information about the binding of small molecules with proteins, such as the 
blinding constants, binding sites and binding affinity. Fluorescence intensity of 
a compound can be decreased or quenched by interactions of protein with 
drugs. 
F-luorescence Spectra of cystatin with Amytriptyline 
The fluorescence spectra of cystatin (IpM) in the presence of different 
concentrations of amytriptyline were recorded in the range of 300-400 nm 
uipon excitation at 280 nm. Amyhlptyline caused quenching of the intiinsic 
fluorescence of cystatin [Fig-45] with no shift in wavelength, however with 
increase in Amytilptyline concentration, fluorescence intensity was further 
decreased. 
The maximum decrease in fluorescence intensity (48%) occurred at 
8p /^l concentration . These results indicated tfiat tiiere were interactions 
betv/een amytilptyline and brain cystatin and the binding reactions resulted in 
non-fluorescent complex. 
Fluorescence quenching data was analysed by the Stern-Volmer 
equation. 
f - l + KJQl 
Where Fo and F are the steady-state fluorescence intensities in the 
absence and presence of quencher, respectively, Ksv the Stern-Volmer 
quenching constant and [Q] is the concentration of quencher. P'able-24] 
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Determination of binding constant (K) and numiser of binding sites 
When small molecules bind independently to a set of equivalent sites 
on a macromolecule, the equilibrium between free and bound molecules is 
given by the equation [Feng et al (1998) Gao et al (2004)] 
^^^^^' ^^ = log K + nlog[Ql 
Where K and n are the binding constant and the number of binding 
s»ites, respectively. Thus, a plot of Log (Fo-F)/F versus [Q] has been used to 
determine K as well as n. The value of K was found to be 3.01x10^ Mol'^  
and the no of binding sites were determined as 1 for amytriptyline. /TaWe- 24] 
Determination of AG° of interaction between Amytriptyline and 
(Nystatin 
The forces of interaction between drugs and biomolecules include 
hydrophobic force, electrostatic interactions, van der Waals interactions and 
l-jydrogen bonds. In order to identify the interacting forces between 
eim r^triptyline with cystatin, the thermodynamic parameters i.e. free change 
(AG°) of the interactions were calculated from the following equations: 
(T3ble-24) 
AG*'=-RTInk(KJ/mol) 
The value obtained for cystatin - amytriptyline interaction was -36.97 
k J/mol indicating the reaction to be spontaneous 
LIV-vis absorption spectra of Amytriptyline cystatin complex 
The interaction between Amytriptyline-cystatin was studied from UV-
\'\S absorption spectral data [Fig-46]. Cystatin concentrations were fixed 
at IpM while the Amtriptyline concentration was varied from 2pM-8pM. 
Absorption spectra of native Cystatin in the presence and absence of 
Amytriptyline were recorded in the range of 200-300 nm. 
148 
2.5-, 
2.0-
O 
I 
O 
CO 
OQ 
1 . 5 -
1.0-
0.5-
0.0 
^statin 
Airytriptylineakxie 
Amytriptyline concentration 
with cysfafin 
< 2nM 
4fiM 
- * - 6MM 
. 8nM 
200 220 240 260 280 
WAVELENGTH 
300 320 
The UV-vis absorption spectra were computed at all the antidepressant 
concentrations. However, no profound changes were noted at 2-8 pM 
>\mytriptyljne .The spectra obtained for BC at 2MM Amytriptyline shows two 
distinct positive peaks at 210 nm and 240 nm, the gross conformation of 
(iiiystatin at ail concentrations of Amytriptyline was found to be unaffected. The 
IJV absorption intensity of Cystatin increased with the variation of 
>\mytriptyline concentration. The Addition of drug did not result in the shift of 
Ji^ na* towards longer wavelength. However there was quenching in 
fluorescence. This evidence clearly indicated the interaction and some 
complex formation between drug and Brain Cystatin [Cui et al (2004) Hu et al 
(2004)] 
inhibitory activity of Cystatin in the presence of Amytriptyline 
Effect of Amytriptyline on Cystatin function was assessed by monitoring 
cihanges in its antiproleolytic activity by caseinolytic assay of papain [Kunitz 
1947] 1pM of Cystatin was incubated with increasing concentration of 
/^ m^ r^iptyline (2-8MM). The results obtained are summarized in [Table-18] 
When Cystatin incubated with Increasing concentration of Amytriptyline, it 
resulted in rapid decline of antiproteolytic activity showing 58% loss at 6pM 
sim>1riptyline with half of its inactivation taking place at a concentration of 
fiipM.The data obtained also indicated that inactivation of Cystatin by 
.Am r^triptyline is concentration dependent. 
3.3.2 INTERACTION OF FLOUXETINE WITH BRAIN CYSTATIN 
Studies on the binding mechanism between protein and small 
molecules provide useful infomiation. For example, a detailed characterization 
of drug-protein binding properties was essential for understanding the function 
of drugs hence, interest in dmg - protein interaction has attracted much 
attention. 
Fluorescence spectra of fluoxetine with brain cystatin 
In this study fluorescence spectra of Cystatin (1|JM) in the presence of 
different concentrations of fluoxetine were recorded in the range of 300-400 
nm upon excitation at 280 nm. 
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TAIBLE-18 Inhibitory activity of Cystatin in the presence 
Amytriptyline 
Changes in the inhibitory activity of cystatin (IJAM) after 
incubation with increasing concentration of Amytriptyline (2 -
S^ iM) for 30min in the final reaction volume of 1 ml In 0.05M 
sodium phosphate buffer pH 7.5. 
S.NO 
1 
2 
3 
4 
5 
Amytriptyline concentration with 
cystatin 
Cystatin alone 
Cystatin + 2 )JM Amytriptyline 
Cystatin +4 pM Amytriptyline 
Cystatin +6 pM Amytriptyline 
Cystatin +8 pM Amytriptyline 
%lnhibitory 
Activity 
Retained 
100 
71 ± 0.922 
57 ± 0.755 
42 ± 0.623 
38 ± 0.98 
All data are expressed as mean ± S.E for four different sets of experiments 
statictil significance was conducted employing ONE WAY ANOVA .a probability 
level of 0.05 was selected showing results are significant. 
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The Drug caused quenching of the intrinsic fluorescence of Cystatin 
[f'ig-47] with 10 nm of blue shift in wavelength. As the concentration of 
fluoxetine increases, fluorescence intensity decreases, maximum decrease in 
fluorescence intensity occurred at 2pM of drug concentration leading to 
quenching upto 51% These resulte indicated that tfiere were interactions 
between fluoxetine and cystatin (BC) moreover the binding reactions resulted 
in non-fluorescent complex. 
The fluorescence quenching data was analysed by the Stern-
Volrner equation as described earlier for amytriptyline. Ksv the stern volmer 
quenching constant value indicates the affinity of binding obtained at 298K 
was is shown in Table-24. 
Determination of binding constant (K) and number of binding sites 
(n) these value were calculated as described earlier in amytriptyline section. 
The value of binding constant K was found to be 5.03 xlO^ Mol'^  and the no of 
binding sites was equal to 1 for fluoxetine [Table-24] 
A G " of interaction between Fluoxetine and Cystatin 
Free energy change (AG°) of the interactions was calculated (as 
described earlier In amytriptyline sectlon).The value was found to be -
3i3.2KJ/mol showing the reaction to be spontaneous. [Table-24] 
UV-vis absorption studies of Fluoxetine Cystatin complex 
The interaction between Fluoxetine with cystatin was also studied from 
UV-\MS absorption spectral data. Cystatin concentrations were fixed at IpM 
whik; the Fluoxetine concentration was varied from 0.5pM-2|jM. Absorption 
spectra of cystatin in the presence of Fluoxetine were recorded in the range of 
200-300 nm.The UV absorption intensity of cystatin increased with the 
variation of Fluoxetine concentration. UV absortance spectra of Cystatin, 
flou>:etine and their complexes are shown in [Fig.48] Cystatin showed peak in 
thie region 200-210 nm, while on complexation with fluoxetine profound 
changes were introduced and their was peak shift of 30nm (red shift) with 
enhanced absorbance as compared to fluoxetine. 
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The UV-vis absorption spectra were computed at all the fluoxetine 
concentrations. However, little change was noted between 0.5-2 pM 
fluoxetine. The spectra obtained for Cystatin interaction with 2 \iM, fluoxetine 
showed peaks at 240 nm, the gross conformation of BC at all concentrations 
of fluoxetine was not effected significantly. 
Inhibitory activity of Brain Cystatin in the presence of fluoxetine 
The results obtained indicate that inactivation of Brain cystatin by 
•fluoxetine is concentration dependent. 1MM Cystatin was incubated with 
increasing concentrations of fluoxetine(0.5-2 pM) in 50 mM sodium phosphate 
buffer pH 7.5 at room temperature for 30 min, its inhibitory activity was 
determined by caseinolytic assay of papain p<unitz, 1947]. The activity of 
native cystatin was taken as 100%. On interaction with 0.5 pM fluoxetine, 48% 
loss of cystatin activity was noticed [Table-19]. However At 1|JM drug 
(^ncentration 52% of inhibitor activity was compromised, a drastic decline 
(90%) was noticed at 2 pM fluoxetine drug concentration and the inhibitor 
retsiined only 10% of its original papain inhibition potential. 
3.3.3 INTERACTION OF HALOPERIDOL WITH CYSTATIN 
Haloperidol is an older antipsychotic drug used in the ti'eatment of 
sjchizophrenia and, more acutely, in tiie ti^eatinent of acute psychotic states 
and delirium. 
F'luorescence spectra of Haloperidol with brain cystatin 
When 1pM of BC was incubated with increasing concentration of 
Haloperidol. IpM of BC ti-eated with increasing concenti-ation of Haloperidol 
(0.02-0.1pM) and was subjected to fluorescence specti-oscopy to assess the 
effect on conformation.the protein samples were excited at 280nm and 
emission range was 300-400nm. Haloperidol at 0.02pM did not induce any 
change in emission A^ ax however 68% decline in fluorescence intensity was 
observed. Beyond this concentration (O-OSpM) profound decline in 
fluorescence intensity (75%) was observed. Significant quenching in parent 
protein was observed (95%) when cystatin was incubated with 0.1 pM of 
Haloperidol. [Fig-49]. 
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TABLE-19 INHIBITORY ACTIVITY OF BRAIN CYSTATIN IN 
THE PRESENCE OF FLUOXETINE 
Table shows changes in the inhibitory activity of Brain cystatin 
after incubation for 30 min with increasing concentration of 
Fluoxetine. BC (IfjM) treated with varying concentration of 
Fluoxetine {0.5|JM-2IJM) for 30 min in the final reaction volume of 
1 ml in 0.05 M sodium phosphate buffer pH 7.5. 
S.NO 
1 
2 
3 
4 
5 
BC vkrith Fluoxetine Concentration 
Cystatin alone 
Cystatin -*• 0.5 |JM Fluoxetine 
Cystatin + 1 pM Fluoxetine 
Cystatin +1.5 |JM Fluoxetine 
Cystatin + 2 pM Fluoxetine 
% Inhibitory 
Activity 
Remaining 
100 
52 ±0.394 
48 ±0.770 
25 ±0.911 
10 ±0.518 
/=^JI data are expressed as mean ± S.E for four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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Stern-Volmer constant 
For fluorescence quenching, the decrease in intensity is usually 
described by the well-known Stern-Volmer equation as described earlier for 
amytriptyline antidepressant. The value of Ksv was found to be 15x10^mol 
"' for Haloperidol [Table'24]. 
Determination of binding constant (K) and number of binding sites 
(n) the value was determined as described eariier in amytriptyline section. 
The binding constant and the number of binding sites was found to be 7.988 
xlO^mol"'' and 1.1 respectively/TaWe-24/ 
AG" of interaction between Haloperidol with Cystatin 
Free energy change (AG°), of the interactions was calculated from the 
equations was -39.37 KJ/ mol as described earlier in amytriptyline section. 
[7able'24] 
Absorption spectra of cystatin in the presence and absence of 
Haloperidol 
The interaction between Haloperidol with cystatin was studied from UV-
VIS absorption spectral data cystatin concentrations was fixed at 1 pM while 
the haloperidol concentration was varied from 0.02pM-0.1pM. Absorption 
spectra of native cystatin and in presence of Haloperidol were recorded in the 
range of 200-300 nm. The UV absorption intensity of cystatin increased with 
the variation of Haloperidol concentration. UV absorbance spectra of cystatin, 
Haloperidol and their complexes are shown in fFig-50j BC showed peak in 
the region 200-210 nm while on complexation with Haloperidol profound 
changes were introduced and their was peak shift of 30nm (red shift), in the 
range of 200-300 nm, with deep enhancement in absori^ ance. 
inhibitory activity of Cystatin in the presence of Haloperidol 
The obtained data indicates that the inactivation of Brain cystatin by 
Haloperidol is concentration dependent. IpM cystatin was Incubated with 
increasing concentrations of the drug (0.02-0.1 pM) in 50 mM sodium 
phosphate buffer pH 7.5 at room temperature for 30 min and its inhibitory 
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activity was determined by caseinolytic assay of papain [Kunitz, 1947]. The 
activity of native cystatin was tal<en as 100%. The exposure of IpM of cystatin 
to varying concentrations of Haloperidol resulted In remarkable loss in Its 
antlproleolytic activity. At concentration as low as 0.06pM haloperidol showed 
42% loss in activity of cystatin .On interaction with 0.02 \M haloperidol ,29% 
loss of BC activity was noticed fJable-20]. At 0.1 pM drug concentration the 
inhibitor retained only 36% of its original papain inhibition potential. 
3.3.4 INTERACTION OF DONEPEZIL WITH BRAIN CYSTATIN 
Alzheimer Disease (AD) is a progressive brain disorder that gradually 
destroys a person's memory and ability to leam reason, make judgments, 
ciDmmunicate and carry out daily activities. The greatiy reduced concentration 
of acetylcholine in the cerebral cortex is a significant factor in Alzheimer 
Disease [German (2003)]. The inhibition of acetyl chollnesterase (AChE) 
activity may be one of the most realistic approaches to the symptomatic 
treatment of Alzheimer Disease. AChE is responsible for degradation of the 
neurotransmitter acetylcholine (ACh) in the synaptic cleft of neuromuscular 
junctions and of neuronal contacts in the central nervous system [Kasa et al. 
(2000); Tabet (2006)]. Many medicinal agents, as donepezil, is used for 
treatment of Alzheimer Disease, belong to the Important dass of acetyl 
chollnesterase inhibitors (AChEls) [Kaurand Zhang (2(X)8)]. The results of the 
interaction of donepezil with cystatin is given below. 
Ilntirinsic fluorescence studies of Cystatin in the presence of 
Donepezil 
Cystatin (IpM) was incubated with various concentration of Donepezil 
var^ fing from 2 to 10 pM forSO min. The fluorescence was recorded in the 
i^ /avelength region of 300-400 nm after exciting the protein solution at 280 nm 
for total protein fluorescence. Donepezil caused unfolding of the Cystatin as 
indicated by enhancement in fluorescence intensity accompanied by the red 
shift of 40nm as compared to Xmax of native Cystatin (330nm) while the drug 
(native) shows Xmax at 370 nm however when it forms complex with Cystatin 
there was shift in Xmax of 10nm with significant enhancement In fluorescence 
intensity at 1.6 pM [Fig-51]. 
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TABLE-20 INHIBITORY ACTIVITY OF CYSTATIN IN THE 
PRESENCE OF HALOPERIDOL 
Changes in the inhibitory activity of cysteitin after incubation for 
30 min with increasing concentration of Haloperidol. Cystatin 
{1pM) was treated with varying concentration of 
Haloperidol(0.02 pM-O.lpM) for 30min in the final reaction 
volume of 1 ml in 0.05M sodium phosphate buffer pH 7.5. 
S.NO 
1 
2 
3 
4 
5 
6 
— 
Haloperidol concentrations with 
cystatin 
Cystatin alone 
Cystatin + 0.02 mM Haloperidol 
Cystatin -(•0.04 pM Haloperidol 
Cystatin +0.06 \iM Haloperidol 
Cystatin +0.08 pM Haloperidol 
Cystatin +0.1 pM Haloperidol 
% Remaining 
Inhibitory 
Activity 
100 
71 ± 0.938 
65 ±0.915 
58 + 0.920 
43 ± 0.770 
36 + 0.911 
All data are expressed as mean ± S.E for four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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UV-vis spectra of Cystatin in the presence and absence of 
Donepezil 
Cystatin concentrations were fixed at 1|JM while tiie Donepezil 
concentrations varied from 0.16|JM-1.6|JM. Absorption spectra of native 
cystatin and in the presence and absence of Donepezil were recorded in the 
range of 200-300 nm. The UV absorption intensity of Cystatin increased with 
increasing concentration of Donepezil concentration, however the absorption 
intensity decrease slighty may be due to disruption or perturbation of 
absorbing groups [Fig-52]. 
Inhibitory activity of Cystatin in the presence of Donepezil 
Changes in the inhibitory activity of cystatin with increasing 
concentration of Donepezil is shown in [Table-21]. Effect of Donepezil on 
cystatin function was assessed by monitoring ite changes In antiproleolytic 
activity by caseinolytic assay of papain [Kunitz 1947] l^iM of cystatin was 
incubated with increasing concentration of Donepezil (0.16-1 .6|JM) . Exposure 
of cystatin to increasing concentration of donepezil resulted in rapid decline of 
antiproteolytic activity , 85% decline In the activity was seen at 1.6 pM of 
donepezil with more than half of the inactivation of cystatin was taking place 
at concentration as low as 0.32pM. 
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TABLE-21 INHIBITORY ACTIVITY OF CYSTATIN IN THE 
PRESENCE OF DONEPEZIL 
Table shows Changes in the inhibitory activity of Brain cystatin 
after its incubation for with increasing concentrations of 
Donepezil. Cystatin (IpM) treated with varying concentration of 
Donepezil {0.16pM-1.6pM) for 30min in the final reaction 
volume of 1 ml in 0.05M sodium phosphate buffer pH 7.5. 
S.NO 
1 
2 
3 
4 
5 
6 
Drug Concentration 
Cystatin alone 
Cystatin + 0.16 )JM Donepezil 
Cystatin +0.32 ^ M Donepezil 
Cystatin +0.64 pM Donepezil 
Cystatin +0.96 pM Donepezil 
Cystatin +1.6 pM Donepezil 
% Remaining 
inhibitory 
activity of 
cystatin 
100 
57 ± 0.623 
40 + 0.938 
38 + 0.772 
24 ± 0.932 
15 ±0.680 
All data are expressed as mean ± S.E for three different sets of experiments 
static^ al significance was conducted employing ONE WAY ANOVA .a 
piobability level of 0.05 was selected shovtfing results are significant. 
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DISCUSSION 
Antipsychotic and antidepressant drugs are imperative in the treatment 
of schizophrenia and other brain disorders. These drugs exert their 
therapeutic effects at least in part through perturbation of the dopamine, 
noradrenalin and serotonin neurotransmitter systems in the brain, but 
adcJitional molecular mechanisms of action are likely to contribute to their 
clinical effects. 
Antidepressants such as SSRIs (Amytriptyiine and Fluoxetine) and 
SNRIs (Haloperidol) produce their effects on the central nervous system via 
their actions on synaptic transmission. In general, these antidepressants work 
on a very limited number of transmitters, including catediolamines and 
acestylchoiine. Antidepressant drugs increase noradrenergic and serotonergic 
transmission in the brain and may affect the secretion of anterior pituitary 
hormones by regulating the hypothalamic secretions [Schule (2006)] the aim 
of the present study was to investigate the effect of antidepressants on 
cystatin structural and functional modification. 
Binding studies are used to determine the ability of an antidpressants 
to cittach to a particular site of a protien. Drug binding is evaluated at various 
drug concenti'ations and Information derived from binding studies have been 
used to determine and compare the affinity of different antidepressants for 
cystatin. However, binding parameters are only the first step in understanding 
overall pharmacologic effects. .In the present study some binding reaction 
F'arameters, including the binding constants and tiie numbers of tiie binding 
siites were detemiined. 
Amitrlptyline is a medication used to ti-eat various forms of 
depression, pain associated witii the nerves (neuropatiiic pain), and to 
prevrent migraine headaches. It is often used to manage nerve pain resulting 
from cancer treatiment. Such injury to nerves causes buming, tingling 
sensation. Amiti^ lptyline acts to block reabsorption of chemicals that ti-ansmit 
nerve messages in tiie brain. 
Intrinsic fluorescence of proteins provide considerable information 
about protein stiucture, quenching, enhancement of intensity and specb-al 
shift which are used for elucidation of related stiucture-dynamics in proteins 
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[Lakowicz (2006)]. In the present study, fluorescence spectroscopic 
measurements were undertaken to gain insight into the Interaction of Brain 
cystatin with amytriptyline. It was found that in the presence of drug 
fluorescence intensity decreased indicating a conformational change in 
protein [Fig-45]. 
When IpM of Cystatin was incubated with 2 pM of amytriptyline for 30 
mini and the samples were analyzed by fluorescence, complex changes were 
obsierved. Fluorescence emission spectrum showed no shift in Xmax, with not 
much decline in fluorescence intensity as compared to native . The negative 
value of AG- reveals that the interaction process is spontaneous. Our finding 
is similar to the binding of Congo red with human serum albumin The value 
for the number of binding sites (n) equal to 0.89 shovwng that there is one 
independent binding site of interaction. The Ksv value reported for 
amytriptyline - cystatin complex was 1.15 x 10' / M indicating the quenching 
in fluorescence to be static. 
Absorption spectral measurements of Cystatin in the presence of 
ami^ptyline provided infomiation related to changes in their structure [Fig-
46] The two positive peaks at 210 and 240 nm observed for amytriptyline -
cystatin complexes at all concentrations studied , shows contribution from 
phenylalanine and histidine residues [Donovan (1969)]. When cystatin 
incubated along with amytriptyline for varying concentration it caused 
decrease in antlproleolytic activity, there was 58% loss in antiproleolytic 
activity at 6pM of Amytriptyline concentration. This loss in antiproleolytic 
activity increased to 62% at 8pM. fTaWe-^ SJ.showing a concentration 
dependent effect 
Fluoxetine, is a selective serotonin uptake inhibitor is clinically useful 
in treating depression and may be useful for management of a variety of other 
pisychiatric and metabolic derangements. Fluoxetine antagonizes the 
neurotoxic effects of p-chloroamphetamine, a compound ttiat depletes 
serotonin [Wong et al. (1975); Wona and Bvmaster (1976)]. Fluoxetine is 
effective in the treatment of depression [Stark and Hardison (1985)] and 
obesity [Carmba et al. (1985)]. 
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Fluorescence technique has been widely used for drug-protein studies 
[Ahmad et at. (2004) ; Yang et al. (2008)] .In this study the addition of 
increasing concentrations of fluoxetine caused a progressive reduction of the 
fluorescence intensity of cystatin fluoxetine complex, [Fig-47] with 10nm of 
blue shift In the wavelength Xmax (emission maximum). Thus, ttie fluorescence 
was strongly quenched, whereas Xmax was decreased from 340 to 330 nm by 
the addition of 2^M of fluoxetinea , shift that reasonably can be attributed to 
the increased hydrophobicity (or a decreased polarity) of the region 
surrounding ttie tryptophan site p<ragh-Hansen (2001)]. Similar spectral 
features were observed for the interaction of compound [Zn(L2)(phen)] with 
BSA. 
Stem-Volmer equation is used to study the interaction of Cystatin with 
ifluoxetine. The interaction forces between proteins and ligands may comprise 
hydrophobic, hydrogen bonds, van der Waals, and electrostatic interactions 
[Timaseffand Peeters (1972)]. The free energy change (AG°) is estimated for 
Ithe interaction of fluoxetine with Cystatin is shown in [Table-24]. The negative 
values of the free energy (AG°), support the assertion that the binding process 
is spontaneous. 
The UV-vis absorption difference spectra were computed at all the drug 
(concentrations. However, profound changes were noted only for those 
obtained at 0.5-2 pM fluoxetine [Fig-49]. The spectra obtained for fluoxetine 
interacted with 1 pM Cystatin, shows peaks at 240 nm with shift of 30 nm. 
When 1 pM Cystatin was incubated with increasing concenti^ ations of 
the fluoxetine (0.5-2 pM) in 50 mM sodium phosphate buffer pH 7.5 at room 
temperature for 30 min, its inhibitory activity dereased in concenti'ation 
dependent manner [Kunitz (1947)]. On interaction with 0.5 pM fluoxetine 48 % 
loss; of Cystatin activity was noticed [Table-19]. At 1 pM drug concentration 
52*'/o of inhibitor's activity was compromised. A drastic decline (90%) was 
noticed at 2 pM dmg concenti^ ation. 
Although fluoxetine is a competitive inhibitor of serotonin uptake and 
interacts witii tiie same portion of the canier protein responsible for tfie 
transport of serotonin, the structural features responsible for substrate-carrier 
pirotein recognition may be different from those responsible for inhibitor-earner 
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prcitein recognition. Additional studies are required to detemiine whether the 
stnjctural overlap between fluoxetine and serotonin is biochemically and 
pharmacologically meaningful. 
Haloperidol it is classified as a highly potent neuroleptic compound 
possessing a strong activity against delusions and hallucinations, most likely 
due to an effective dopaminergic receptor blockage in the mesocortex and the 
limbic system of the brain. The dmg is rapidly absorbed. Plasma-levels reach 
their maximum within 20 minutes after injection. Concenti-ations 4-25 
micrograms per liter are required for ttierapeutic action. 
The Haloperidol drug- cystatin was chosen as an example for this kind 
of analytical study because of Its importance as a common antidepressant. 
Sulkowska et al.2007 investigated the binding interaction of methotexate to 
IBSi'V by monitoring the changes in the fluorescence emission spectra of tiie 
protein in the presence of Methotexate .The results are very similar to our 
results when binding of haloperidol with Cystatin was studied. The binding 
constant between haloperidol and Cystatin was found to be K= 7.988 x 10® . 
showing sb^ ong binding affinity .Haloperidol- cystatin Interaction gave one 
bin(Jing site with negative value of AG and one binding sites showing the 
leaction to be spontaneous P'3ble-24]. The interactions between gemcitabine 
hydrochloride (GEM) and BSA showed similar results [Kandagal et al. 
(2006)],The values of n for GEM- BSA interaction varied from 1.16 to 1.09. 
The purified inhibitor was incubated witii increasing concentrations of 
Haloperidol and its antiproteolytic potential was detennined. Haloperidol 
diminished tiie activity of cystatin witii maximum inactivation of the inhibitor at 
|-iigher concentiration within a short span of time [Table-20]. At lower 
comcentration inhibitor inactivation was less significant Considerable activity 
(-58%) was retained by cystatin at 0.06 pM of drug concentration. Even at 
maximum concenb-ation of the drug (0.1 pM) brain cystatin retained 36% 
acti\/ity. Drug induced inactivation of proteins has been reported eariier for 
otheir proteins also like horse liver alcohol dehydrogenase activity which was 
affected differentially by various drugs. Few like bariDrtal, caffeine and 
diazepam exerted no effect however chlorpromazine, sulpiride, morphine etc. 
rejduced the activity and phenytoin enhanced ADH activity [Roig et al. (1991)]. 
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>\bsence of any drug induced confomiational change in cystatin suggest that 
inactivation of the inhibitor may be related to subtle changes in the 
(information at the active site region induced by ttie drugs. Similar ligand 
binding functional changes have been shown for isocitrate dehydrogenase 
[Seirry and Farrell (1990)]. 
Donepezil is a cholinesterase inhibitor tiiat Is specific for acetyl 
cholinesterase.Donepezii has a relative bioavailability of 100% following oral 
administiration.Alzheimer's disease is the most common cause of dementia 
and is a primary degenerative disease of the brain of unknown cause. Onset 
is usually late in life with increasing impairment of memory, developing 
gradually into a global impairment of cognition, orientation, linguistic ability 
and judgement Acetylcholine is an important neurotransmitter associated with 
memory, and abnormalities in cholinergic neurones are among the many 
neurological and neurochemical abnormalities that develop in Alzheimer 
[Disease. One approach to lessening the impact of these abnormalities is to 
inhibit the breakdown of acetylcholine by blocking the relevant enzyme. 
([Cholinesterase inhibitors are the 'first-line' agents in the tireatment of 
Alzheimer's disease. Cholinesterase inhibitors are rapidly absorbed through 
the gasti'ointestinal trad. 
Drug induced changes in enzyme activities leading to adverse effects 
is the area of continual scientific investigation [Priyamvada et al. (2008)] 
.Whien drugs bind to a protein, the intramolecular structures can be altered, 
resulting in confomiational change of the protein [Salvi et al. (2001)]; Guo et 
al (2004a); Cheema et al. (2008); Ahmed-Ouameur et al. (2006)] In the 
presence of donepezil, fluorescence intensity increased profoundly.Such a 
kindl of change has also been documented earlier, after Interaction of ligands 
(ph r^tohormones, cytokinins, abscisic and gibberellic adds) with wheat gerni 
aigglutinin resulting in 60% increase in fluorescence intensity of native protein 
[Bogoeva etal. (2004)] 
Donepezil-Cystatin complexation showed 40 nm red shift in Amax 
indicating exposure of aromatic residues to the solvent caused by 
confomiational rearrangement of tiie two proteins [Monsellier and Bedouelle 
(2005); Vivian and Callis (2001)] Absorption spectral measurements of 
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cystatin in the presence of dmgs showed a peak noticeable at 275 nm and 
210 nm in spectra obtained at 0.16 |JM Donepezil suggesting changes around 
tyrosine residues and mainly due to tryptophan pDonovan, (1973)]. There 
was a gradual decline in cystatin activity with increasing drug concentration 
resulting in 62% loss at 0.64 pM Donepezil [Table-21]. Further magnitude of 
(decline was relatively smaller with increasing drug concentration at 1.6 pM , 
Donepezil the inhibitor retained 15% of Its antiproteolytic potential. 
Thus, the results indicate that the UV absorption and fluorescence 
emiission changes on donepezil mediated interaction are due to minor 
c^ oniformational changes in Cystatin mainly arising firom local interactions 
affecting the chromophoric groups of the protein 
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3.4. RESULTS 
3.4.1 INTERACTION OF NEUROTRANSMITTER (DOPAMINE) WITH 
BRAIN CYSTATIN 
SPECTRAL STUDIES 
Fluorescence analysis of brain cystatin in the presence of 
Dopamine 
The fluorescence spectra of BC (1|JM) was recorded in the presence of 
different concentrations (2-10 pM) of Dopamine after 30 min of incubation 
intensities were recorded in the range of 300-400 nm upon excitation at 280 
nm. Dopamine caused quenching of the intrinsic fluorescence of BC 
accompanied by a blue shift (20 nm) [Fig-53] in wavelength at 2pM 
c:oncentration. These results indicated that there were interactions between 
dopamine and brain cystatin and the binding reactions resulted in non-
fluorescent complex. 
Fluorescence quenching data was analyzed by the Stern-Volmer 
equation. (As discussed earlier for Amytriptyline) Stern-Volmer equation 
giave BC-Dopamine complex the Ksv value at 298K was 0.5 x10 * mol "^  which 
is shown in Table-24. 
Determination of binding constant (K) and number of binding sites 
(n) When small molecules bind independently to a set of equivalent sites on a 
macromolecule, the equilibrium between free and bound molecules is given 
by the equation [Feng et al. (1998), Gao et al (2004)] [As discussed earlier for 
Am^fthptyline chapter-3] the value of binding constant K was found to be 2.59 
x10 ® mol "^  and the number of binding sites calculated as 1 [Table-24] 
A G ° of interaction between Dopamine and Cystatin 
The forces of interaction between drugs and biomolecules are 
gen(5rally noncovalent. In order to identify the interacting forces between 
Amytriptyline with Cystatin the thermodynamic parameter, that is. Free energy 
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change (AG°), of the interactions were calculated from the equations, it was 
found to be -36.58 KJ/mol [As discussed earlier for Amytriptyline chapter-3] 
[Table-24] 
UV-vis absorption Spectra of Dopamine - Cystatin complex 
The interaction between Dopamine-Cystatin was studied from UV-vis 
sibsorption spectral data. Absorption spectra of native BC in the presence and 
absence of Dopamine were recorded in the range of 200-300 nm. Cystatin 
concentration was fixed at I^M while the Dopamine concentrations were 
varied from 2-10|JM. The UV absorption intensity of Cystatin increased with 
the increase in dopamine concentration lFig-54]. This evidences clearly 
indicated the interaction and some complex formation between Dopamine and 
Cystatin as reported for other proteins [Cui et al. (2004), Hu et al. (2004)]. 
Iinhiibitory activity of Cystatin in the presence of Dopamine 
Changes in the inhibitory activity of Cystatin after Incubation for 30 min 
v/ith increasing concentration of Dopamine is shown in Table-22 .The result 
showed that cystatin lost significant amount of inhibitory activity (34%) at 2pM 
of dopamine concentration, this loss in inhibitory activity increased with 
increasing concentration of Dopamine, cystatin losed half of its inhibitory 
activity at 6 pM concentration Indicating changes on complex formation. 
3.4.2 EFFECT OF SEROTONIN ON CYSTATIN 
Intrinsic fluorescence studies of Cystatin in the presence of 
Serotonin 
The fluorescence spectra of Cystatin in the presence of different 
concentrations of Serotonin were recorded in the range of 300-400 nm upon 
excitation at 280 nm for fluorescence. Cystatin (1pM) was incubated with 
various concentration of Serotonin varying from 10 nM to 50 nM for 30min. 
The slits were set at 10 nm for excitation and emission. The path length of the 
sample was 1 cm.Serotonin causes unfolding of the BC as Indicated by 
enhancement in fluorescence intensity [Fig-55]. 
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TABLE-22 INHIBITORY ACTIVITY OF CYSTATIN IN THE 
PRESENCE OF DOPAMINE 
Changes in the inhibitory activity of Brain cystatin after 
incubation with increasing concentration of Dopamine are shown 
in the table Cystatin (1MM) was treated with varying 
concentration of Dopamine (2 -lOpM) for 30min in the final 
reaction volume of 1 ml in 0.05M sodium phosphate buffer pH 
7.5. 
S.NO 
1 
2 
3 
4 
5 
I 
Dopamine Concentration 
Cystatin alone 
Cystatin + 2 |JM Dopamine 
Cystatin + 4 pM Dopamine 
Cystatin -(- 6 pM Dopamine 
Cystatin + 8 pM Dopamine 
Cystatin + 10 pIM Dopamine 
% Remaining 1 
inhibitory 
activity 
100 
66 ± 0.985 
56 ±0.1.22 
44 ± 0.605 
38 ± 0.772 
28 ± 0.788 
All data are expressed as mean ± S.E for four different sets of experiments 
slatic^al significance was conducted employing ONE WAY ANOVA .a 
probability level of 0.05 was selected showing results are significant. 
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UV-vis absorption studies of serotonin complex with cystatin 
Cystatin concentration was fixed at IpM while the serotonin 
concentration was varied from 10-50 pM. Absorption spectra of native cystatin 
in the presence and absence of serotonin were recorded in the range of 200-
300 nm .The UV absorption intensity of BC decreased with increasing 
concentration of serotonin [Fig-56]. Decrease in absorption intensity may 
arise due to perturbation of absorbing groups. 
Inhibitory activity of BC in the presence of Serotonin 
Changes in the inhibitory activity of cystatin with increasing 
concentration of serotonin is shown in [Table-23]. The result showed that 
cystatin lost significant amount of inhibitory activity at 10 nM concentration of 
serotonin. Profound loss was seen at 30 nM of serotonin concentration this 
loss further increases and at 50nM major loss seen in inhibitory activity 
(85%) of cystatin. 
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TABLE-23 INHIBITORY ACTIVITY OF CYSTATIN IN THE 
PRESENCE OF SEROTONIN 
Changes in the inhibitory activity of Brain cystatin after 
Incubation with increasing concentration of Serotonin. Cystatin 
(^\iM) was Incubated with serotonin (10nM-50nM)for 30min in 
the final reaction volume of 1 ml In 0.05M sodium phosphate 
buffer pH 7.5. 
S.NO 
1 
2 
3 
4 
5 
6 
Concentration of Serotonin 
Cystatin alone 
Cystatin+10 nM Serotonin 
Cystatin-i-20 nM Serotonin 
Cystatin+30 nM Serotonin 
Cystatin+40 nM Serotonin 
Cystatin+50 nM Serotonin 
% Remaining 
inhibitory 
activity of 
cystatin 
100 
46 ± 0.761 
32 ± 0.745 
25 ±1.084 
20 ± 0.926 
15 ±0.789 
All data are expressed as mean ± S.E fcr four different sets of experiments 
statical significance was conducted employing ONE WAY ANOVA .a 
pi obabllity level of 0.05 was selected showing results are significant. 
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DISCUSSION 
Dopamine It is a member of the catecholamine femily, it is a precursor 
of norepinephrine and epinephrine. Dopamine is crucial for human movement 
and is tlie neurotransmitter that helps transmit messages to the striatum it 
initiates as well as controls the movement and balance of the body. These 
dopamine messages make sure that muscles work smoothly, under precise 
control, and no unwanted movement occur. 
Many endogenous compounds exist in human body and drugs can 
bind to them to fbmi stable complexes, which effect the function of regulating 
proteins directly or indirectly./" Silva et al. (2004) ; Huang B. et al. (2002)] In 
addition, tha effectiveness of dmgs depends on their binding ability to target 
proteins. It has been shown that the distribution, free concentration and tiie 
metabolism of various drugs may be strongly affected by drug protein 
interaction in the blood stiream./Kamaf and Seetharamappa (2004) ; Seedher 
(2000); Cui et al. (2004) ; Channu et al. (1999) J Therefore, study of the 
interactions between proteins and drug molecules help to provide basic 
information on the pharmacological actions and bio-distiibution. 
When cystatin was interacted with dopamine it shows decrease in 
fluorescence .The quenching of cystatin is accompanied by the blue-shift in 
fluorescence [Fig-53]. This indicates the increase of polarity of the 
fluorophore environment in \he cystatin, probably due to the hydrogen bonds 
between dopamine and NH2, OH and SH groups in the inhibitor which 
stabilizes the complex [Bures et al (1990)]. 
Negative value of AG° -36.589KJ/mol [Table- 24] showed that complex 
formation between dopamine and Cystatin occur spontaneously, Our finding 
is simiilar to the binding of mettiotexate and berberine drug witfi human serum 
albumin [Khan et al. (2007) Yan-Jun Hu et al. (2008)] The number of binding 
sites (n) for dopamine - BC complex showed the value approximately equal 
to 0.798 indicating that there is one independent binding site for interaction. 
Inhibitory activity assay and fluorescence result of cystatin in the 
presence of dopamine cleariy indicates that dopamine causes functional and 
st'uctural modification in cystatin. Dopamine was found to be a modest 
inactivator of BC relative to serotonin. The treated inhibitor lost only 44% of its 
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antiproteolytic activity in the presence of 4nM dopamine frable-22J. In case 
of doipamine marked blue shift of 20nm was observed Indicating a change in 
microenvironment of tryptophan residues towards polar environment resulting 
in thie loss of native folded state of cystatin. The obtained result is in 
accordance vwth the binding of sodium diethyl dithiocarbamate (SDD) with 
phytocyistatin [Sharma et al. (2005)] and is further supported by the similar 
other results in literature [Shahper et al. (2007)]. 
Interaction between dopamine- cystatin complex was also studied from 
UV-v'is absorption spectroscopy. Equimolar complex of cystatin and dopamine 
shov/ed only a broad absorption band in the region of 200-300 nm, suggesting 
that the native structure of both the proteins is altered on complexatlon. [Fig-
54]. At higher ratios, shift of spectra towards longer wavelengths was 
observed. These evidences clearly indicated that there is interaction and 
complex formation between dopamine and cystatin results are supported from 
literature. [Cui et al. (2004); Hu et al. (2004)] 
Serotonin is a neurotransmitter, a type of chemical that helps relay 
signals from one area of the brain to another. Although serotonin is 
manufactured in the brain, where it performs its primary function, some 90% 
of the serotonin supply is found in or from the digestive tract and in blood 
platelets. Because of its widespread distribution in cells, it is believed to 
influence a variety of psychological and other body functions. Out of 
approximately 40 million brain cells, most are influenced either directly or 
indirectly by serotonin. 
Imbalance in serotonin levels may Influence mood in a way that leads 
to depression. Possible problems include low production of serotonin in brain 
cell, a lack of receptor sites able to receive the serotonin that is made, inability 
of serotonin to reach the receptor sites, or a shortage in tryptophan( the 
chemical from which serotonin is made). If any of these biochemical glitches 
occur, researchers believe it can lead to depression, as well as obsessive-
a)mpulsive disorder, anxiety, panic, and even excess anger. 
Drugs that enhance serotonergic neurotransmission are useful or potentially 
useful in treating a variety of major psychiatric and metabolic derangements, 
including depression, eating disorders, alcoholism, pain, anxiety, and obsessive-
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compulsive behavior./" Fuller (1986)] Serotonin released at synapses is actively 
removed from the synaptic cleft via a presynaptic serotonin transport earner 
proteins. Inhibitors of presynaptic reuptake augment physiological signals 
mediated by serotonin by increasing its availability in the synaptic cleft, thereby 
increasing postsynaptic receptor activation. The availability of a variety of 
compounds that selectively inhibit neuronal uptake of serotonin, without an effect 
on uptake of the catecholamine, Dopamine, has been invaluable in elucidating 
the central role of serotonin in several physiological systems and 
pathophysiological states[Lemberger (1985) ]. 
The interaction between serotonin and cystatin leads to unfolding of the 
protein, Intrinsic fluorescence studies of cystatin in the presence of Serotonin 
shows enhancement in fluorescence intensity with no shift in maximum emission 
(Amax) \vhich indicates perturbation in the environment of aromatic residues and 
unfolding of cystatin in the presence of serotonin [Fig-55]. ^^M cystatin treated 
wiOi increasing concentrations of the serotonin (10-50 nM) was analyzed 
spectroscopically by fluorescence and U.V measurements in the emission range 
from 300-400 nm and 200-300nm respectively. The results are shown in [Fig-55], 
at low concenti-ation only mild changes were induced in cystatin in the presence 
of 10 nM serotonin, the fluorescence intensit increased slightiy .However, at ail 
the diTjg concentrations, wavelength of maximum emission (Amax) remained 
unaltered.The U.V specti^ a obtained for cystatin -serotonin complex showed 
decrease in absorbance witii increase in serotonin concenti-ation/F/g -56]. 
The concenftration of serotonin depicts the effect on cystatin activity. IpM 
cystatin was incubated with increasing concentrations of serotonin (10-50 nM) in 
0.05 M sodium phosphate buffer pH 7.5 at room temperature for 30 min. The 
activity of native cystatin was taken to be 100%. As shown in the Table-23, 75% 
loss in cystatin activity occurred at 30 nM concentration and 80% loss 
precipitsited at 40 nM serotonin , at 50 nM only 15% activity was left. 
All these results taken together show that serotonin causes unfolding in the 
cystatin as compared to binding taking place in case of dopamine. The two 
neurotransmitter dopamine and serotonin react differentiy with cystatin therefore 
cystatin might be playing some role in the mechanisim of action of this 
neurotransmitters.ttius interaction of cystatin with dopamine and serotonin need 
to be further investigated to work out the mechanisim of tiiese neurotransmitters. 
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SUMMARY 
Cysteine proteinase iniiibitors of the cystatin superfamily are ubiquitous in 
mammalian system. They serve a protective function and regulate the 
activities of endogenous proteinases, which if not regulated may cause 
uncontrolled proteolysis and damage to cells and tissues. Cystatin are widely 
distributed in mammalian system these proteins are non covalent tight 
binding inhibitors and they have been found to be evolutionary, structurally 
and functionally related proteins 
On tiie ba^s of sub cellular localization, disuiphide bonds, number of 
amino acid residues and sequence homology, cysteine proteinase inhibitors 
tiave been classified into three families. Family I called as Stefins which 
include members containing about 100 amino add residues (MW 11,000), 
they lack disuiphide bridges and carbohydrate content. These inhibitors are 
present in cells and tissues, Family 11 known as Cystatin family includes 
inhibitors of about 115 amino acid residues (MW 13000) and two disuiphide 
loops towards the carboxyl terminal. They are found both in the cells and body 
fluids. Kininogens or family I I I cystatins are large precursor molecules of the 
vasoactive kinins. They are single chain high molecular weight glycoprotein, 
v/hich serve a variety of physiological functions such as kinin delivery and 
induction of endogenous blood coagulation cascade. They are found only in 
blood plasma. These cystatins all together comprise of the cystatin 
superfamily. 
Cystatins have been purified from several mammalian sources like 
rTJuscle, heart, kidney, spleen, liver, skin and placenta. In the present study a 
cystatin, of molecular mass (44,000) has been purified from buffalo brain. The 
purification has been achieved by a simple three step procedure involving 
alkaline treatment (pH 11) ammonium sulphate fractionation and gel filtration 
chromatography on Sephadex G-75. Two protein peaks (peak-I and peak - II) 
with significant inhibitory activity in peak -I was obtained it was named as BC 
(EJrain Cystatin) the pooled ft-actions of this peak on PAGE showed 
homogeneity on the basis of charge, BC was obtained with 64.13% yield and 
3JJ4.72 fold purification peak - I I was not taken into consideration because of 
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its insignificant inhibitory activity and low protein content. Purified protein 
consist of two polypeptide chains as determined by SDS-PAGE in the 
firesence and absence of p-mercaptoethanol, The molecular weight of the 
inhibitor was found to be 31.62 KDa and 12.58KDa .however by gel filtration 
Hie molecular weight was 43.6 KDa .The stoke's radius of BC was revealed 
ais 27 A°. Purified Cystatin was lacking In both cart)ohydrate and disulphlde 
bionds and the protein was found to be maximally active in the temperature 
range of 25 - 60 °C The pH stability was in between pH 6.0-10.0. 
BC strongly Inhibited activities of proteases like papain, bromelain and 
ficin, with no inhibition of serine proteases namely trypsin and chymotrypsin. 
The inhibition kinetics revealed that the cystatin Is a tight binding inhibitor. The 
respective Ki values of BC obtained for the three proteinases In the order of 
papain, ficIn and bromelain were 1.0 nm 1.85 nm and 2.25nm. The ICso 
values for BC were O.OQpM, 0.12|JM and 0.15pM for papain, ficin and 
bromelain, respectively, kinetic parameters taken together imply that the 
cystatin binds more effectively to papain, then bromelain and least with ficin. 
The results of the study show that purified cystatin may be considered as a 
variant of type I cystatin , the stefins class of cystatin superfeimlly. 
The effect of nitric oxide on functional and structural modifications of BC 
v^ ras also investigated, it was found that nitric oxide quenched tryptophan 
fluorescence. Protective effect of Curcumin and querecitin (widely used as 
sicavengers of NO) were analyzed on cystatin dysfunction by NO . Both the 
scavengers were found to have very significant preventive effect against NO 
induced functional and structural damage to BC, they were able to protect 
910% of the antiproteolytic activity of cystatin damage by NO. 
To investigate the effect of ROS on cystatin, HOCI and H2O2 were used 
as oxidants. The results reveal that BC, in tiie presence of HOCI lost Its 
antipiroteolyfic activity rapidly. Another oxidant hydrogen peroxide (H2O2) 
shov/ed significant functional and stiuctural damage at 250mM concenfi-ation. 
Eiffect of riboflavin studied with BC showed that oxidant inactivated tiie 
Inhibitor, leading to 76% loss of inhibitory activity at 50 ^M riboflavin 
concenti^ ation . Various antioxidants namely Quercetins ,curcumln glucose 
and scavengers Mannitol ,Sodlum azide, Thiourea .Potassium iodide and 
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Sodium benzoate used in the study indicated the involment of hydroxy! 
radicals and flavin triplet in the damage. 
To investigate the effect of drugs on cystatin four drugs (amytriptyline, 
fluoxetine , haloperldol, donepezil) and two neurotransmitter (dopamine and 
serotonin) were used in this study . Amytriptyline vinth its increasing 
concentration it caused quenching of the intrinsic fluorescence of cystatin, 
v/ith no shift in wavelength. 
Fluoxetine is approved for the treatment of major depression. This Drug 
also causes quenching of the intrinsic fluorescence of Cystatin vwth 10 nm of 
bJue shift in wavelength. Fluorescence intensity decreased, with a maximum 
decrease at 2\iM concentration of the drug. On interaction of cystatin with 
0.5 |JM fluoxetine, loss of cystatin inhibitory activity was also noticed. 
Maloperidol is a typical antipsychotic drug it also gave a decline in 
fluorescence intensity and inhibitory activity. All ftiese results indicated 
binding of Amytriptyline Fluoxetine and Haloperldol with cystatin. 
Donepezil, a reversible acetylcholinesterase inhibitor. It caused unfolding of 
Itlie cystatin as indicated by enhancement in fluorescence intensity. The 
inhibitor was further analyzed for its interaction with neurotransmitters 
dopamine and serotonin. Dopamine is essential for ttie normal functioning of 
the iDentral nervous system. It caused quenching of the intrinsic fluorescence 
writh a blue shift. However Serotonin caused unfolding of the BC as indicated 
by enhancement in fluorescence intensity. The result showed that cystatin lost 
significant amount of inhibitory activity at 10 nM concenti-ation of serotonin. 
(Results of fluorescence on binding of ttie drugs were furttier analyzed by 
stern volmer equation for the no binding site , binding affinity and free energy 
change of the reaction .Results indicated one binding site for each drug 
amtriptyline (0.89) Fluoxetine (0.79) haloperldol (1.1) and dopamine (0.798). 
The binding affinity value was found to be in tiie range of 3.018 x 10®, 
5 0317 X 10^ , 7.988 x 10^ and 2.592 x 10® for amtiiptyline , Fluoxetine, 
haloperidol dopamine respectively showing highest binding affinity for 
haloperidol. The free energy change (AG°) value was in the order of -39.377 
> -38.232 > -36.966 >-36.589 for Haloperidol, Fluoxetine, Amytriptyline and 
Dopamine respectively, showing that the reaction of tiiese drugs with cystatin 
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was spontaneous. Investigations in this work not only gives a detailed 
IJhysiochemical characterization of the cystatin purified from buffalo brain but 
also gives a comprehensive infomiation about drug-protein interaction. 
Understanding the conformational changes that result in a protein by various 
drug treatments may provide a powerful tool for drug design. 
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